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Abstract 
 
Typical Rett syndrome (RTT) is a paediatric neurological disorder caused in >95 % 
of cases by loss-of-function mutations in the X-linked gene, methyl-CpG-binding 
protein 2 (MECP2). The gene product, MeCP2, is a widely expressed nuclear 
protein that is especially abundant in postmitotic neurons of the central nervous 
system (CNS). Knocking out Mecp2 function in mice recapitulates many of the 
overt neurological features seen in RTT patients and provides a very useful 
model for testing potential therapeutic applications. The absence of a curative 
therapy together with the monogenecity of the disorder and established 
reversibility of the phenotype in mice suggest that replacement of the MECP2 
gene is a potential therapeutic option worthy of exploration. In this study I used 
several viral vectors to test the potential of gene therapy in RTT mice. First, I 
generated different viral vectors which can express tagged-MeCP2 under the 
control of ubiquitous and cell-type specific promoters. Secondly, I assessed the 
ability of these vectors to deliver the Mecp2 transgene into Mecp2 knockout 
mice at both neonatal and adult stages of development. I then aimed to 
investigate the effect of exogenously delivered Mecp2 on RTT-like phenotypes. 
The results demonstrated that lentiviral vectors were able to effectively deliver 
an RFP-tagged Mecp2 minigene into neurons of Mecp2-null mice both in vitro and 
in vivo. Exogenous Mecp2 was targeted to the nucleus and displayed 
heterochromatin localization with no evidence of ectopic expression. Use of the 
synapsin1 (syn1, neuron-specific) promoter resulted in cellular levels of Mecp2 
equal to 85 ± 0.1% of endogenous protein levels, whereas the phosphoglycerate 
kinase (PGK) promoter  produced cellular levels of exogenous Mecp2 at a 
relatively high levels  (210 ± 0.1 % of endogenous levels). Direct brain injection 
of Lentiviral vector was able to deliver exogenous Mecp2 into the CA1 region of 
the hippocampus and to produce high transduction efficiency around the 
injection sites but with limited spread. The early mortality of the injected mice 
precluded assessment of the functional consequences of exogenous Mecp2 
expression. However, assessment of the cellular morphology was possible and 
this analysis revealed delivery of exogenous Mecp2 to normalise neuronal nuclear 
volume deficits seen in the Mecp2stop/y mice from 86 ± 0.1 % of WT values to 100 
± 0.04 % of WT levels. At the molecular level, I showed that exogenous Mecp2 
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becomes phosphorylated at serine 421 under basal conditions and that the level 
of phosphorylation of exogenous Mecp2 is disproportionately higher (5.5 ± 0.4 
times) than that seen for endogenous Mecp2. I also showed the Mecp2 
overexpression in WT neurons is associated with a reduction in the cellular levels 
of total histone 4 (78 ± 0.01 % of the endogenous level) and a parallel reduction 
in cellular levels of acetylated histone 4 (79 ± 0.01 % of the endogenous levels). 
In second phase of experiments, I showed that the single stranded Adeno-
associated virus (ssAAV)-based vector with chicken beta actin (CBA) promoter 
and encapsulated with capsid of AAV serotype 9, was able to efficiently deliver 
exogenous MECP2 into the brain of Mecp2-null as well as WT neonatal mice after 
intracranial (IC) injection. In contrast to lentiviral vectors, there was widespread 
transduction of cells throughout the nervous system with transduction efficiency 
varying between 6.8 ± 2.3 % and 41.5 ± 11.3% of all cells dependent on the brain 
region. The transgene was mostly expressed in neurons which represented 67 ± 
11.8 % to 98 ± 0.8 % of all transduced cells. ssAAV9 vector expressed exogenous 
MeCP2 at near-physiological levels (100-125 % of endogenous levels). At the 
cellular level, exogenous MeCP2 was able to rescue the neuronal nuclear volume 
of Mecp2-null mice (69 ± 0.02 % of WT values) to WT comparable values (97 ± 
0.03 % of WT values). At the organismal levels Mecp2-null mice treated with 
ssAAV9/MECP2 showed extended survival (median survival of 16.7 weeks 
compared to 9.3 weeks for the GFP-treated control) and also displayed a 
modest, but significant, reduction in the RTT-like phenotype severity score 
compared to the GFP-treated control group. The most robust improvement 
reported in this study was in the locomotion activity (velocity and total distance 
moved in the open field test and in performance on a forced motor task). 
Interestingly, WT mice receiving neonatal injections of ssAAV9/CBA-MECP2 did 
not show any significant deficits, suggesting a tolerance for modest MeCP2 
overexpression. 
In a further experiment, I showed that the self-complementary AAV 9 (scAAV9) 
vector with an Mecp2-endogenous core promoter fragment was able to deliver 
exogenous MECP2 into the brain of neonatal mice after intravenous (IV) or (IC) 
injection. Brain transduction efficiency was 8 - 12 % after IV injection and 48 - 
68 % after IC injection in neonatal mice. Cellular levels of exogenous MeCP2 
were between 1.4-1.8 times the endogenous levels. At the organismal level, 
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scAAV9/MECP2-injected mice displayed an overt hindlimb motor dysfunction 
which was observed 3 and 5 weeks post-injection after IV and IC injection 
respectively. The stereotyped hindlimb dysfunction suggested a toxicity issues 
with this vector and examination of the lumbar segment of the spinal cord 
confirmed evidence of axonal degeneration in the dorsal columns.  IV injection 
of scAAV9/MECP2 into RAG-/- knockout mice (immunocompromised) displayed 
hindlimb motor dysfunction similar to that observed with Mecp2stop/y mice 
suggesting that the adaptive immune response is not likely to be involved in the 
pathogenesis of this phenotype. MECP2stop/y mice treated with scAAV9/MECP2 
displayed higher RTT-like phenotype severity score than GFP-treated controls 
which is probably due to the effect produced by the hindlimb motor dysfunction 
on regular RTT-like phenotype (gait, mobility and hindlimb clasping). 
In summary, I have demonstrated the successful application of lentiviral and 
AAV2/9 vectors to deliver exogenous MECP2 both in vitro and in vivo. I showed 
that lentiviral vectors are unlikely to be useful for global brain delivery of MECP2 
due to limited spread of the virus. However the lentiviral vectors I developed 
are potentially useful where localized brain injection is desirable. The main 
translational finding is the first, at the proof of concept level, demonstration of 
therapeutic benefits (including enhanced survival) of exogenously delivered 
MECP2 using the ssAAV9/CBA-MECP2 vector.  I also however, identify potential 
toxicity issues of exogenous MECP2 delivery whereby a scAAV9 vector was found 
to produce overt neuromotor deficits. Overall, my data supports the potential of 
gene therapy in RTT but also emphasises the importance of issues including 
careful vector design, choice of delivery methods and the timing of treatment in 
any future clinical translation. 
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Chapter 1 
Introduction  
  
1.1 General introduction 
Rett syndrome (RTT) is a paediatric neurological disorder with a delayed onset of 
symptoms and is a leading cause of severe mental retardation in girls. First 
described in the 1960s by Andreas Rett (Rett, 1966) and thereafter by Bengt 
Hagberg in 1983 (Hagberg et al., 1983) , RTT was shown in 1999 to be caused 
primarily by mutations in the X-linked gene, MECP2 (Amir et al., 1999). After a 
number of groups had developed Mecp2 knockout mouse models (Chen et al., 
2001, Guy et al., 2001, Shahbazian et al., 2002a) and shown their utility in 
modelling aspects of the disorder, a number of attempts to reverse the signs 
after onset, or to prevent onset, were made. The initial successes reported have 
demonstrated the tractability of various aspects of the phenotype and 
highlighted the potential for treatments for Rett patients that address early 
stages in the pathogenetic pathway and go beyond merely ameliorating the 
downstream consequences. In this thesis I used Mecp2 knockout mice to evaluate 
therapeutic approaches based on virus-mediated delivery of a wild-type copy of 
Mecp2 to cells lacking this protein. Delivery of exogenous Mecp2 to the brain is a 
challenging approach not just because of the inherent obstacles to delivering 
substances to the CNS but also because of the difficulties in transducing large 
number of cells and also to maintain exogenous Mecp2 levels within physiological 
limits to prevent overexpression-related toxicity. Evaluation of the outcomes of 
these experiments should provide information about challenges, benefits, 
drawbacks and prospect of gene therapy application in the treatment of Rett 
syndrome. 
1.2 Clinical manifestations of RTT 
 RTT (MIM 312750) is traditionally considered a neurodevelopmental disorder and 
is a primary cause of severe mental retardation in girls with an incidence of 
approximately 1 in 10,000 female births (Neul et al., 2010). RTT is characterized 
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by its almost exclusive occurrence in females and by a constellation of clinical 
features (Neul et al., 2010). These features, which distinguish RTT from the 
autism spectrum disorders that they are often co-classified with, include an 
initial period 6-18 month of apparently normal growth, however  low mean birth 
weight and head circumference were also observed (Leonard and Bower, 1998, 
Huppke et al., 2003), followed by a highly characteristic developmental 
regression period during  which the patients display loss of hand skills, impaired 
mobility and speech, development of stereotypic hand movements (continuous 
repetitive wringing, twisting, clapping hand automatism during wakefulness) and 
social interaction deficits (with features reminiscent of autism, figure 1-1). This 
regression phase is usually followed by a recovery or stationary phase for years, 
with some patients partially regaining skills. Nevertheless, the late motor 
deterioration phase usually takes place with its characteristic severe motor 
disabilities (Engerstrom, 1992, Hagberg, 2002).  
Epilepsy is a common feature of RTT that occurs most often during the 
stationary phase (Hagberg, 2002), however the severity tends to decrease after 
the age of 20 years (Steffenburg et al., 2001). Other features include 
musculoskeletal abnormalities  in the form of scoliosis, which starts at early 
school age, and lower limb distal deformity (Hagberg, 2002). Autistic features 
are frequent in RTT and include expressionless face, hypersensitivity to sound, 
indifference to the surrounding environment, and un-responsiveness to the social 
cues (Nomura, 2005) and mental retardation (Chahrour and Zoghbi, 2007). 
Episodic hyperventilation, breath holding and frequent apnoea during 
wakefulness are among the autonomic features of RTT (Julu et al., 1997, Kerr et 
al., 1997, Julu et al., 2001). Swallowing dysfunction, gastro oesophageal reflux, 
constipation and distension are also observed in RTT patients (Hagberg, 2002, 
Isaacs et al., 2003). Some of the previously mentioned features may be a direct 
result of the primary CNS deficits, but several may also be influenced by 
peripheral effects. 
Clinical presentation and severity show a wide variation, and patients may 
exhibit all the essential features necessary for the RTT diagnosis (typical RTT), 
or they may show differences that enable their assignment to one of a range of 
atypical RTT diagnoses (Neul et al., 2010). 
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Figure 1-1 Clinical manifestations of Rett syndrome 
Representative diagram showing the characteristic RTT clinical presentation.* indicates 
main criteria essential for typical RTT diagnosis. 
1.3 Genetic basis of RTT 
1.3.1 MECP2 and Rett Syndrome 
RTT cases are usually the result of dominantly-acting, de novo (Girard et al., 
2001) mutations in the X-linked gene MECP2, which encodes methyl-CpG-binding 
protein 2 (MeCP2). More than 600 pathogenic MECP2 mutations have been 
reported (RettBase: http://mecp2.chw.edu.au/mecp2/), including missense, 
nonsense, frameshift and large deletion mutations. Most pathogenic mutations in 
MECP2 cause RTT in heterozygous females (Bienvenu and Chelly, 2006), but a 
range of MECP2 mutations associated with other phenotypic outcomes, including 
milder forms of learning disability and, rarely, autism, are also known (Moretti 
and Zoghbi, 2006). Boys inheriting a mutant MECP2 allele that would normally 
cause typical RTT in a female are much more severely affected, presenting with 
infantile encephalopathy and usually not surviving infancy. The differences 
between the observed phenotypes in males and in females are explained in 
terms of the proportion of cells in the nervous system expressing the mutant 
allele. Whilst all MeCP2-containing cells will express the mutant allele in males 
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that have inherited a single mutant X chromosome, the female brain, due to 
random X-chromosome inactivation, will develop into a mosaic network of cells 
with some expressing the mutant allele and others expressing the normal allele. 
In this way the pathology associated with the mutant allele is diluted (at the 
network level) in the female brain, albeit for direct cell-autonomous actions of 
the mutation.  
1.3.2 MECP2 structure 
MeCP2 is predominantly a nuclear protein that was first discovered through its 
affinity for DNA sequences containing methylated 5‟-CpG-3‟ dinucleotides (Lewis 
et al., 1992). It is a member of a small family of methylated DNA binding domain 
(MBD) proteins some of whose members can act as transcriptional repressors 
(Klose and Bird, 2006). MeCP2 is expressed quite widely throughout the body, 
with notably high expression in postnatal neurons (LaSalle et al., 2001, 
Shahbazian et al., 2002b, Zhou et al., 2006). It is expressed as two major splice 
variant isoforms, e1 and e2, that encode proteins with different N-termini 
(Kriaucionis and Bird, 2004, Mnatzakanian et al., 2004)(Figure 1.2). The first 
identified isoforms, MECP2_e2 (MECP2β or MECP2a) uses a translational start site 
within exon 2, whereas the new isoform, MECP2_e1 (MECP2α or MECP2b) derives 
from mRNA in which exon 2 is excluded and a new in-frame ATG located within 
exon 1 is used (figure 1-2).  
Mecp2_e1 is the most abundant Mecp2 isoform throughout the brain 
(Mnatzakanian et al., 2004, Dragich et al., 2007) and is translated more 
efficiently in vivo (Kriaucionis and Bird, 2004). Mutations in exon1 (only 
translated in Mecp2_e1) are sufficient to produce neurological manifestation and 
affect MECP2_e2 translation. In contrast, there is no RTT-associated specific 
exon 2 mutation observed so far (Mnatzakanian et al., 2004, Saxena et al., 
2006). A recent report showed that Mecp2_e2 is up regulated during neuron- 
induced toxicity and it‟s forced over expression enhanced apoptosis in healthy 
neurons. In addition to this knocking down Mecp2_e2 was found to be neuro-
protective (Dastidar et al., 2012). In another study, knocking down Mecp2_e2 by 
exon 2-specific deletion produced no RTT-associated symptoms suggesting this 
isoform is dispensable.  However, further analysis showed that mutations of the 
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Mecp2_e2 allele were associated with placental defects and survival 
disadvantage. 
 
 
Figure 1-2  Composition and splicing pattern of MECP2 gene 
(a) Representative figure showing the Splicing patterns of MECP2 gene. Two mRNA 
isoforms are generated; MECP2_e1 and MECP2 _e2. (b) The two isoforms generate two 
protein isoforms of MeCP2 with differing N-termini due to the use of alternative translation 
start sites (bent arrows). Yellow and green shadows referee to the amino acid differences in 
the N-terminal of both MeCP2_e1 (GenBank accession no. NM_001110792.1) and MeCP2_2 
(GenBank accession no. NM_004992.3) isoforms respectively.   
Both isoforms are thought to have two primary functional domains (figure 1-3), a 
methyl-CpG binding domain (MBD; 85 amino acids in length and has high affinity 
binding to 5-methyl cytosine) and a transcriptional repressor domain (TRD; 104 
amino acid in length), that interacts with, amongst other things, histone 
a 
b 
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deacetylase (Nan et al., 1997, Jones et al., 1998) and the Sin3a repressor 
complex (Nan et al., 1998). MeCP2 protein has two nuclear localization signals 
(NLS) which are responsible for nucleus targeting of the Mecp2 (Nan et al., 1996) 
and a C-terminal  segment which helps its binding to the nucleosome core 
(Chandler et al., 1999). 
 
Figure 1-3 MeCP2 protein structure with the most frequent mutation sites, 
Representative figure showing the distinct functional domains of MeCP2. Apart from the N-
terminus, both MeCP2 isoforms are identical and contain several functionally distinct 
domains: NTD, N-terminal domain; MBD, methyl binding domain; ID, inter domain; TRD, 
transcription repression domain; CTD, C-terminal domain; NLS; nuclear localisation signals. 
Locations of 7 of the most common point mutations in RTT are indicated (). Below each 
domain are indicated major (bold) and other (grey) interactors and functions). HP1; 
heterochromatin protein 1, TFIIB; transcription factor IIB, YB1; Y box binding protein 1. This 
figure was taken from (Gadalla et al., 2011). 
1.3.3 Functions of MeCP2 
MeCP2 is expressed in neuronal stem cells (Jung et al., 2003, Namihira et al., 
2004) with an observed role in embryonic neurogenesis in Xenopus (Stancheva et 
al., 2003). However, neuronal  proliferation and differentiation from neural 
precursor of Mecp2 knockout  and WT mice were identical indicating that Mecp2 
is not likely to be involved in early cell fate decision or neuron differentiation 
but rather  that it impacts neuronal maturation and maintenance (Kishi and 
Macklis, 2004, Smrt et al., 2007). During development, Mecp2 expression is very 
low or absent in immature neurons and increases during neuronal maturation to 
reach its highest levels in postmitotic neurons and remains high throughout adult 
life (Kishi and Macklis, 2004, Matarazzo et al., 2004). Knocking out Mecp2 in the 
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adult mice brain resulted in very similar neurological and motor deficits to germ 
line knockout mice suggesting an essential role of Mecp2 in the maintenance of 
neuronal function (McGraw et al., 2011). 
Recent biophysical studies have probed the binding specificity of MeCP2 and 
have reported the interaction (via hydration within the major groove) with 
methylated DNA and also the interaction with nucleosomes (Ho et al., 2008, 
Yang et al., 2011). Despite this knowledge, the precise biological function of 
MeCP2 remains unclear. Proposed additional or alternative functions include 
selective enhancement/activation of gene expression (Chahrour et al., 2008), 
chromatin regulation (Nikitina et al., 2007), and RNA processing (Long et al., 
Young et al., 2005). It has recently been established that MeCP2 is distributed 
across the genome very much in parallel with methylation density, and to the 
exclusion, in neurons, of histone H1 (Skene et al., 2010). These data suggest 
that MeCP2 plays a major role in the suppression of transcription throughout 
very large scale genome-wide actions; in this way it may be best to describe 
MeCP2‟s function in terms of global dampening of transcriptional noise. 
1.4 Animal models of Rett syndrome 
RTT‟s status as, relatively common, monogenic disorder has created 
considerable interest in investigating the underlying pathology. A large part of 
this interest comes from a desire to develop rational therapies for patients, but 
it has also emerged that gaining a fuller understanding of the underlying 
pathology and neuronal dysfunction in RTT may provide insights into the 
pathophysiology of neurodevelopmental disorders more generally (Neul and 
Zoghbi, 2004). Since most MECP2 mutations leading to RTT involve loss of 
function of the mutant allele, RTT can be modelled using Mecp2 knockout mice.  
Several of the models that have been created recapitulate many of the cardinal 
features that characterize RTT in humans, although there are important 
differences. An early animal model of RTT was generated by deletion of exon 3 
(encodes 116 amino acids most of it located in the MBD of Mecp2 protein)(Chen 
et al., 2001). Mecp2-/y male mice in which Mecp2 was knocked out either 
globally or specifically in the central nervous system were apparently normal in 
the first few weeks of life. However abnormal behaviours such as nervousness, 
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body trembling, pila erection and occasionally hard respiration were observable 
by the age of 5 weeks. With the disease progression, these mice displayed 
hypoactivity, increased trembling, loss of the bodyweight and premature death 
around 10 weeks of age. In contrast heterozygous females, Mecp2-/+ (more 
accurate model of human RTT) that have mosaic network of cells expressing WT 
Mecp2 allele and cells expressing the mutant Mecp2 allele (lacking Mecp2) 
displayed, similar to RTT patients, initial period (~4 months) of apparently 
normal growth followed by weight gain, reduced activity and ataxia and gait 
abnormalities at a later stage. To test the effect of neuron-specific deletion of 
Mecp2 on the RTT-like phenotype, another mouse model in which Mecp2 was 
knocked out specifically in postnatal neurons was generated by the same 
authors. Interestingly these mice displayed a phenotype similar, however milder, 
to that seen in animals carrying a germ line Mecp2 deletion. The close similarity 
in the phenotype between these animal models (global, brain- and neuron-
specific deletion of Mecp2) suggests that a lack of functional Mecp2 in neurons is 
the primary cause of the RTT-like phenotype. 
Another early model was created by Guy and colleagues in which Mecp2-exon 3 
and 4 were deleted (Guy et al., 2001). Mecp2-/y mice from this line displayed a 
relatively normal phenotype in the first 3-4 weeks of postnatal life that was 
followed by the development of uncoordinated gait, reduced spontaneous 
movement, irregular breathing, hindlimb clasping, uneven wearing of the teeth 
and un-descended testes. Four weeks later these mice showed rapid loss of 
bodyweight and died prematurely at approximately 8-10 weeks. On the other 
hand, brain-specific deletion of Mecp2 resulted in a phenotype similar to that of 
the germ line deletion providing further evidence for the importance of the 
brain in the development of the RTT-like phenotype. Heterozygous female mice 
(Mecp2-/+) recapitulate a similar phenotype trajectory to that observed in female 
patients (Hagberg, 2002) with initial period of apparently normal development 
lasting about 3 months followed by development of inertia and hind limb 
clasping. This is then followed by a period of long term phenotype stability 
similar to that observed in the stationary phase in human patients.  Most of 
these females develop similar RTT-like phenotype by the age of nine months, 
however some remain without symptoms even at one year. 
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Another functional knockout mouse model was generated through silencing the 
endogenous Mecp2 gene by the insertion of a lox-Stop cassette (Dragatsis and 
Zeitlin, 2001) into intron 2 of Mecp2 gene (Guy et al., 2007). Mecp2stop/y male 
mice were phenotypically comparable to Mecp2-null mice and displayed tremor, 
abnormal breathing, lack of spontaneous mobility, wide-based gait, hind limb 
clasping and bad general condition. These mice were underweight and died as 
early as 11 weeks. A modification of this animal model was used in a reactivation 
study in which Cre recombinase and a modified oestrogen receptor (Cre-ER) 
were combined with the Mecp2lox-Stop allele allowing conditional activation of 
endogenous Mecp2 under its own promoter and regulatory elements (Guy et al., 
2007).  
Most of these Mecp2 knockout mice display an anxiety phenotype including 
reduced exploration, increased thigmotaxis and altered plus and zero maze 
behaviour (Pelka et al., 2006, Stearns et al., 2007). The motor dysfunction that 
is a characteristic part of the RTT phenotype places severe limits on the range of 
cognitive tests that can be carried out but impairments in fear conditioning and 
novel object recognition have been reported.  
Mecp2-null (Chen et al., 2001, Guy et al., 2001) or stop (Guy et al., 2007) male 
mice recapitulate severe neurological diseases comparable to that observed in 
the human males making them a good model to test efficacy of new therapies. 
However, the early morbidity and mortality observed in these models prohibits 
long-term behavioural analysis. Therefore Shahbazian and colleagues have 
created a mouse model with a truncated version of Mecp2 which contains the 
first 308 amino acids and hence is called Mecp2308 (Shahbazian et al., 2002a). 
This truncated Mecp2 protein preserves the MBD, TRD, and both nuclear 
localization signals, but lacks the C-terminal domain which includes important 
phosphorylation sites. The Mecp2308/y mouse model displays a classic albeit 
milder RTT phenotype that recapitulates many of the features of RTT but display 
an extended survival (up to one year) and more modest phenotype trajectory 
that starts late in life, at approximately five months, in the form of tremor, 
myotonic jerks, seizures and forelimb stereotypic movement and clasping. 
Mecp2308/y mice also display impairments in hippocampus-dependent spatial 
memory as well as social memory (Moretti et al., 2006). In contrast to Mecp2-
null models, these mice are fertile and exhibit normal body and brain weights 
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with no detectable morphological changes in the peripheral tissues or in the 
CNS. Heterozygous female Mecp2308/+ display milder and more variable 
phenotype features even at one year old. 
A cell-type specific knockout study in which Mecp2 was silenced specifically in 
inhibitory GABAergic cells revealed a range of subtle RTT-like neuropsychiatric 
phenotypes (table 1-1) including autistic-like repetitive behaviours (Chao et al., 
2010). In another study in which MeCP2 was silenced in tyrosine hydroxylase-
containing neurons, mice were found to display motor abnormalities and 
breathing problems including an increased incidence of apnoeas suggesting that 
dysfunction in aminergic systems may be responsible for some RTT-like breathing 
phenotypes (Samaco et al., 2009). A more recent mouse model of RTT was 
generated by insertion of missense mutation in Mecp2 to replace amino-acid 
threonine T158 with methionine to mimic one of the most common missense 
mutations in human (Bienvenu and Chelly, 2006). Mecp2T158M/y male mice showed 
RTT-like phenotypes that were similar, however less severe, compared to the 
Mecp2-null mice with slightly extended survival (Goffin et al., 2012) suggesting 
that a single MECP2 mutation could be almost as detrimental as complete 
absence of the protein.  
1.5 Cellular alterations in RTT patients and animal 
models 
In addition to the gross neurological and behavioural abnormalities observed in 
RTT, a number of structural changes in the brain were also observed in RTT 
patients as well as in Mecp2 knockout mice.  In RTT patients, the most obvious 
features are a reduced brain size and weight with subtle changes in neuronal 
packing density and neuronal morphology, e.g. reduced dendritic branching 
complexity and changes in spine density and morphology (Armstrong et al., 1995, 
Bauman et al., 1995). Similar changes are observed in Mecp2-null mice (Chen et 
al., 2001) with an evidence of both cell autonomous and non-cell autonomous 
changes in neuronal morphology (Kishi and Macklis, 2010). Mecp2 level was also 
reported to regulate number of excitatory synaptic connections (Chao et al., 
2007) and axonal guidance (Degano et al., 2009).  Electrophysiological studies 
revealed relatively modest alterations in the salient electrical properties of 
cortical neurons (Dani et al., 2005) although more pronounced changes are 
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reported in subcortical regions (Bauman et al., 1995). In contrast, a robust body 
of evidence exists for changes in synaptic signaling, affecting both excitatory 
and inhibitory amino acid neurotransmission (Kline et al., Dani et al., 2005, 
Nelson et al., 2006, Medrihan et al., 2008). Regarding inhibitory connections, 
loss of Mecp2 has been shown to reduce quantal GABA release consistent with a 
presynaptic reduction in neurotransmitter content (Chao et al., 2010). This may 
account for the tendency for seizures to occur in the RTT brain. In addition to 
changes in the baseline properties (frequency and amplitude) of synaptic events, 
several studies have reported deficits in both short- and long-term forms of 
synaptic plasticity (Le Roith, 1997, Moretti et al., 2006, Guy et al., 2007, Weng 
et al., 2011). Interestingly, synaptic plasticity appears normal in young Mecp2-
mutant mice (Guy et al., 2007), but becomes progressively more impaired with 
the disease progression in older mice (Guy et al., 2007, Weng et al., 2011). The 
exact mechanism by which absence of functional Mecp2 in the nucleus produces 
a synaptic deficit phenotype remains to be established. 
1.6 Reversibility and treatment strategies for the RTT-like 
phenotype 
The conventional view is that abnormalities in brain development during critical 
periods of growth and maturation will produce aberrations in the nervous system 
with subsequent essentially irreversible neurological and psychiatric features 
due to the limited ability of the brain to generate new neurons or to radically 
rewire itself. However, a number of studies of animal models of diseases ranging 
across Down syndrome (Fernandez et al., 2007, Rueda et al., 2008), fragile X 
syndrome (McBride et al., 2005, Dolen et al., 2007), and Angelman syndrome 
(van Woerden et al., 2007) are beginning to show an unexpected propensity for 
phenotypic reversal, even in adult mice (Ehninger et al., 2008). This propensity 
has also recently been reported in RTT (Guy et al., 2007, Derecki et al., 2012). 
RTT is considered to result from a failure of neurons to mature, a developmental 
process, and / or of their failure to maintain a mature phenotype, a 
maintenance process, (Kishi and Macklis, 2004, Palmer et al., 2008, Degano et 
al., 2009). MeCP2 is also present in astrocytes and other non-neuronal cell types 
in the brain, albeit at much lower levels (Schmid et al., 2008). Although a 
deletion and a neuron-specific expression of Mecp2 studies in mice show that the 
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dominant mutant phenotype is principally due to absence of MeCP2 in neurons 
(Chen et al., 2001, Guy et al., 2001, Luikenhuis et al., 2004), loss of MeCP2 
function in astrocytes leads to altered release of neurotrophic factors, changes 
to dendritic outgrowth (Ballas et al., 2009, Maezawa et al., 2009) and contribute 
to non-cell autonomous aspects of RTT pathology. Moreover astrocyte-specific 
Mecp2 delayed activation rescued RTT-like phenotypes in Mecp2 knockout mice 
(Lioy et al., 2011) and bone marrow transplantation of WT microglia into pre-
symptomatic Mecp2-/y mice arrested the progression of the RTT-like phenotype 
(Derecki et al., 2012). 
In considering whether the phenotype is reversible or even preventable, three 
scenarios must be considered. Firstly, since neurons lacking MeCP2 display long-
term survival and since neurons seem to require MeCP2 throughout their lives, it 
is possible that the introduction of normal MeCP2 or therapeutic strategies 
targeting MeCP2-related signaling might restore function and, thereby, reverse 
deficits seen in RTT. Alternatively, it may be that MeCP2 is essential for 
neuronal development during a specific time window, after which damage 
caused by its absence is permanent.  A third scenario combines  both of these 
ideas, whereby certain RTT-like features can be rectified in the mature nervous 
system if cells begin expressing MeCP2 whilst other features are critically 
dependent upon the presence of MeCP2 during essential, developmentally 
inflexible, processes and are thus insensitive to simple restoration of MeCP2 or 
other intervention beyond a critical period.  
1.6.1 Reversibility of the RTT-like phenotype in Mecp2 knockout 
mice models 
Mouse models of RTT have played an important role in studying the requirement 
for Mecp2 in different cell types and at different stages of development as well 
as in testing the reversibility of RTT-like phenotypes. For instance, Luikenhuis 
and colleagues have created an animal model in which Mecp2 coding sequence 
was cloned into exon 1 of the tau locus to allow neuronal-specific expression of 
Mecp2 in WT as well as Mecp2-null mice. This report showed that Mecp2-null 
mice heterozygous for the transgene displayed a modest over-expression of 
Mecp2 transgene and an absence of the RTT-like phenotype. However the same 
study showed that WT and Mecp2-null mice homozygous for the transgene 
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showed severe overexpression of Mecp2 transgene (2-4 fold of the WT level) that 
was associated with profound motor dysfunction (Luikenhuis et al., 2004). This 
experiment provided evidence of a critical requirement for MeCP2 in neurons 
but it also highlighted the importance of maintaining MeCP2 protein expression 
at an appropriate level, which has therapeutic significance when considering 
potential gene therapy strategies.  In another study, (Giacometti et al., 2007), 
early brain-specific activation of Mecp2 under either nestin (drive Mecp2 
expression on pre-mitotic cells) or tau (drive expression of Mecp2 in post-mitotic 
neurons) promoter resulted in prolonged lifespan, normalized bodyweight, 
delayed development of motor deficits and improved motor activities that had 
been reported in Mecp2-null mice (Chen et al., 2001). On the other hand 
delayed forebrain activation of Mecp2 showed modest effects compared to the 
whole brain activation. These results suggest that the introduction of Mecp2 to 
the nervous system under artificial promoters is sufficient to enable a modest 
amelioration of RTT-like phenotypes and to prolong life span. 
In another study, Guy and colleagues (Guy et al., 2007) created a mouse model 
in which the endogenous Mecp2 gene is silenced by insertion of a lox-Stop 
cassette but which can be conditionally activated (cre mediated Stop cassette 
excision) following tamoxifen injection. Importantly, this enabled the activation 
of Mecp2 at its endogenous locus and under the control of its own promoter and 
regulatory elements. The control mice Mecp2cre-stop/y (no tamoxifen-induced 
activation of Mecp2) typically developed the RTT-like phenotype with premature 
mortality, however hemizygous male mice showed no RTT-like phenotype when 
treated with tamoxifen in the first 4 weeks of life (presymptomatic) and showed 
robust symptom reversal and dramatically enhanced survival if treated once 
symptoms had developed. Furthermore, heterozygous female mice (the accurate 
model of RTT in humans) displayed a dramatic improvement of RTT-like 
phenotypes, a normalization of bodyweight and a restoration of synaptic 
plasticity deficits, even when treated as fully adult mice (>6 months). These 
findings confirm the propensity for phenotypic reversal, at least in the mouse 
model. This reversibility may bring into question the categorization of RTT as a 
neurodevelopmental disorder as it suggests that MeCP2-deficiency during brain 
development does little lasting damage. However, it remains to be established 
whether improvement in overt signs (tremor, locomotion, abnormal breathing 
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etc.) is accompanied by improved cognition and other behavioural correlates. 
Nevertheless, a following study by the same authors show improvement in a 
wide range of locomotor and respiratory phenotypes as well as evidence for 
structural remodelling in the brain following Mecp2 activation (Robinson et al., 
2012). These mouse genetic studies suggest that there is the opportunity, even 
in the fully mature nervous system, to modulate MeCP2 levels or target 
downstream processes by pharmacological means to prevent, or reduce the 
severity of, the condition. Interestingly, recent complementary experiments in 
an adult onset model of RTT (tamoxifen-induced excision of a floxed Mecp2 
allele) suggest that MeCP2 is critical for ongoing neurological function in the 
adult nervous system and that potential therapies for RTT are likely to be 
required throughout life (McGraw et al., 2011).   
In contrast to the significant reversal seen following a global reintroduction of 
Mecp2, studies focusing on more restricted expression of Mecp2 and using 
promoters other than the endogenous Mecp2 promoter have shown a more 
modest effect. For instance,  Mecp2 expression under either  Ca2+/calmodulin-
dependent protein kinases II (CamKII) or enolase promoter in the forebrain and 
cerebellum/striatum respectively was unable to prevent the occurrence of the 
RTT-like phenotype in Mecp2-/y mice (Alvarez-Saavedra et al., 2007). However 
Mecp2 expression under the control of CamKII promoter in the forebrain of 
Mecp2-/+ female mice revealed improvement of the mobility and locomotor 
activity to WT levels (Jugloff et al., 2008). It is unclear from these studies 
whether the sustained deficits result from an inherent irreversibility due to 
neurodevelopmental aberrations or to dysfunction of regions or cell types in the 
brain still devoid of Mecp2, or to the exogenous promoters driving cellular Mecp2 
expression at levels outside the physiological range, or to other unknown mouse-
specific processes. 
Mecp2 is a widely expressed protein which is especially abundant in post-mitotic 
neurons (Skene et al., 2010). The neurological phenotype of RTT together with 
the fact that neuron-specific deletion of Mecp2 resulted in RTT-like phenotypes 
suggests that neurons are the key contributor to RTT phenotypes (Chen et al., 
2001, Guy et al., 2001). However glia lacking Mecp2 negatively affects neurons 
in a non-cell autonomous manner (Ballas et al., 2009, Maezawa et al., 2009). 
Interestingly delayed astrocyte-specific activation of Mecp2 in Mecp2-null mice 
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resulted in improved locomotion, anxiety levels and normalized the breathing 
pattern with great extension of the life span (Lioy et al., 2011). This study 
emphasises the importance of glia in both pathogenesis and reversal of RTT. In 
support of this notion is the recent study that showed the ability of bone marrow 
transplantation of WT microglia in Mecp2-null mice to arrest disease progression 
and extend the survival of Mecp2-/y mice (Derecki et al., 2012).    
In addition to targeting Mecp2 itself, genetic approaches in mice have also been 
used to explore interactions with other signaling processes in the brain. Bdnf 
(brain-derived neurotrophic factor) is a neurotrophic factor whose expression is 
proposed to be regulated by Mecp2 protein (Chen et al., 2003b, Martinowich et 
al., 2003). Neural activity leads to phosphorylation of Mecp2, which correlates 
with the transcriptional induction of Bdnf. It has been reported that Mecp2-null 
mice display lower levels of Bdnf protein and that Bdnf knockout mice also 
exhibit some of the RTT-like phenotypes including hindlimb clasping and reduced 
brain weight (Chang et al., 2006). To explore the potential involvement of Bdnf 
in RTT pathogenesis a Mecp2 and Bdnf double knock out mouse line was created 
(Chang et al., 2006). This was found to result in an earlier onset of RTT-like 
features and lethality. In contrast, Mecp2-null mice in which Bdnf is 
overexpressed resulted in a delayed onset of RTT-like signs and a significantly 
increased life span. These experiments suggest that increasing the level of Bdnf 
expression could influence the disease progression in RTT.  
1.6.2 Treatment strategies for RTT 
The demonstrated reversibility of the Mecp2 knockout phenotype in Mecp2-STOP 
mice (Guy et al., 2007), as described above, has stimulated a good deal of 
activity in exploring therapeutic approaches designed both to reverse existing 
dysfunction in RTT and to prevent its onset. In addition to the question of which 
of these two basic approaches to take therapeutically, there is also the question 
of where in the pathogenetic pathway to target the therapy. Two main 
categories of intervention suggest themselves - targeting the primary underlying 
cause (i.e. a loss of function mutation in MECP2) or targeting processes further 
downstream in the pathway. In the following sections I review the potential for 
such therapeutic approaches and describe any progress thus far.  
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1.6.2.1 Pharmacological approaches in RTT - current challenges 
Many groups have argued that identifying factors that are downstream of MeCP2 
function and targeting those pharmacologically is the most sensible approach to 
developing rational therapies in RTT. Nevertheless it is unlikely for drug 
molecules to replace the, yet unknown, function of MeCP2. The widely believed 
proposition that MeCP2 has distinct „target genes‟ whose expression becomes 
significantly aberrant in the absence of functional MeCP2 has little corroborated 
support (Skene et al., 2010). If MeCP2 truly functions to sense/interpret the DNA 
methylation signal then the action of MeCP2, or more specifically the precise 
dysfunction caused by its absence, will be uniquely dependent on the 
methylation status within a given neuronal type or indeed individual neuron. 
Moreover, the high abundance of MeCP2 together with the ubiquity of DNA 
methylation suggests that candidates for targeting its core chromatin-binding 
function therapeutically will be multiple and diverse (Skene et al., 2010). 
Furthermore, it is unclear which of the various reported changes in gene 
expression, brain neurochemistry, neuronal / synaptic morphology, cellular / 
synaptic function, and network electrical activity patterns (Pintaudi et al., 
Zhang et al., 2008, D'Cruz et al., 2010) in the RTT brain are a primary result of 
MeCP2 dysfunction and which may represent secondary effects. Identifying the 
primary molecular dysfunction in RTT and the important and tractable 
downstream changes in signaling processes remains an important challenge.  
The brain signaling pathway that has received most attention in relation to 
MeCP2 to date is the neurotrophic factor Bdnf (brain-derived neurotrophic 
factor) whose level shows consistent changes in the RTT brain (Chen et al., 
2003b, Martinowich et al., 2003). Moreover, overexpressing Bdnf ameliorates key 
symptoms in Mecp2-null mouse (Chang et al., 2006). Therefore, Ogier and 
colleagues tested the ampakine CX546, a positive modulator of AMPA receptors 
and known enhancer of Bdnf levels (Lauterborn et al., 2000) in Mecp2-null mice. 
Ampakine was able to restore normal breathing pattern and respiratory minute 
volume (Ogier et al., 2007). This study is consistent with the hypothesis that 
elevation of Bdnf level is associated with improved phenotype and supports the 
concept of targeting Bdnf signaling in RTT. Ampakine-induced Bdnf up-regulation 
was able to reverse deficits in synaptic plasticity and to improve the long-term 
memory in animal model of Huntington disease, however with no effect on the 
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impaired locomotor activity (Simmons et al., 2009). Therefore it will be 
interesting to find out whether ampakines or novel TrkB receptor ligands may 
improve other features of the Mecp2-null phenotype. 
Table 1-1 Mapping the effect of Mecp2 deletion or activation in the RTT mice models. 
Adopted from (Gadalla et al., 2011). 
Intervention
Stage: Early (prenatal/early postnatal) Late (post-onset)
Location: Neuronal 
subset
Neuronal 
subset
Neurons All CNS Global Brain-region Global Global
Objective: Prevent MeCP2 expression in 
specified cells
Deliver MeCP2 to MeCP2-ve cells Drive MeCP2 
expression in 
specified 
cells
Deliver 
Mecp2 to 
Mecp2-ve 
cells
Deliver  
Mecp2 to 
Mecp2 -ve
astrocyte
Strategy: GAD65 
promoter 
drives cre to 
delete floxed 
Mecp2 in 
GABAergic 
neurons
TH promoter 
drives cre to 
delete floxed
Mecp2 in 
aminergic
neurons
Tau-
promoter 
drives Mecp2
transgene 
expression
Nestin-cre
activates 
exogenous, 
PGK 
promoter-
driven Mecp2
by STOP 
cassette 
deletion
Tamoxifen 
re-activates 
native Mecp2
by STOP 
cassette 
deletion
Region-
specific 
promoters 
enhance 
Mecp2 in 
specific brain 
regions
Tamoxifen 
re-activates 
native Mecp2
by STOP 
cassette 
deletion
Tamoxifen 
re-activates 
native Mecp2
by STOP 
cassette 
deletion in 
astrocyte
Result: •Autistic-like 
behaviours
•↓GABA 
transmission
•↓ Motor 
function
•breathing 
problems
Prevent 
phenotype 
(Motor 
dysfunction 
etc with over-
expression)
•↑ life span
•↑ nocturnal          
activity
•↑ brain / 
body weight 
Prevent 
phenotype
•↑ survival
•↑ nocturnal 
activity
Rescue of 
Rett 
phenotype in 
symptomatic 
mice
Rescue of 
Rett 
phenotype in 
symptomatic 
mice
Refs. Chao
2010
Samaco
2009
Luikenhuis
2004
Giacometti
2007
Guy
2007
Luikenhuis
2004
Guy
2007
Lioy 2011
 
 
Another growth factor that has attracted attention is a derivative of IGF1 
(insulin-like growth factor 1). Full length IGF1 which is important in neuronal 
maturation and as a regulator of synaptic plasticity, is widely expressed in the 
brain  and its function is to regulate neuronal survival and synaptic maturation 
(Bondy and Cheng, 2004). IGF1 signaling is reduced in RTT patients as well as in 
Mecp2-null mice as a consequence of elevated levels of the IGF-binding protein 3 
(Itoh et al., 2007). The N-terminal tripeptide of IGF1 (known as GPE) has 
neuromodulatory and neuroprotective effects and administration to Mecp2-null 
mice significantly extended the survival and improved locomotor activity and 
cardiorespiratory function.  Moreover, at the cellular level, it increased PSD-95 
(a major postsynaptic density protein and synaptic marker) labelling, cortical 
spine density and the amplitude of the excitatory post synaptic currents (Tropea 
et al., 2009). Nevertheless, treated mice developed all the characteristic RTT-
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like features and died prematurely. In addition, full-length IGF1 increased the 
number of glutamatergic synapses in neurons that were differentiated from 
pluripotent stem cells taken from RTT patients (Marchetto et al.). Recombinant 
IGF1 is available as a clinical formulation and is currently undergoing initial 
phase clinical trials in RTT patients 
(http://clinicaltrials.gov/ct2/show/record/NCT01253317?term=rett+syndrome). 
1.6.2.2 Neurotransmitter systems – monoamines  
Another transmitter system that has attracted attention in RTT is the 
monoamines. Monoamines (noradrenaline, serotonin and dopamine) are 
important regulators of brainstem function whose levels have been reported to 
be decreased in brain biopsies taken from RTT patients (Brucke et al., 1987, 
Lekman et al., 1989). This reduction was also observed in Mecp2-null mice  in 
conjunction with reduced levels of the primary synthesizing enzyme tyrosine 
hydroxylase in the brain, peripheral neurons and the adrenal medulla (Viemari et 
al., 2005, Roux et al., 2008, Roux et al., 2010). In vitro application of 
noradrenaline to the brainstem of Mecp2-null mice, which displayed irregular 
rhythms, stabilized the respiratory network rhythmogenesis (Viemari et al., 
2005) suggesting a potential role of monoamine in RTT therapy. In a follow up 
experiment, administration of Desipramine (an antidepressant which increases 
noradrenaline levels by blocking its re-uptake) to Mecp2-null mice resulted in 
delayed onset of breathing abnormalities in young animals and improvement of 
respiratory phenotype (apnoeas) in symptomatic mice (Roux and Villard, 2007, 
Zanella et al., 2008). However, whilst Desipramine treatment improved 
respiratory function and extended the lifespan of Mecp2-null mice (from a 
modest increase up to double), it failed to alter growth curves or, surprisingly, 
levels of noradrenaline (Zanella et al., 2008). 
1.6.2.3 Neurotransmitter systems – glutamate 
Glutamate is the primary excitatory transmitter in the central nervous system. 
Loss of MeCP2 is associated with structural and functional changes in the 
glutamatergic synapses with consistent reduction in various forms of short and 
long-term synaptic plasticity in Mecp2-null mice brains. Neuron-to-neuron 
signaling and the neurotoxic actions of glutamate released from microglia are 
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suggested to contribute to the onset and progression of RTT (Maezawa and Jin, 
2010). Mice lacking Mecp2 show altered NMDA subunit distribution within 
glutamatergic synapses (Maliszewska-Cyna et al., 2010). NMDA receptors are key 
component of many forms of synaptic plasticity and are important in excitotoxic 
processes. Memantine is a weak non-competitive antagonist of the NMDA 
receptor and is used in Alzheimer‟s disease therapy by virtue of its proposed 
antagonism of sustained pathological activation of NMDA receptors and 
promotion of synaptic plasticity through reducing synaptic noise (Frankiewicz 
and Parsons, 1999). In a recent report, Weng and colleagues (Weng et al., 2011) 
showed that the progressive reduction in both short and long term forms of 
synaptic plasticity seen in Mecp2-mutant hippocampus can be partially reversed 
ex vivo using clinically relevant concentrations of memantine. However, when 
applied in vivo, memantine failed to show any improvement in RTT-like 
phenotypes suggesting that the improvement seen at the synaptic level is not 
reflected when considering the overall phenotype. However, it is possible that 
memantine may be useful in targeting other aspects of RTT such as the cognitive 
impairment. 
1.6.2.4 Neurotransmitter systems - GABA 
GABA (gamma-aminobutyric acid) is the major inhibitory neurotransmitter in the 
brain. The selective silencing of Mecp2 in the GABA-releasing neurons revealed 
that Mecp2 is crucial for their normal function (Zhang et al., Chao et al., 2010).  
Dysfunction of GABA signaling is suggested to mediate some of the autism-like 
behaviours as well as other RTT-like phenotypes including altered locomotor 
activity, motor function and breathing patterns (Chao et al., 2010). Previous 
report has shown that increased GABA level by using GABA reuptake blocker 
improved respiratory phenotype in Mecp2-null mice. In addition, the 
combination of GABA reuptake blocker and serotonin 1a receptor agonist 
completely rescued the breathing abnormalities in Mecp2-/+ heterozygous 
females (Abdala et al., 2010). Moreover, Pre-treatment with midazolam (a 
positive allosteric modulator of several common GABAA receptor subtypes) 
resulted in a reduction in apnoeas, that take place after hypoxic or hypercapnic 
exposure (Voituron et al., 2009), and reduction in the prolonged inspiration 
events (Voituron et al.) in Mecp2-null mice (Voituron and Hilaire). This data 
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indicates that drugs targeting GABAergic neurotransmission may be of important 
therapeutic benefits in RTT patients. 
1.6.2.5 Drugs targeting MECP2 mutations 
In addition to targeting downstream systems that are disrupted in the absence of 
functional MeCP2, another pharmacological approach would be to target, further 
upstream, the immediate consequences of the specific mutation responsible for 
the MeCP2 abnormal functions in the particular patient. Many patients carry 
nonsense mutations in MECP2 (e.g. p.R168X, p.R255X, p.R270X), which are 
associated with premature stop codons (PSCs). Agents, such as aminoglycoside 
antibiotics, which permit ribosomal read-through of PSCs during translation 
would enable production of full length functional protein (Martin et al., 1989, 
Manuvakhova et al., 2000). Aminoglycoside-induced read-through has been 
applied in some clinical applications such as Duchenne muscular dystrophy (Malik 
et al.) and cystic fibrosis (Howard et al., 1996, Bedwell et al., 1997). Based on 
these previous studies and considering the fact that up to ~40% of typical RTT 
patients with MECP2 mutations have one of the nonsense mutations (Philippe et 
al., 2006), aminoglycosides seem a promising avenue by which to achieve a 
restoration of full length functional MeCP2. In cultured cell line aminoglycosides 
were able to produce full length Mecp2 protein from cells expressing different 
type of Mecp2 nonsense mutations, e.g. R168X and R255X, however with variable 
expression levels dependent on the type of mutation and the drugs used 
(Popescu et al., Brendel et al., 2009). The low read-through efficiency together 
with the known toxicity of these drugs indicates that the currently available 
aminoglycoside drugs are unlikely to represent a new therapeutic approach. 
Nevertheless a new generation of  aminoglycoside-related compounds with 
relatively high readthrough efficiency and less toxic effect such as PTC124 
(Welch et al., 2007) and NB54 (Nudelman et al., 2009) could be more promising, 
However  little is known about the ability of these compounds to cross the BBB 
and so their likely efficiency in treating CNS disorders including RTT is unknown. 
1.6.2.6 Environmental and epigenetic factors 
Exposure to an enriched  environment (EE), by increasing social stimulation and 
increasing the complexity of housing through additional nesting material 
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(Nithianantharajah and Hannan, 2006), can delay the onset and progression of 
neurological signs in a range of disease models including models of Huntington 
disease (Hockly et al., 2002) and Alzheimer disease (Jankowsky et al., 2005). 
Moreover, EE is known to result in a number of morphological changes in the 
brain (increased cortical thickness, dendritic branching and spine density) and 
promotes neurogenesis and the production of various neurotrophic factors 
(Leggio et al., 2005). At the molecular level, EE is also known to alter the 
expression of a large number of genes (Rampon et al., 2000) and brain proteins 
(McNair et al., 2007). Clinical studies suggest that modification of the 
environment may have useful application in the management of children with 
RTT (Lotan and Shapiro, 2005). Furthermore, exposure of pre-symptomatic 
Mecp2-null mice to EE resulted in reduced motor coordination deficits and 
increased Bdnf level in Mecp2-/+ heterozygous females (Kondo et al., 2008) and 
in Mecp2-/y male mice (Lonetti et al., Nag et al., 2009). Although the exact 
mechanism by which EE influences aspects of RTT-like phenotypes is unclear. 
These results however suggest that epigenetic modulators may be a possible 
route to therapeutic intervention. In support of this notion is the recent study 
which demonstrated that RTT-like anxiety phenotypes can be mirrored by local 
administration of a histone deacetylase inhibitor (Adachi et al., 2009). Future 
discovery of new therapeutic compounds that can specifically target abnormal 
transcriptional repression may be useful in treating RTT close to the upstream 
end of the pathogenic process. 
1.6.3 RTT therapeutic strategies at the level of the gene 
1.6.3.1  Reactivation of the normal allele 
As mentioned above, MECP2 is located on the X chromosome and is subject to X 
chromosome inactivation (XCI), such that in each cell in a heterozygous female 
RTT patient expresses only the normal (thus having an MeCP2 +ve phenotype) or 
only the mutant MECP2 allele (thus having an MeCP2 -ve phenotype, in the case 
of substantial loss of function mutations), never both. This process is usually 
random and results in an approximately 50:50 mixture of cells of each type 
although ratios may vary somewhat from tissue to tissue and between 
individuals. Studies of the distribution of brain cells expressing the normal and 
mutant Mecp2 alleles have revealed that in this critical tissue Mecp2 -ve cells 
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tend not to be clustered but intermingle with the Mecp2 +ve cells in a fine-scale 
mosaic pattern (Guy et al., 2007). 
A number of studies have reported skewing of the XCI ratio away from 50:50 in 
RTT patients (Schanen et al., 1997, Knudsen et al., 2006). It is well known that 
the rare familial cases of RTT are usually explained by the fact that mothers of 
these patients carry the causative mutation but are highly skewed towards 
expression of the normal allele (Villard et al., 2001). A study investigating the 
direction and extent of skewing in sporadic RTT cases (Archer et al., 2007) found 
that most of the included patients had some degree of skewing towards 
expression of the normal allele and that the direction and extent of XCI alone 
explained approximately 20% of the variance in severity of the disorder. The 
conclusion that in several patient tissues there may be a tendency of selective 
survival advantages for MeCP2 +ve cells does need to be verified in view of the 
fact that most skewing studies have been conducted in peripheral tissues such as 
blood with much higher cell turnover and that the ratio may not be the same in 
affected brain regions. There is at least some evidence to suggest that similarly 
skewed patterns are found in brain in the mouse models however (Young and 
Zoghbi, 2004, Smrt et al., 2011).  
One strategy for delivering MECP2 to those cells expressing the mutant allele 
could be to encourage the re-activation of the inactive X to allow expression of 
the normal allele in the same cells. Results of studies conducted before the X 
inactivation process was understood suggested that simple chemical 
interventions (application of 5-azacytidine) designed to reduce genomic 
methylation levels could result in activation of X-linked genes in cell culture 
models (Mohandas et al., 1981). However, this approach is unlikely to be 
applicable. Amongst the likely problems that may be encountered are that if the 
entire inactive X is re-activated, the X-linked gene dosage problem, for which X 
inactivation evolved, will supervene and pathological levels of gene expression 
are likely to result at many loci. If the re-activation can be targeted only to the 
MECP2 locus or the immediate vicinity, that might avoid the general dosage 
problem; however, there are currently no obvious resources that can be used to 
target re-activation in this way, and neither are there any ways to target only 
those cells that have inactivated the normal allele. 
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1.6.3.2 RTT therapeutic strategies at the level of the gene - gene therapy 
Another approach at the level of the gene is gene therapy. The scope of this 
study is focusing on the potential application of gene therapy in RTT mice 
models, therefore in the next section I will give an overview on gene therapy 
principles and RTT propensity and challenges to this approach. Finally I will 
discuss possible delivery vectors that could have potential in treating RTT. 
1.7 Gene therapy 
Gene therapy is a promising approach for treating multiple disorders including 
infectious, genetic, neurologic diseases and cancer (Karlsson, 1991, Blomer et 
al., 1996). Generally this approach deploys delivering new genetic instructions 
into target tissues to compensate for aberrant or missing genes or to convey a 
new function.  Gene therapy remains the only hope of cure for many patients 
with inherited and acquired diseases that cannot be treated with conventional 
methods, e.g. drugs, recombinant proteins or transplantation. Gene therapy for 
genetic disorders provides treatment at the molecular level to fix the primary 
underlying cause of the disorders instead of tackling variable secondary effects.  
1.7.1 Types of gene therapy 
Gene therapy of the monogenic disorder comprises two main types; the first is to 
introduce new genetic material (transgene) into germ cells (sperms or ova) to fix 
an inherited genetic disorder allowing the transgene to eventually pass to any 
future offspring. This type of therapy has many ethical problems and has not 
implemented so far. The second type involves introducing the transgene into 
somatic cells to restrict the transgene action only to the treated patient without 
subsequent inheritance. Thus somatic gene therapy is similar to other 
conventional pharmacological interventions. The therapeutic transgene could be 
applied to somatic cells by ex vivo or in vivo methods. The ex vivo method 
includes transfecting target cells in vitro with the gene of interest followed by 
re-implantation of transfected cells, however this approach is limited by the 
accessibility of the target organs/cells. In vivo approaches include direct 
delivery of the transgene to target cells by systemic or local application which 
requires a vehicle to facilitate gene delivery.  
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Essential requirements should be fulfilled in a given disorder to be a candidate 
for gene therapy such as; identification of the underlying genetic defect, 
presence of a correcting gene, availability of vehicles or vectors and suitable 
method of delivery to transduce target tissues or cells (Nathwani et al., 2004). 
Therefore the success of gene therapy is dependent on the ability of a vector to 
deliver the transgene to the target cells at efficient levels. Gene transfer to 
somatic cells can be achieved through using non-viral or viral vectors. 
1.7.1.1 Non-viral methods 
These methods involve either direct introduction of the naked plasmid DNA into 
the target cells, by gene gun (Yang et al., 1990) or electroporation (Rols et al., 
1998), or encapsulating the DNA within an artificial lipid sphere with an aqueous 
core (liposome) that is capable of transferring therapeutic DNA through the 
target cell`s membrane (Felgner et al., 1987). These methods are simple and 
easy to produce with reduced toxicity, however they are less effective for in 
vivo transgene delivery and usually mediate Relatively short term gene 
expression (Li and Huang, 2000)  
1.7.1.2 Viral vectors 
Sustained transgene expression is needed for the treatment of many diseases. 
Viruses have developed a way of encapsulating and delivering their genome to 
human cells in a pathogenic manner, therefore especial attention has been paid 
to viral vectors. Recombinant viral vectors are designed to replace the disease-
causing- and replication-responsible genes with a transgenic cassette containing 
the gene of interest and an appropriate promoter. An ideal vector for gene 
delivery should be capable of entering target cells and transferring the 
transgenic cassette to the host nucleus (with or without integration into the host 
genome) as well as conveying enduring expression with minimal induced-
toxicity. The number of viruses whose genomes can be manipulated to generate 
viral vectors are steadily increasing and include; retroviruses, adenoviruses, 
adeno-associated viruses and herpes simplex virus (Hermens and Verhaagen, 
1998). Each specific vector group has its own advantages and disadvantages for 
human gene transfer. For example adenoviruses transduce cells very efficiently 
and have a large cloning capacity but they also strongly trigger the host-immune 
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response and produce transient gene expression. Retroviruses despite producing 
enduring gene expression are unable to transduce non dividing cells (with the 
exception of lentiviruses). Adeno-associated viruses convey long-term expression 
and do not activate the immune system, however they have a very limited 
cloning capacity (Walther and Stein, 2000). 
1.7.2 Gene therapy application for RTT 
1.7.2.1 RTT Propensity to gene therapy 
As previously described, Rett syndrome is caused mainly by dysfunctional 
mutations in the MECP2 gene whose encoding sequences, isoforms and resultant 
protein products are well studied. The lack of effective conventional therapeutic 
approaches and a lack of understanding of the downstream effects of MeCP2 
highlight the importance of tackling this disorder at the genetic level. This, 
along with the reported phenotype reversibility of RTT-like phenotypes in Mecp2 
knockout mice models makes RTT an attractive candidate for gene therapy. The 
major objective of this therapy will be to deliver a working copy of MECP2 to as 
many affected brain cells) as possible to raise function (at both molecular and 
cellular level) above a threshold required for improvement of the clinical 
picture. A preliminary attempt to use adenovirus to deliver a construct driving 
Mecp2 expression in the striatum of Mecp2-null mice reported decreased motor 
deterioration and restoration of voluntary motor activity (Kosai, 2005). However, 
this study has never been followed up, reported in detail or repeated. Rastegar 
and colleagues (Rastegar et al., 2009) demonstrated the potential for lentiviral 
transgene delivery to improve the phenotype of Mecp2-null neurons derived from 
neuronal stem cells in culture. These neurons displayed increased dendritic 
growth and branching than non-transduced controls. The same authors also 
showed the endogenous Mecp2 promoter to be a sensible choice in driving cell 
type-appropriate expression thus avoiding overtly ectopic patterns of expression. 
1.7.2.2 Challenges for gene therapy application for RTT 
 However encouraging these results are, there are many challenges to overcome 
for this approach to be successful including; finding an appropriate vector, 
transducing sufficient cells, avoiding transgene repression and avoiding 
overexpression of exogenous MeCP2 in the mosaic female brain.  
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Whilst MeCP2 is expressed throughout the body, particular attention has been 
directed to the brain as brain-specific deletion in a mouse model resulted in a 
RTT-like phenotype whereas brain-specific expression of MeCP2 prevented/ 
rescued RTT-like phenotypes in RTT mice models. MeCP2 functioning in a mainly 
cell-autonomous manner, therefore MeCP2 has to be expressed in each 
individual cell for proper cellular function. In addition, a recent study showed a 
positive correlation between the degree of phenotype rescue and the number of 
cells expressing endogenous Mecp2 after being activated in RTT mice models 
(Robinson et al., 2012). Given that the RTT phenotype results from effects on 
post-mitotic neurons with long lifespans and cannot simply be fixed by delivery 
of cells with the right characteristics into the tissue, it is clear that if gene 
therapy is to work it will have to involve in vivo delivery, which is not a trivial 
undertaking. The current lack of viral vector that can achieve widespread 
delivery of Mecp2 transgene across the BBB with transduction efficiency capable 
of producing therapeutic benefits represents one of the major hurdles for 
meaningful gene therapy application for RTT. However several groups are 
actively developing such tools for delivery of genes encoding MeCP2, particularly 
for use in the mouse models described above, but to date there are no reports 
that viral vector-based delivery of Mecp2 to the brain of Mecp2-null mice can 
rescue any aspects of the RTT phenotype.  
Maintaining MeCP2 expression levels within a physiological level is important for 
normal function and is one of the more difficult challenges. It has been shown 
that elevated levels of MeCP2 may be detrimental, since patients with 
duplication of Xq28 in regions spanning the MECP2 locus show a range of 
neurological features including altered head growth rates, ataxia, seizures and 
mental retardation (Meins et al., 2005, Van Esch et al., 2005, Friez et al., 2006). 
Similarly, mice overexpressing Mecp2 show behavioural changes. While mice 
with modest overexpression of MeCP2 show motor coordination impairment, 
cognitive deficits and anxiety-like phenotype (Collins et al., 2004, Na et al., 
2012), mice expressing higher (2-4) fold levels of Mecp2 in neurons display 
tremors and motor dysfunction (Luikenhuis et al., 2004). In the mouse Mecp2 
reactivation study (Guy et al., 2007) it was assumed that removal of the STOP 
cassette would not have a large effect on later expression levels of Mecp2 driven 
by its endogenous promoter and regulatory elements and that expression would 
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effectively be at WT levels in each rescued cell. Gene therapy approaches will 
therefore have to deliver an extra copy of MECP2 to each cell that becomes 
transduced, while avoiding a significant multiplicity of infection, which could 
lead to large numbers of cells overexpressing MeCP2 at high levels. Even in cells 
transduced by a single virus particle and expressing MeCP2 from a single extra 
copy of the gene, the fact that female patients (and heterozygous mice) are a 
mosaic of MeCP2 expressing and non-expressing cells due to X-inactivation itself 
causes problems. Virus particles delivering Mecp2-expressing constructs to cells 
expressing the mutant allele are unlikely to cause problems, but those delivering 
constructs to cells expressing the WT allele could cause overexpression.  
Two strategies to avoid overexpression-induced toxicity in the female cellular 
mosaic network of Mecp2 expression have been devised. In one strategy, the 
construct itself is designed in such a way that pre-existing expression of MeCP2 
leads to the transgene not being expressed. One potential means for doing this is 
to design a highly efficient MeCP2 binding target into the promoter driving 
transgene expression in the hope that this would stimulate heterochromatin 
formation and long-term repression of the transgene. In cells expressing the 
mutant allele, this shutdown would not occur until sufficient transgenic MeCP2 
had built up in the cell to produce a negative feedback effect on its own 
expression. The other strategy, employed by (Zhou et al., 2006), is to design a 
construct that includes an agent that will suppress endogenous MeCP2 expression 
while leaving the transgene to do its work. A polycistronic construct 
incorporating a siRNA that will suppress both WT and mutant MeCP2 translation 
from endogenous mRNA was designed. Base changes in the sequence of the 
MECP2 transgene in the same construct ensured that translation of the mRNA 
from exogenous Mecp2 transgene was not suppressed. Both these approaches can 
be seen as varieties of the „suppression and replacement‟ strategy currently 
being developed for a range of dominant disorders, but modified for use in 
relation to an X-linked gene.  
Based on the previous challenges, the development of an appropriate vector for 
gene delivery is the success limiting step in any future attempt for gene therapy 
application in RTT. Therefore in the next part of this chapter, I will discuss the 
characteristic features, advantages and disadvantages of Lentivirus- and Adeno-
associated virus-based vectors as potential tools for Mecp2 gene delivery. 
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1.8 Lentiviruses 
Lentiviruses include a range of primate (e.g. human immunodeficiency viruses 
[HIV-1 and 2], and simian immunodeficiency viruses [SIV]) and non-primate 
viruses (e.g. feline immunodeficiency virus [FIV] and equine infectious anemia 
virus [EIAV],) viruses. Lentiviruses are very attractive tools for gene therapy due 
to; (1) the ability to integrate into the host genome and produce enduring gene 
expression (Trowbridge et al., 1980); (2) the relatively large cloning capacity 
that makes these vectors suitable for application in many disorders (where large 
gene transfer is required); (3) the ability to transduce dividing and  non-dividing 
cells (e.g. neurons, hepatocytes and myocytes); (4) the ability to produce 
transgene expression with a minimal immune response (Walther and Stein, 
2000). 
The lentivirus genome is composed of structural, regulatory and accessory genes 
flanked by two long terminal repeats (LTRs). The structural genes are; (1) gag, 
which produces three proteins; Matrix, capsid and nucleocapsid (figure 1-4). 
These proteins are important for virion assembly and maturation; (2) pol gene, 
which produces enzymes responsible for replication and integration to the host 
genome (protease, reverse transcriptase and integrase); (3) env gene, which 
encodes for the glycoprotein envelope that is essential for viral binding and 
entry into the host cells. The genome also encodes some regulatory proteins 
such as Rev, which is responsible for nuclear export of mRNAs that encode the 
viral structural protein, and Tat protein, which regulates post transcriptional 
elongation of viral mRNAs (Wei et al 1998). Another group of genes includes; vif, 
vpr, vpu and nef. Proteins encoded by these genes are not essential for virus 
replication and are therefore called accessory genes (Zufferey et al., 1997). 
1.8.1 Lentivirus-based vectors 
The preliminary design of replication incompetent lentivirus-based vectors is 
based on isolation of the cis-acting elements in virus genome (non-coding region 
necessary for vector RNA synthesis, packaging, reverse transcription, and 
integration) in one plasmid (vector cassette) whereas the trans elements 
encoding enzymatic, structural, and accessory proteins are incorporated in 
another plasmid, packaging cassette, (Naldini et al., 1996b). The envelope 
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encoding sequences are contained in a third separate vector (envelope 
cassette). Viruses production is carried out by concomitant transfection of 
human embryonic kidney cells with the three plasmid cassettes followed by virus 
collection and concentration (detailed virus production protocol is discussed in 
chapter 2).  
 
 
Figure 1-4 Genomic structure of WT lentiviruses. 
(a) Representative diagram showing genomic structure of the lentivirus. Lentivirus genome 
consists of 3 structural genes (gag, pol and env), regulatory genes (tat and rev) and 
accessory genes (not shown) flanked between two LTRs. (b) representative diagram of 
lentivirus particles showing the main structural proteins; env, matrix, capsid and 
nucleocapsid encapsulating 2 single stranded virus RNA. LTR; long terminal repeat. 
  
1.8.1.1 The vector cassette  
The lentivirus-based vector cassette encodes the full-length vector RNA which 
contains all cis-acting elements and the transgene expression cassette (includes 
the heterologous promoter and the transgene of interest, figure 1-5a). The cis-
elements include (1) 3`LTR and 5`LTR that helps nuclear localization and 
integration into the host genome as well as acting as a promoter (Toyama et al., 
1992); (2)  5` UTR which contains the primer binding site (PBS), splice donor 
site, packaging signal, rev-response element (RRE), and splice acceptor; and (3) 
a 3` UTR containing a poly purine tract (PPT) and the 3` LTR.  
a 
b 
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1.8.1.2 The packaging cassette 
The packaging cassette of the lentivirus-based vector encodes all trans-elements 
(expressed from gag and pol genes), which involve structural and enzymatic 
proteins required for vector particle production and transduction of target cells. 
The initial packaging cassette (first generation vector) retained all structural 
proteins, except Env, together with the accessory proteins (Naldini et al., 1996a, 
Naldini et al., 1996b). However the structure of this cassette has been further 
modified to increase the biosafety of lentivirus-based vectors.  
1.8.1.3 The envelope cassette 
The parental lentivirus envelope protein restricts the viral tropism to CD4 
receptor-expressing cells. In order to increase lentivirus tropism, the parental 
envelope was substituted with vesicular stomatitis virus G protein (VSV-G) 
(Akkina et al., 1996) which extends the vector tropism to include many cell 
types in vitro and in vivo. Moreover the VSV-G envelope helps stabilization of 
the vector particles, thus enabling vector concentration by ultracentrifugation. 
In addition, it directs vector cellular entry to an endocytic pathway that 
compensates for the absence of the viral accessory proteins (Aiken, 1997). 
However the presence of complement and antibody mediated immune response 
against the VSV-G envelope decreases the efficiency of systemic administration 
of VSV-G- pseudotyped lentivirus-based vectors (DePolo et al., 2000). 
Pseudotyping lentivirus-based vectors with envelope proteins other than VSV-G, 
e.g. Rabies virus glycoprotein, allow peripheral administration of the virus with 
axonal retrograde spread to the central nervous system (Mazarakis et al., 2001, 
Mentis et al., 2006). 
Packaging of the vector cassette (transgenic cassette flanked by 2 LTRs, figure 
1-5a) to the viral proteins occurs in human embryonic kidney cells with 
subsequent viral assembly and release to the culture media. These virus 
particles are capable of transferring the expression cassette to target cells in 
vitro and in vivo. Lentivirus cellular entry starts by binding of the envelope 
glycoprotein to a specific receptor (which defines the viral tropism) on the cell 
membrane (Maddon et al., 1988). The viral membrane then fuses with the 
cellular membrane with disassembly of matrix and capsid proteins and 
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subsequent delivery of nucleoprotein complex (nucleocapsid-binding viral 
genome) inside infected cells (figure 1-5b). In the cytoplasm of the host cell, 
single stranded viral RNA is converted to linear double-stranded DNA by reverse 
transcription. Viral integrase facilitates permanent integration of the double-
stranded DNA to the host genome (Sakai et al., 1993). Transcription from the 
provirus (integrated virus genome) results in production of mRNA transcripts that 
encode for the gene of interest and lack all virus structural genes. These lenti-
virus based vectors are therefore considered replication incompetent. 
1.8.2 Biosafety of lentivirus-based vectors 
The ultimate aim of transgene delivery with lentivirus-based vector is to achieve 
transduction events without disturbing normal function of the transduced cell. 
However many potential hazards could emerge from this transduction, such as; 
insertional mutagenesis and generation of replication competent lentivirus. 
Several methods are deployed to reduce the potential risk of insertional 
mutagenesis such as the use of zinc finger technology (Bibikova et al., 2001) to 
direct the insertion of lentivirus based vectors to a specific site in the genome or 
the  development of a non-integrating lentivirus-based vectors, in which the 
vector persists as an episome without integration into the host genome. 
Interestingly, the non-integrating vector achieved stable expression in non-
dividing cells (Rahim et al., 2009). To decrease the risk of generation of 
replication competent virus, the structure of the packaging cassette was 
modified by deletion of all accessory genes, important for virus replication in 
vivo, except Tat and Rev Proteins (Zufferey et al., 1997). To augment vector 
biosafety, the Tat encoding gene was deleted from the packaging cassette with 
further split of gag/pol and rev into two separate plasmids (Dull et al., 1998). 
This constitutes the third generation vector in which the risk of the virus 
becoming replication competent is reduced by increasing the minimal number of 
recombination events necessary for generation of replication competent vector 
to three, thus substantially increasing biosafety. A further modification involves 
a deletion in the downstream long terminal repeat (LTR) which, after 
transduction, leads to transcriptional inactivation of the upstream LTR and 
considerably reduces the risk of vector mobilization and recombination, self-
inactivating design,(Zufferey et al., 1998, Bukovsky et al., 1999). 
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Figure 1-5 Lentivirus-based vector, structure and transdcution. 
(a) Representative diagram showing structure of lentivirus-based vector. The transgene 
cassette (promoter and gene of interest) are flanked by the 2 LTRs. (b) Representative 
diagram showing the steps of lentivirus transduction; (1) virus entry, (2) release of the 
provirion to the cytoplasm of infected cells, (3) formation of the complementary DNA strand 
by reverse transcriptase, (4) formation of double stranded DNA, (5) nuclear localization and 
integration to the host genome, (6) transcription of the lentivirus mRNA and (7) transgene 
expression. 
 
1.8.3 Application of lentivirus-based vectors in neurological 
disorders and its tractability in RTT. 
Lentivirus-based vectors are attractive tools for treating several disorders 
including; genetic and metabolic disorders as well as various forms of cancer. 
This is in part, because of their ability to transduce a wide range of tissues 
including the CNS, kidneys, muscle, heart and hematopoietic system. Transgene 
delivery to the CNS by lentivirus is particularly challenging as it requires invasive 
surgical methods/intervention to achieve direct CNS delivery. Despite the 
requirement to deliver into what is an extremely delicate structure, the 
enduring nature of lentiviral transgene expression nevertheless avoids the 
necessity for repeated administration. 
a
v
b
v
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Lentivirus-based vectors have been extensively used in preclinical trials to 
investigate their potential for treating neurological disorders. For instance, 
lentivirus-mediated delivery of tyrosine hydroxylase, aromatic L-amino acid 
decarboxylase, and guanosine 5'-triphosphate cyclohydrolase 1 in the striatum 
improved motor deficits in an animal model of Parkinson (Jarraya et al., 2009). 
In the same context, lentivirus-mediated delivery of ciliary neurotrophic factor 
prevented striatal degeneration in a rat model of Huntington disease (de 
Almeida et al., 2001). Another study showed the ability of lentivirus 
pseudotyped with the rabies virus glycoprotein coat to deliver survival motor 
neuron 1 protein  into the lower motor neurons in an animal model of spinal 
muscular atrophy with subsequent improvement of the motor activity and 
extended survival (Azzouz et al., 2004b).  
Lentivirus-based vectors meet most of the criteria required for Mecp2 gene 
delivery in RTT (table 1-2). Firstly, Mecp2 can be easily cloned into a lenti-
vector backbone, with sufficient space left for large or complex promoters (e.g. 
GFAP), to drive cell-type specific expression of Mecp2. The vector also benefits 
from a relative ease of particles production and the generation of high titre 
preparation. Secondly, Lentiviruses are able to transduce both neurons and glia 
which are the main contributors to RTT pathogenesis. Thirdly, Lentivirus 
integrates into the host genome providing stable long-term transgene expression 
(Bienemann et al., 2003) and with a low incidence of transgene repression (Lois 
et al., 2002). This is critical in RTT as Mecp2 is necessary for the normal function 
of adult neurons (McGraw et al., 2011). Other attractive features of lentivirus 
based vectors are that they (independent of insert) do not alter the 
electrophysiological properties of transduced cells (Dittgen et al., 2004), and 
they elicit a minimal immune response both in the brain and systemically 
(Abordo-Adesida et al., 2005). One important limitation of lentivirus-based 
vectors is that they cannot pass the blood brain barrier (BBB). This means that 
any brain delivery attempts will involve direct brain injections which are not 
practical as there is only limited spread of viral particles from the injection site 
but global expression of Mecp2 in the brain is required. A previous study showed 
lentivirus-based vectors were able to deliver exogenous Mecp2 into neurons in 
culture with a pattern of expression similar to endogenous Mecp2 (Rastegar et 
al., 2009). However, the functional consequences of this expression have not 
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been evaluated. Lentivirus could still be useful for local Mecp2 delivery to the 
brain to investigate potential rescue of brain region-specific phenotypes.  
Table 1-2 Comparison between lentivirus- and AAV-based vectors as a potential tools for 
Mecp2 delivery 
  
Lentiviruses 
 
 
Adeno-associated 
viruses serotype 9 
(AAV9) 
 
Type of cells transduced 
 
Both can transduce dividing and  non-dividing cells 
with high efficiency 
Ability to accommodate 
Mecp2 
Mecp2 encoding sequences (1500 bp) is within the 
cloning capacity of lenti vector (8,000 bp) and 
Adeno-associated virus (4,600bp) 
Particle Size ~100-120nm 22-25nm 
Ability to cross the BBB Cannot pass BBB  
Efficiently cross BBB 
after IV administration  
Viral tropism in the 
mouse brain 
Transduce mainly 
neurons but also glia 
 
Transduce mainly 
neurons (neonatal 
injection) and both 
neurons and glia (adult 
injection)  
Advantages 
 Integrate into the host 
genome (may be 
undesirable) 
 Long-term expression  
 Minimal immune 
response 
 
 Accessible method of 
delivery (IV) 
 Minimal risk of 
insertional mutagenesis  
 Widespread after local 
or systemic 
administration 
 
Disadvantages 
 
 Potential for insertion 
mutagenesis 
 Limited spread after 
focal application 
 limited application 
approaches/need for 
invasive CNS delivery 
 
 Relatively short term 
expression  
 Limited cloning 
capacity 
 Variable immune 
response stimulation 
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1.9 Adeno-associated virus 
Adeno-associated virus (AAV) is a small (22-25 nm), nonenveloped virus. It is a 
member of the family parvoviridae and classified as a dependovirus because it 
requires the presence of helper virus in order to replicate (Daya and Berns, 
2008). The majority of humans are seropositive for AAV infection which in the 
absence of helper virus can establish latency by site-specific integration into 
chromosome 19q13.4 (Kotin et al., 1992). The effectiveness of AAV as a vehicle 
for gene therapy comes from; (1) the ability to transduce dividing and non-
dividing cells; (2) wide range of cellular tropism; (3) low immunogenicity; (4) 
stable transgene expression and (5) absence of disease production in humans 
(McCarty et al., 2004). 
The AAV/2 genome is the most studied AAV serotype and all AAV-based vectors 
developed so far are based on AAV/2 backbone. It comprises a linear, single-
stranded DNA of 4.7 kb (Srivastava et al., 1983). The structure of the genome is 
composed two inverted terminal repeats (ITRs) flanking two open reading fames 
(ORF) (figure 1-6a). ITRs are the origin of replication and act as a priming site 
for synthesis of the complementary strand by DNA polymerase. Moreover they 
are also involved in AAV genome packaging, transcription and site-specific 
integration (Daya and Berns, 2008). The left ORF contains the Rep (replication) 
gene that encodes four Rep proteins, Rep78, Rep68, Rep52 and Rep40. Rep78 
and Rep68 are produced under the control of the P5 promoter and act as 
regulatory proteins and are essential for virus replication (Pereira et al., 1997). 
Rep52 and Rep 40 are produced under the control of the P19 promoter and are 
responsible for the accumulation of single-stranded viral DNA used for packaging 
inside AAV capsids. The right ORF contains the Cap (capsid) gene (figure 1-6a) 
that encodes for three capsid proteins (VP1, VP2 and VP3 in 1:1:10 molar ratio) 
and are produced under the P40 promoter (Grieger and Samulski, 2005a). 
1.9.1 AAV-based vector transduction 
In the current AAV based vector (figure 1-6b), the encoding sequences for cap 
and rep are replaced by the transgene cassette (the promoter and the gene of 
interest) flanked by the two ITRs (vector cassette) that constitute the cis signal 
essential for packaging and priming for generation of the second strand 
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(Samulski et al., 1982, Schnepp et al., 2005). Other posttranscriptional 
regulators are also included to control transgene expression. The packaging 
cassettes are split into two plasmids, one to supply the encoding sequences for 
rep and cap genes and the other to provide the adenovirus helper genes (E4, VA 
and E2A). Production of the virus is accomplished by triple transfection of human 
embryonic kidney cells with  the vector and packaging cassettes as described in 
chapter 2 (Gray et al., 2011a).  
 
Figure 1-6 Genomic structure of the WT AAV and AAV-based vector. 
(a) Representative figure showing the genomic structure of AAV wild-type virus. Two main 
structural genes, rep and cap flanked by two ITRs. Different rep and cap transcripts 
produced from their respective promoter (P5, P19 and P40, arrows). (b) Structure of AAV-
based vector in which the expression cassette replaced rep and cap genes and still flanked 
by the 2 ITRs. PA; polyadenylation signal, ITR; inverted terminal repeat. 
 
AAV cellular entry starts by the virus binding to heparan sulfate proteoglycan 
receptors on the cell surface (Summerford and Samulski, 1998), followed by viral 
internalization inside the cells (figure 1-7). Afterwards, AAV virus is either 
engulfed by endocytic vesicles and cleared or escapes these endocytic vesicles 
and achieves successful infection (Duan et al., 1999). Intracellular trafficking of 
AAV using microtubules is further enhanced by cellular signaling such as RAC1 
and phosphotidylinsitol 3-kinase pathway activation (Sanlioglu et al., 2000). The 
mechanism of directed nuclear transport of AAV particles is not clear. However 
it could be mediated through a nuclear pore complex- dependent /or 
independent mechanisms (Hansen et al., 2001). For successful transgene 
expression the single stranded DNA packaged in the AAV vector must be 
converted to a double stranded DNA. The generation of the second strand of DNA 
is accomplished either by; de novo synthesis of the second strand or by strand 
a 
b 
59 
 
annealing (SA) of complementary  strands from two infecting viruses (figure 1-7, 
(Nakai et al., 2000). AAV packages either the plus or minus DNA strand with 
equal efficiency (Berns, 1990). However precluding the SA pathway (by 
packaging ssAAV by either positive or minus strand only) showed no impact on 
the transduction efficiency of ssAAV indicating de novo synthesis play a major 
role in second strand synthesis during vector transduction (Zhong et al., 2008). 
Inside the nucleus the rAAV genome requires synthesis of the complementary 
strand to start gene expression. Failure of AAV transduced cells to achieve 
transgenic expression is mainly due to their inability to generate the 
complementary strands and this is therefore considered as a rate limiting step in 
the AAV vector transduction process (Miao et al., 2000). 
 
1.9.2 Self-complementary AAV 
The key steps in rAAV transduction process are virus trafficking to the nucleus 
and second–strand generation (Ferrari et al., 1996). Generation of the second 
strand is followed by a transient period of genome instability that compromises 
gene expression (Wang et al., 2007). Two of these critical steps can be 
circumvented by packaging AAV with both strands (sense and non-sense) as a 
single molecule to form self-complementary AAV (scAAV). This enables the two 
complementary strands to produce a dimeric inverted repeat genome (Carter et 
al., 1972). scAAV vectors display a substantial increase in transduction efficiency 
and in the speed of onset of transgene expression compared to ssAAV vectors 
(McCarty et al., 2001). The relatively low transduction efficiency observed in 
ssAAV is because some of the transfected cells are not competent to generate 
the secondary strand which is mandatory for gene expression. In contrast, the 
formation of the second strand is independent of the host-cell DNA synthesis in 
scAAV (McCarty et al., 2001). scAAV vector also displays rapid onset and an 
approximately 15 fold increase in transgene expression compared to the ssAAV 
(Ren et al., 2005). The limiting factor for extensive applications of scAAV in the 
field of gene therapy is the reduction of the cloning capacity to approximately 
half that of the ssAAV vector.  Despite this drawback scAAV still has the 
potential to be useful in a number of applications and this limitation can be 
partially overcome through reduction/optimization of the size of promoter and 
transcription regulatory elements  (Wu et al., 2008) and by using AAV capsids 
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that can accommodate inserts with larger genome sizes, e.g. capsid 5, (Grieger 
and Samulski, 2005b). 
 
 
Figure 1-7 AAV-based vector transduction. 
Representative diagram showing the transduction of AAV-based vector; (1) virus binding to 
heparin sulphate proteoglycan, (2) virus endocytosis to the early endosome followed either 
by (3) maturation to late endosome and degradation or (4) escape early endosome and (5) 
translocation to the nucleus. (6) in the case of ssAAV (green circles), the single stranded 
DNA must be converted to double stranded DNA either by de novo synthesis (6a) or strand 
annealing between plus and minus strands (6b) followed by (7) transcription of the 
transgene. Whereas, in the case of scAAV (red circles), once inside the nucleus it can 
bypass 2
nd
 strand synthesis via intramolecular annealing and start transcription faster than 
the ssAAV vector. HSPG; heparin sulphate proteoglycan, ssAAV; single stranded Adeno-
associated virus, scAAV; self-complementary Adeno-associated virus. 
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1.9.3 AAV capsids 
Despite the extended infectivity of the AAV2 capsid in many tissues and cells, 
certain cells still cannot be infected with AAV2 (Gigout et al., 2005). The use of 
different AAV serotypes in a pseudo-typing approach (the genome of one ITR 
serotype being packaged into a different serotype capsid) has allowed extended 
tissue tropisms. Analysis of the difference in transduction efficiency and 
expression levels between AAV capsids 1-9 revealed that AAV virus pseudotyped 
with capsid 7 and 9 displayed the highest expression levels whereas the quickest 
onset of expression was achieved by AAV capsids; 1, 6, 7, 8 and 9. Among all 
investigated capsids, AAV capsid 9 showed the best viral genome distribution and 
the highest protein levels (Zincarelli et al., 2008). Another study showed the 
high transduction efficiency of AAV capsid 8 and 9 in the liver, skeletal muscle, 
pancreas after IV injection with additional relatively high cardiac tropism for 
AAV9 virus (Inagaki et al., 2006). 
Gene delivery to the CNS is very challenging due to the presence of the BBB 
which impedes large drug molecules, many proteins and viruses from passively 
crossing into the brain. The BBB is an important element to protect the brain 
from different pathogens and toxin. However, in doing so it also, represents a 
barrier for many viral-based gene delivery applications. Gene delivery to the 
brain has been accomplished through direct brain injection of the vector to the 
target area, both in animal and in human studies. However, this approach is very 
challenging and may require more than one injection site to produce a 
therapeutic effect. In addition, transient disruption of the BBB using 
hyperosmotic drugs such as mannitol permits gene delivery to the brain using 
small-sized vector (McCarty et al., 2009).  Recently AAV capsid 9 has emerged as 
a potential vector for gene delivery to the brain after peripheral injection and 
this can be achieved without the necessity for disrupting the BBB (Duque et al., 
2009, Foust et al., 2009). This ability to transduce the CNS was further improved 
by the generation of the scAAV9 vector, which is 10-100 time more efficient than 
the ssAAV9 vector (Gray et al., 2011c). Therefore this scAAV9 vector has been 
the focus of several studies to determine the transduction efficiency and cell-
type specific tropism after different routes of administration. 
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Foust and colleagues showed that peripheral administration of scAAV9 to 
neonatal mice transduces mainly neurons however adult peripheral injection 
produces mixed glia and neuronal transduction (Foust et al., 2009). The authors 
explained this age-dependent differential cell tropism to be due to the presence 
of a fully developed BBB in adult mice that relatively increases the exposure of 
glia, but not neurons, to the virus through the astrocyte-foot processes. In 
contrast, the neuronal tropism in neonates is probably due to the undeveloped 
nature of the BBB at this age which allows the virus to spread throughout the 
brain. Saunders and colleagues disagree with the previous explanation because 
the BBB is fully functional in neonatal mice and they attribute the neuronal 
tropism in neonates to the low number of glia relative to neurons in the 
developing brain at this time point (Saunders et al., 2009). Nevertheless these 
results disagree with a recent study that showed high glial transduction after 
peripheral injection of scAAV9 in neonatal mice (Rahim et al., 2011). Moreover a 
recent quantification study in the rodent brain showed that adult peripheral 
injection of scAAV9 could also produce high neuronal transduction (2X glial 
transduction; (Gray et al., 2011c). Interestingly the same study showed that 
peripheral injection of scAAV9 virus in non-human primates resulted in limited 
brain transduction and decreased neuronal transduction. However it is not clear 
whether the reduced transduction efficiency in the brain is a dose-dependent 
effect and whether it can be augmented by dose modification.  
1.9.4 Clinical applications and potentials in RTT 
The recent advances in vector /capsid design of the Adeno-associated virus-
based vectors has led to extensive preclinical and phase 1 clinical studies to 
implement these vectors in the treatment of various human diseases (Warrington 
and Herzog, 2006).  Published data from recent human clinical trials has shown 
AAV-based vectors to produce significant therapeutic effects in the treatment of 
cystic fibrosis (Wagner et al., 1998, Moss et al., 2004) and Hemophilia B (Kay et 
al., 2000, Manno et al., 2003). However these trials have also uncovered some 
restrictions to the current vectors including; limitations in the biological effect, 
immune response stimulation, induction of liver transaminases, and inefficient 
transduction of progenitor cells. Many CNS disorders are being tested for 
potential AAV mediated gene therapy, including; amyotrophic lateral sclerosis 
(Azzouz et al., 2000, Kaspar et al., 2005), spinal muscular atrophy (SMA) (Valori 
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et al., 2010), Huntington disease (McBride et al., 2003, Kells et al., 2004), 
lysosomal storage disorders (Sferra et al., 2004), Parkinson`s disease (Eslamboli 
et al., 2005, Feigin et al., 2007) and Canavan`s disease (Klugmann et al., 2005).  
AAV is very promising in the case of RTT gene therapy (Tables 1-1) as; it can 
cross the blood-brain barrier, especially pseudo-typed with AAV9 capsid (Foust 
et al., 2009), infect neurons efficiently, mediate long-term transgene expression 
(Herzog et al., 1997, Arruda et al., 2005, Jiang et al., 2006) and does not 
integrate in a random fashion into host chromosomes (the vector DNA usually 
persisting as an episome in the nucleus) with accompanying safety benefits 
(Duan et al., 1998, Nakai et al., 2001). In spite of achieving high neuronal 
transduction, great attention has to be given to the transcription levels of Mecp2 
as overexpression is predicted to be detrimental. On the other hand, the 
disadvantages of this vector include immune system stimulation and potential 
issues of the endurance of transgene expression over the long term.  
Summary and aims 
Rett syndrome is not uncommon neurodevelopmental/ maintenance disorder 
that occurs mainly in girls and is characterized by neurological, motor and social 
disabilities. Dysfunctional mutations in MECP2 gene are responsible for > 95% of 
typical RTT cases and also implicated in other neurological conditions. Mice 
models of RTT have been invaluable tools to help understand the underlying 
pathological changes occurring in RTT at the cellular and molecular levels and 
help to evaluate the efficacy of possible therapeutic interventions. The observed 
phenotype reversibility shown in these mice models, after reactivation of 
endogenous Mecp2, highlights the potentials for treating and or preventing RTT 
in patient. There is no current curative treatment for RTT and the exact 
function of Mecp2 and its downstream effects is not clear. For these reasons, 
therapeutic intervention at the Mecp2 gene level either by reactivation of the 
inactive X chromosome, which contains a normal Mecp2 allele or by viral-
mediated delivery of exogenous copy of normal Mecp2 offer attractive possible 
strategies. Lentivirus- and AAV-based delivery systems have been shown to have 
good potentials for introducing various transgenes to the CNS and suggest a 
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possible application for these vectors in delivering exogenous as a first step to 
developing gene therapy strategies in RTT models. 
Therefore the main aim of my PhD is to investigate the potential of gene therapy 
in RTT by investigating the viral-mediated delivery of MECP2 in genetic mouse 
models of RTT. Specific goals were as follows: 
1 To develop lentivirus-based vectors with various promoters and tag 
epitopes to enable in vitro and in vivo expression of exogenous Mecp2. To 
further examine the transduction efficiency, pattern and levels of 
transgenic Mecp2 expression and to ascertain the phenotypic 
consequences that result.  
2 Investigating the potentials of ssAAV9-based vector mediated delivery of 
MECP2 in modifying the trajectory of RTT-like phenotypes in Mecp2-
deficient mice. 
3 To quantify the transduction efficiency and cellular protein levels 
achieved by AAV9-mediated MECP2 delivery. 
4 To examine the potential for overexpression-related toxicity and identify 
the threshold of Mecp2 overexpression that is tolerable. 
5 Testing whether increasing the transduction efficiency through 
implementing the scAAV9 vector could achieve more therapeutic benefits 
on RTT-like phenotype. 
The overall objective of my thesis research was thus to take the first step 
in developing a gene therapy-based approach in Rett syndrome.
 
 
Chapter 2 
Materials and methods 
  
2.1 General materials  
2.1.1 Enzymes and reagents 
Table 2-1 list of enzymes 
 
Enzymes 
 
Supplier 
 
GoTaq hot start Polymerase Promega 
2xThermo-start high performance PCR master mix Thermo-scientific 
Phire hot start DNA polymerase NEB   
Crimson Taq DNA Polymerase NEB 
T4 DNA ligase Invitrogen 
T4 DNA ligase NEB 
 
 
 
Table 2-2 list of the Kits and their suppliers 
 
Kits  
 
Supplier 
 
 
Rapid DNA ligation kit 
 
Roche 
 
Qiaquick PCR purification kit    
 
 
Qiagen 
Qiaquick gel extraction kit   Qiagen  
 
Qiaprep spin miniprep kit  Qiagen 
 
Qiagen plasmid maxi kit Qiagen  
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2.1.2 Primers  
All the primers listed below are supplied from Sigma Aldrich except the first two 
primers that were supplied from Eurofins MWG/Operon 
Table 2-3 Oligonucleotide list 
 
Primer name 
 
Nucleotide sequences 
(5` 3`) 
 
Fpr-MECP2 (Nhe1) PCR 
 
TTTGCTAGCATGGCCGCCGCTGCC 
Rpr-MECP2-FLAG(BamH1) PCR 
 
AAAGGATCCGCCTTGTCATCGTCGTCCTTGTA 
GTCGCTAACTCTCTCGGT 
Fpr –pCDNA RFP-(Seq)T7 
 
TAATACGACTCACTATAGGG 
Rpr –pCDNARFP (Seq) BGH 
 
TAGAAGGCACAGTCGAGG 
Fpr pEGFP-C1(MECP2-E1) Seq 
 
GACAACCACTACCTGAGC A 
Rpr pEGFP-C1(MECP2-E1) SEq 
 
CCACAACTAGAATGCAGTG 
Fpr-pcdnaMecp2RfpSeq 
 
AGTCATCGCTATTACCATGGTGATGC 
Fpr- pLL4MECP2RFPSeq 
 
TTTCGGCATTCTGCACGCTTC 
 
Rpr-pLL4MECP2RFPSeq 
 
GGATCCAGAGGTTGATTATCG 
Fpr-plenti-syn Seq 
 
ACCACGCGAGGCGCGAGATAG 
Fpr BamH1LentiGFPMCS2 
 
AAAGGATCCGGCGCGCCTAGGCGATCGCTAGCA 
TGGTGAGCAAG GC 
Rpr EcoR1LentiGFPMCS2 
 
GAATTCTTAATTAACACCGGCGGTCCGCTACTTGTA 
CAGCTC 
FprNot1BDNF promoter 
 
GCGGCCGCTTTCACTTTGTTAACCATCAGCCC 
Rpr Nhe1BDNF promoter 
 
GCTAGCGCGAGAGCAGTCCTCTCCTCGGTGAAT 
Fpr Not1 Mecp2 promoter 
 
GCGGCCGCTAGCAAATAAATGAATAGAGAGGGG 
AGC 
Rpr Nhe1 Mecp2 promoter 
 
GCTAGCTTTCCGGACGGGTTTTACCACAGCC 
Fpr WRE seq 
 
ATCACTCTCGGCATGGACG 
Rpr WRE seq 
 
GCCAGGCACAATCAGCAT 
Fpr BDNF promoter seq 
 
GCTCGCTTCACGAGATT 
Rpr BDNF promoter seq 
 
GGTGGTGCAGATGAACT 
New P5 TGGTAAAGACCCATGTGACCCAAG 
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New P6 
 
TCCACCTAG CCTGCCTGTACTTTG 
P7 GGCTTGCCACATGACAAGAC 
 
 
 
Table 2-4 List of Bacterial strains 
 
Bacterial strains 
 
Supplier 
 
DH5 alpha cells sub cloning eff/1ML Invitrogen  
XL1 Blue Competent Cells Agilent  
 
 
 
 
Table 2-5 List of the vectors 
  
Vector name 
 
Type 
 
Encoded product 
 
Source 
 
 
pCDNA(+) zeo RFP Mammalian RFP Prof. Manuela Zaccolo 
Balliol college, 
University of Oxford, 
UK. 
 
pLenti-syn1-GFP Lenti-virus GFP Prof. Kumlesh Dev 
Trinity college, 
Dublin, Ireland. 
 
 
pLenti-PGK-GFP Lenti-virus GFP 
pRSV-40 Mecp2_e1 Mammalian mouse Mecp2_e1 prof. Adrian Bird 
University of 
Edinburgh, UK. pRSV-40 Mecp2_e2 Mammalian mouse Mecp2_e2 
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2.2 General solutions 
All chemicals below without specified origins were supplied from Merck Ltd. 
(BDH laboratories, UK) or Sigma-Aldrich Company Ltd. (Sigma, UK). 
2.2.1 Phosphate buffer (PB) Solution 
2.2.1.1 0.2 M PB 
Ingredients  
 Solution A: 37.44 g of NaH2PO (2H2O) in 1200 ml H2O 
 Solution B: 84.90 g of Na2HPO4 in 3000 ml H2O 
 Add 1120 ml of solution A to 2880 ml of solution B and mix well. Adjust pH to 
7.4 with either HCl or NaOH. Add 3000 ml distilled water to the final solution. 
2.2.1.2 0.1 M PB 
0.1 PB was made by 50/50 (v/v) dilution with distilled water. 
2.2.1.3 0.3 M PBS 
100 ml of 0.2 M phosphate buffer, Distilled water 1900 ml and NaCl 36 g. 
2.2.2 1x TBE 
  Trizma base (90 mM), Orthoboric acid (90 mM) and EDTA (2 mM). 
2.2.3 1kb DNA ladder 
1Kb DNA ladder (NEB, N3232) 
2.2.4 5x DNA loading dye 
SDS 0.5% (w/v), Xylene cyanol 0.25% (w/v), Bromophenol blue 0.25% (w/v) and 
FicollR 400 1.5% (w/v) in 3x TBE. 
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2.2.5 Ethidium Bromide 
 Stock solution: 10 mg/ml in H2O (Sigma, E-1510). 
2.2.6 TE buffer 
 10 mM Tris-HCl and 1mM EDTA (pH 8.0). 
2.2.7 Ampicillin solution 
Stock solution of 25 mg/ml in distilled water. Aliquots of 1 ml of the stock are 
kept at -20oC freezer. Final concentration is 50 µg/ml. 
2.3 Bacterial solutions  
2.3.1 Luria-Bertani (LB) medium 
 3 % (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-Yeast extract and 1% (w/v) NaCl. 
2.3.2 LB agar 
LB medium plus 7-10% agar (w/v). 
2.3.3 SOB media  
2% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-Yeast extract, 10 mM NaCl, 0.25 mM 
KCl, 10 mM MgCl2 and 10 mM MgSO4, PH = 7.0. Sterilized by autoclaving. 
2.3.4 SOC media 
SOB media with 0.04 % (w/v) glucose. 
2.4 Solutions for DNA plasmid preparation (Alkaline lysis 
methods)  
2.4.1 Solution I (resuspension solution) 
50 mM glucose, 25 mM Tris-HCL (pH 8.0) and 10 mM EDTA.  
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2.4.2 Solution II (Lysis solution) 
 0.2 N NaOH and 1% SDS.  
2.4.3 Solution III (neutralization solution) 3M KAC 
 294.45 g potassium acetate and 115 ml glacial acetic acid in a final volume of 1 
litter of water. 
2.5 Methods  
2.5.1 Restriction endonuclease digestion of plasmid DNA 
Restriction digests were carried out to generate DNA fragments for either 
ligation or validation of the insert size of a recombinant plasmid. Double 
restriction digest reactions (containing two different enzymes in the same 
buffer) were carried out whenever possible to minimize the DNA loss that 
accompanies sequential simple restriction digests. Table 2-6 demonstrates the 
components of each restriction digest reaction. 
Table 2-6 Components of the restriction digestion reaction 
 
Reagent 
 
Volume 
 
Restriction buffer 2.5 µl 
DNA ?µl (1µg of plasmid DNA) 
Enzyme 1 1 µl 
Enzyme 2 1 µl 
Water  top u to 25 µl 
Final volume 25 µl 
 
All reaction components were thoroughly mixed by pipetting up and down 
several times then pulse spun. The reaction mixture was incubated at 37°C for 
1-2 hours depending on the enzyme used. 
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2.5.2 Ligation reaction 
DNA ligase was used to clone various gene encoding sequences into different 
vector backbones. Insert to vector molar ratio of 3:1 is mostly used to set up the 
reaction mix. 50 ng of the vector was used per reaction and the amount of the 
insert was calculated using the following formula: amount of insert in ng = 
amount of the vector (50 ng) X molar ratio (3) X insert size / vector size. The 
reaction conditions are summarized in the following table 2-7. A control reaction 
which contains all the ligation reaction components except the insert was also 
performed.  
Table 2-7 Components of the ligation reaction 
 
Reagent 
 
Ligation reaction 
 
Negative control 
 
Ligation buffer 4µl 4µl 
Insert Estimated from the 
above formula 
- 
Vector 50ng 50ng 
T4 ligase 1 µl 1 µl 
Water top up to 20 µl  
Total volume 20 µl 20 µl 
 
Ligation reactions were carried out at 26oC for one hour for sticky-end ligation 
and at 16 oC overnight for blunt-end ligation. These conditions and reaction 
reagents were varied according to which ligase enzyme was used. 
2.5.3 Preparation of chemically competent cell  
E-Coli, DH5α, bacterial cells were spread on an antibiotic-free LB agar plate and 
incubated overnight at 37°C. A single colony was picked and sub-cultured in 5 ml 
LB medium followed by an overnight incubation at 37°C in the shaking 
incubator. To generate a large volume of bacterial culture, 3 ml of the overnight 
culture was added to 200 ml of LB medium and incubated for another 2-3 hours at 
37°C in the shaking incubator. The optical density (OD) of the culture was tested every 
30 minutes until it reached 0.6-1.0. The culture medium was spun down at 3000 rpm 
for 15 minutes at 4°C to precipitate the bacterial pellet. The pellet was then fully 
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re-suspended in 80 ml of 0.1 M MgSO4 by pipetting up and down several times on 
ice. To remove the MgSO4 solution, the solution was centrifuged at 3000 rpm for 
15 minutes at 4°C. Lastly the bacterial pellet was re-suspended in 2ml of ice-
chilled 0.1M CaCl2. Aliquots of 50 µl of the competent DH5α were stored at –
80°C in cryo-protective tubes.  
2.5.4 Heat shock transformation of chemically competent E-Coli 
Two 50 µl aliquots of competent cells were defrosted on ice for 15 minutes.10-
100 ng of the vector or 5 µl of the ligation-mix was added to the cells and gently 
mixed by gentle pipetting up and down several times on ice, then left 
undisturbed for 30 minutes. The competent cells were then exposed to a heat 
shock by transferring them from ice to pre-heated water bath at 42°C for 30-45 
seconds then incubated on ice for a further 3 minutes. 900 µl LB or SOC medium 
was added to the transformed cells and they were then incubated for 60-90 
minutes at 37°C in the shaking incubator.100 µl of the transformed competent 
cells were plated on the pre-warmed LB agar plate with appropriate antibiotic 
and incubated overnight at 37°C. 
2.5.5 Plasmid mini-preparation (alkaline lysis) 
A single bacterial colony was chosen and sub-cultured in 5 ml of LB medium with 
ampicillin (final concentration of 50 µg/ml) in a loosely capped 50 ml tube and 
incubated overnight at 37°C with vigorous shaking (200-250 rpm). The bacterial 
culture was spun down at 13000 rpm for 2 minutes at room temperature to 
harvest the bacterial pellet. 100 µl of ice-cold solution 1 (resuspension solution) 
was used to fully resuspend the bacterial pellet by either vortexing or pipetting 
up and down followed by incubation for 5 minutes at room temperature. 200 µl 
of solution II (lysis solution) was then added to the tube to lyse the bacterial 
cells. The tube was mixed gently by inversion, to avoid excessive shearing of the 
genomic DNA, and incubated on ice for 5 minutes.   
 To isolate the plasmid DNA from the genomic DNA, 150 µl of ice-chilled solution 
III (neutralization solution) was added to the tube and mixed by vortex then 
incubated on ice for 5 minutes. The mixture was centrifuged at 13000 rpm for 10 
minutes at room temperature. The supernatant, containing the plasmid DNA, 
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was transferred to another tube and incubated with 1 µl of 10 mg/ml RNAse A 
for 15 minutes at 37°C. 500 ul phenol/ chloroform was added and mixed 
vigorously by vortex. The aqueous top layer was then obtained by centrifugation 
at 13,000 rpm for 10 minutes at room temperature. Precipitation of plasmid DNA 
was carried out by adding 1/9 volume of 3 M sodium acetate and 2.5 volume of 
absolute alcohol followed by vortex and centrifugation at 13000 rpm for 10 
minutes at room temperature. Lastly the DNA pellet was washed with 70% 
ethanol and centrifuged for 2-3 minutes. The pellet then air dried and 
resuspended in 20-30 µl of TE buffer solution. 
2.5.6 Making glycerol stock 
For long term storage of the bacterial cells containing the plasmid of interest, 
500 µl of the overnight culture was added to 500 µl of 50% glycerol (filtered 
sterilized) and mixed by vortex giving a final concentration of 25% glycerol. This 
mixture was incubated for 30 minutes at 37°C in the shaking incubator followed 
by storage at –80°C. 
2.5.7 Determination of DNA concentration 
The concentration and purity of DNA in aqueous solution were estimated by 
measuring the UV absorbance of the solution at wavelength of 200-300nm using 
Nano drop 1000. An optical density of 1 corresponds to 50mg/ml of DNA in the 
solution. The purity of the DNA samples was measured by comparing the ratio of 
the OD at 260nm (OD260) to 280nm (OD280). An OD260/OD280 ratio of 1.8-2.0 is 
taken as an acceptable level of purity. The base line of the Nano-drop1000 was 
corrected using TE buffer as a blank. 
2.5.8 Polymerase chain reaction (PCR) for transgene 
amplification 
Standard PCR reactions were carried out to amplify various transgenes used in 
this study. Restriction sites usually added to the amplified PCR by the forward 
and reverse primers. The components and concentration of the PCR are included 
in table 2-8. The reactions were set up in 0.2 ml PCR tubes (Themoscientific). 
The PCR conditions varied according to the polymerase type, primers and the 
size of the constructs to be amplified. 
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Table 2-8 Components of the PCR reactions 
 
Reagent  
 
Volume 
 
PCR buffer 10 µl 
dNTPs mix X µl (0.25 µM) 
Forward primer x µl (0.5 µM) 
Reverse primer x µl (0.5 µM) 
DNA template x µl (100 pg-1 ng) 
Polymerase 1 µl 
Water top up to 50 µl 
Final volume 50 µl 
 
 
The PCR reaction mix was incubated in the Gene Amp thermal cycler (PCR 
system 9700; Applied Biosystems, UK) using the following standard amplification 
conditions that are listed in table 2-9. 
Table 2-9 Standard PCR condition 
 
Step 
 
Temperature 
 
Duration 
 
Initial denaturation 94 oC 5 minutes 
x30 cycles 
Denaturation 94 oC 30 seconds 
Annealing 55-60 oC (dependent on the 
TM of the primers) 
 
30 seconds 
Extension 72 oC dependent on the type 
of the polymerase 
Final extension 72 oC 10 minutes 
Hold 4 oC α 
 
  
2.5.9 Agarose gel electrophoresis 
DNA molecules were separated according to their size by agarose gel 
electrophoresis. A solution of 0.8-1 % (w/v) agarose in 0.5 X TBE buffer was 
prepared in a microwave till the Agarose was completely dissolved. When the 
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TBE solution had cooled down (~40°C), Ethidium bromide was added to a final 
concentration of 200 ng/ml. Gels were poured in a horizontal tray and allowed 
to set at room temperature for one hour. DNA samples were mixed with 5 X DNA 
loading dye and electrophoresed for one hour at 100-120 volts. An aliquot of a 
DNA size ladder (1.5-2 µg) was also electrophoresed and used as a marker. 
Separated DNA samples were visualized using an UV transilluminator (UV-TM-40; 
Upland, USA; wavelength 254nm) and photographed using Canon digital camera 
(PC1192; Japan). 
2.6 Animals  
2.6.1 Design of the Mecp2-KO mouse models 
The Mecp2-knock out mouse models were created and supplied by prof. Adrian 
Bird‟s laboratory at the University of Edinburgh, Edinburgh, UK. The first model 
was generated by cre-lox mediated deletion of part of exons 3 and 4 of Mecp2 
gene to produce the Mecp2-null model (Guy et al., 2001). Several years later the 
second model was created by insertion of a NEO-STOP cassette into intron 2 of 
Mecp2 to generate an incomplete Mecp2 mRNA that precludes translation of 
Mecp2 protein (Mecp2-stop model). This model allows selective deletion of the 
stop cassette to enable activation of endogenous Mecp2 expression and is thus a 
functional knockout rather than structural knockout (Guy et al., 2007). 
2.6.2 Breeding strategy of Mecp2-KO mice 
Local Mecp2-KO colonies at University of Glasgow were established by breeding 
heterozygous Mecp2stop/+ and Mecp2 -/+ females (C57BL/6 background) with WT 
males (BALB/C and B57BL/6 background respectively) purchased from Harlan 
laboratories (Shardlow, UK). All mice used in this work were hemizygous 
Mecp2stop/y  or Mecp2-/y males and their WT male littermates. Different 
genotypes/genders that were created from the mating of Mecp2-/y females with 
WT males are summarized in table 2-10. Offspring genotypes were determined 
by PCR. Mice were housed in groups of 2-3, maintained on a 12-hour light/dark 
cycle and provided with food and water ad libitum. All experiments were 
conducted in accordance with the European Communities Council Directive 
(86/609/EEC) and a project license with local ethical approval under the UK 
Scientific Procedures Act (1986). 
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Table 2-10 Breeding scheme for Mecp2 knockout mice 
 
Females  
 
Male WT (Mecp2+/y) 
 
 
Mecp2-/+ 
sex Male Male Female Female 
genotype WT hemizygous WT heterozygous 
Mecp2+/y Mecp2-/y Mecp2+/+ Mecp2-/+ 
 
Mecp2stop/+ 
 
sex Male Male Female Female 
genotype WT hemizygous WT heterozygous 
Mecp2+/y Mecp2stop/y Mecp2+/+ Mecp2stop/+ 
 
 
2.6.3 Genotyping  
2.6.3.1 DNA extraction 
Genomic DNA was extracted from either tail samples (mice neonates) or ear 
samples (adult mice) using DNAreleasyTM reagent (ANACHEM ltd.UK). Ear or tail 
samples were added to 20 µl of DNAreleasy buffer then incubated in a GeneAmp 
thermal cycler (PCR system 9700; Applied Biosystems, UK) under the 
manufacturers` recommended conditions (table 2-11).  
Table 2-11 DNA extraction conditions 
 
Temperature  
 
Duration 
 
  
75°C                  5 minutes 
96°C                  2 minutes 
20°C hold 
 
2.6.3.2 PCR verification of mouse genotypes 
PCR reactions were carried out to genotype offspring in each litter. For each 
genomic DNA sample two PCR reactions were performed, the first reaction using 
primers specifically designed to anneal with the WT Mecp2 allele (P5 and P7) 
and the second reaction using primers that anneal with the KO Mecp2 allele (P5 
and P6). The reaction set up and PCR conditions are summarised in tables 2-12.  
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Table 2-12 PCR reaction sets for genotyping of Mecp2-null mice and their WT littermates 
 
Reagent 
 
WT set 
 
Mecp2-null set 
 
Thermo-start HP PCR master mix 13µl 13µl 
Forward primer P5 (0.4µM) P5 (0.4µM) 
Reverse primer P7 (0.4µM) P6 (0.4µM) 
DNA template 5ng-10ng 5ng-10ng 
Water 9µl 9µl 
 
Final volume 
 
26 µl 
 
26 µl 
 
The PCR reactions were carried out in GeneAmp thermal cycler (PCR system 
9700; Applied Biosystems, UK). The reaction conditions are summarized in table 
2-13. 
Table 2-13 PCR conditions for genotype discrimination 
 
Step 
 
Temperature 
 
Duration 
 
Initial denaturation 
 
94°C 
 
15 minutes 
 X30 cycles  
Denaturation 94°C 45 seconds 
Annealing 60°C 45 seconds 
Extension 72°C 1 minute 
Final extension 72°C 10 minutes 
Hold 4°C α 
 
PCR products were separated by agarose gel electrophoresis. PCR products for 
the P5/P7 primer set (WT allele) are 416bp, and PCR products for the P5/P6 
primer set (Mecp2-KO allele) are 470bp. 
2.6.4 Phenotype severity score 
Mecp2 KO mice were phenotyped weekly after weaning (postnatal day 21-23) 
according to the scoring system developed by (Guy et al., 2007). The score uses 
six cardinal features of the RTT-like phenotype as a semi-quantitative measure 
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for the disease trajectory. These features are; mobility, gait, hind limb clasping, 
tremor, breathing abnormality and general appearance. Each of these feature 
scores 0 for a phenotype indistinguishable from WT, 1 for mild phenotype and 2 
for severe phenotype (table 2-14) with total score ranging between 0-12. Tremor 
and breathing are observed while the mouse is standing still whereas hind limb 
clasping is tested by suspending the mouse by the base of the tail with the 
mouse supporting itself by its forelimbs.  
Table 2-14 Detailed phenotype severity score of Mecp2 KO mice 
 
Phenotype features 
 
Scores 
 
  
 1 2 
Mobility  Reduced movement or 
prolonged freezing 
periods 
No spontaneous 
movement 
 
 
 
Gait 
Wider than WT or 
reduced pelvic elevation 
“waddling” gait 
Tremor when feet are 
lifted, walks 
backwards or lifting 
both rear feet at once 
 
 
Hindlimb clasping 
Hindlimbs are drawn into 
the midline (without 
touching) or one leg is 
drawn into the trunk. 
Both legs are pulled 
into the midline 
tightly or touching 
body 
 
Tremor intermittent mild tremor continuous or violent 
tremor 
 
 
Breathing 
short periods of rapid 
breathing or pauses in 
breathing 
very irregular 
breathing - gasping or 
panting 
 
General conditions eyes dull, coat dull/un-
groomed 
eyes crusted or 
narrowed, piloerection 
or hunched posture 
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2.7 Hippocampal dissociated cell culture. 
Hippocampal dissociated neuronal cell culture was conducted according to 
(Greenwood et al., 2007) 
2.7.1 Animal 
Pups (postnatal day 1-3) from; 
 Mouse; Mecp2stop/Y males, Mecp2stop/+  females and their WT littermates. 
 Rat (used occasionally during the course of the study) 
2.7.2 Materials 
Enzymes and media used for cell culture are listed in table 2-15. 
Table 2-15 Materials for dissociated hippocampal cell culture 
 
Materials  
 
Supplier 
 
Poly-L-lysine  
 
Sigma 
L-Glutamine  
 
Sigma 
Neurobasal-A medium  
 
Invitrogen 
B27 medium  
 
Invitrogen 
Bovine serum albumin (BSA) 
 
Invitrogen 
Papain 
 
Sigma 
 
The components of the cell culture buffer that used during preparation of the 
hippocampal cell culture are listed in table 2-16. 
 
 
 
  80 
 
Table 2-16 Components of the cell culture buffer 
 
Compound  
 
Working concentration 
 
g/L 
 
NaCl 116 mM 6.78 
KCl 5.4 mM 0.40 
NaHCO3 26 mM 2.18 
NaH2PO4 1.3 mM 0.16 
MgSO4.7H2O 1 mM 0.25 
CaCl2.2H2O 1 mM 0.15 
EDTA.2Na.2H2O 0.5 mM 0.15 
Glucose 25 mM 4.5 
 
The PH of the Cell culture buffer is =7.4 
2.7.3 Method 
Each mouse pup was euthanized by intra-peritoneal injection of a lethal dose of 
pentobarbital Na+ (Euthatal; Merial Animal Health Ltd., Harlow, UK). The pup 
was then decapitated, the skin was removed, and the skull was opened by 
making three cuts, two horizontal cuts through the foramen magnum and one 
longitudinal cut through the sagittal suture of the skull. The brain was removed 
and placed on a pre-sterilized (with 70% alcohol) filter paper (figure 2-1). The 
brain was cut through the midline into 2 halves, using a No. 11 scalpel blade, 
followed by dissection of the hippocampus, which was kept in a pre-chilled 
buffer in a 35 mm petri-dish. The hippocampus was chopped into small pieces by 
scalpel blade and the pieces were transferred to 15 ml falcon tube containing 
pre-warmed filtered-sterilized Papain (7.5 mg in 5 ml of the buffer) and 
incubated for 20 minutes at 37°C in the water bath. The papain was then 
inactivated by mixing with pre-warmed BSA (60 mg in 6 ml of the buffer). The 
cell suspension was centrifuged at 3000 rpm for 4 minutes at room temperature 
to remove any residual papain. The pellet was resuspended in 1 ml of complete 
neuro-basal medium (supplement with 2% B27 and 1% L-Glutamine). 100 µl of the 
cell suspension was plated on a poly-L-lysine-coated 12mm sterilised cover slip 
and incubated for one hour at 37°C, 5% CO2. One hour later 1 ml of complete 
neuro-basal media was added to the cover slip containing petri dish and 
incubated at 37°C, 5% CO2. 
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Figure 2-1 Hippocampal dissociated cell culture 
Diagram showing preparation steps of the hippocampal dissociated cell culture. The brain 
of a P1-3 mouse pup was extracted (1) and the hippocampus was cut out (2) and chopped 
using a scalpel blade into small pieces (3). The hippocampal pieces were then incubated in 
papain followed by neutralization by BSA (4). The dispersed cells were plated on the 
coverslips in a 35 mm petri-dish with 1ml of neuro-basal media (5). (6) Micrograph showing 
bright field image of 7 days old hippocampal dissociated neuronal culture. Scale bar in 6 = 
10 µm.  
2.8 Calcium phosphate transfection 
Ca2+  phosphate transfection of dissociated neuronal cultures was carried out 
according to Jiang et al 2004 (Jiang et al., 2004) 
2.8.1 Materials  
Table 2-17 Materials for Ca
2+
 phosphate transfection 
 
Materials 
 
Supplier 
 
Neuronal dissociated cell culture  
 
 
Neuro basal-A media  
 
Invitrogen 
CaCl2  
 
Riedel-de-Haen 
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2X HEPES (pH 7.2) 
 
Fisher-scientific BP 
5X Kynurenic acid (stock,10mM) 
 
Sigma 
Acidic 10% CO2 equilibrated culture medium 
 
 
 
 
2.8.2 Preparation of the transfection mix (for single coverslip) 
Plasmid DNA (1-4 µg) was diluted in 1XTE buffer (PH = 7.3) to a final volume of 
45 µl and mixed gently by vortex. 5 µl of 2.5 M CaCl2 in 10 mM HEPES (to give a 
final concentration of 250 mM CaCl2) was added in drop-wise fashion to the 
DNA/TE solution and mixed gently by vortex. This DNA/CaCl2/TE (50 µl) solution 
was added to 50 µl of 2X HEBS (HEPES Buffered Saline) pH 7.2 and mixed by 
pipetting up and down. The mix containing tube was wrapped in tin foil and 
incubated at room temperature for 30 minutes with intermittent vortexing for 2-
3 seconds every 5 minutes to allow formation of the transfection precipitate. 
2.8.3 Preparation and transfection of the cell culture.  
To protect neurons against the excitotoxic effect of Ca2+  ions, 50 µl of 10 mM 
Kynurenic acid (an NMDA receptor antagonist) was mixed with 200 µl of the 
conditioned neuro-basal medium (conditioned by the cultured neuronal cells) to 
make enough volume for one well of a 24 well plate. The cover slip to be 
transfected was transferred to this well and incubated at 37°C, 5% CO2 until the 
transfection mix become ready. 50 µl of the transfection precipitate was added 
in a drop-wise fashion to the cover slip and mixed to ensure that the precipitate 
completely covered the cover slip. The culture was then incubated for 1-3 hours 
at 37°C, 5% CO2. After that the transfected cover slip was transferred to a fresh 
well of 24 wells plate containing 1ml of acidic 10% CO2 equilibrated culture 
medium and incubated at 37ºC, 5% CO2 for 15-20 minutes. A single wash of the 
cover slip with unconditioned medium is recommended to remove any traces of 
kynurenic acid. The transfected cover slip was finally transferred to a fresh well 
of 24 wells plate containing 500 ul of the conditioned medium and incubated at 
37ºC, 5% CO2 for 24 hours. 
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2.9 Generation of Lentivirus particles  
Lentivirus production was carried out according to (Kuroda et al., 2009) 
2.9.1 Materials 
Table 2-18 Materials for the generation of lentivirus particles 
 
Material  
 
Supplier 
 
Human embryonic kidney  (HEK) 
293T/17 cells 
ATCC 
Sodium pyruvate 
 
Sigma 
L-Glutamine  
 
Invitrogen 
Fetal bovine serum (FBS) heat 
inactivated 
 
Sigma 
Phosphate buffer solution (PBS) 1X w-
out calcium 
 
Invitrogen 
Pen-Strep 10K units  
 
Invitrogen 
DMEM medium (high glucose, no 
glutamine, with sod. pyruvate 
 
Sigma 
Trypsin/ EDTA 0.25% 
 
Sigma 
Optimem medium  
 
Invitrogen 
Polyethylenimine (PEI) 
 
Sigma 
Trypan blue solution (0.4%) 
 
sigma 
Plasmid pMD2.G 
 
Addgene 
Plasmid pMDLg/pRRE  
 
Addgene 
Plasmid pRSV-Rev 
 
Addgene 
Nunc Cryo-tube vial  
 
sigma 
TC flask 150 cm2 vented   
 
Corning 
Syringe filter 0.2um 25mm dia. 
 
Sartorius 
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2.9.2 Preparation of HEK 293T/17 cells  
2.9.2.1 Recovery of HEK 293T cells from liquid nitrogen 
Gradual recovery of HEK293T is critical to minimize cell death. One vial of 
HEK293T-containing medium was taken from storage in liquid nitrogen and 
transferred to the cell culture lab on dry ice. The vial was kept at room 
temperature (approximately 22°C) for two minutes before being incubated in a 
pre-heated water bath at 37°C till the cell-containing media became fully 
defrosted. The vial was wrapped in an alcohol-soaked tissue (70% EtoH) and 
transferred to a sterilized fume hood to prevent contamination. The contents of 
the vial was added to 9 ml of pre-conditioned (37°C, 5% CO2) complete DMEM 
medium (DMEM with 10% FBS,1% L-Glutamine,1% Pen-Strept and 1% Sodium 
pyruvate) and centrifuged at 4000 rpm for 4 minutes at room temperature. The 
supernatant was discarded and the cell pellet was dispersed in 1 ml of complete 
pre-conditioned media by pipetting up and down. The dispersed cells were then 
added to 30 ml of preconditioned complete media in a T150 cm2 flask and 
incubated at 37°C, 5% CO2. After 24 hours, the medium was changed and cell 
growth was monitored. 
2.9.2.2 Passage of HEK293T cells 
HEK293T cell passage was carried out to maintain the cells in the log phase of 
growth to ensure maximum growth rate and avoid over confluence and 
subsequent cell death. Cell confluence of 75-80 % was considered as optimal for 
cell passage. To passage HEK293T cells, the culture media was removed and the 
cells were washed with pre-heated (37°C) PBS to remove any residual serum-
containing medium. To induce cellular detachment from the flask, 3 ml of 
trypsin was added to the cell layer and mixed then incubated at 37°C, 5% CO2 for 
3 minutes. To inactivate the trypsin, 7 ml of pre-warmed (37°C)  complete 
medium was added and mixed by pipetting up and down several times to fully 
disperse the cells. HEK293T cell suspension was then transferred to a 50 ml 
falcon tube. To determine the cell count, 20 µl of HEK293T cell suspension was 
Mixed with 20 µl of Trypan blue dye and 8 µl of this mix was placed on each 
counting chamber of a haemocytometer slide (LW Scientific, Inc. 800/726-7345) 
to determine the cell numbers per ml. Afterwards, a defined cell number was 
added to preconditioned complete medium-containing flasks.   
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2.9.3 Lentiviral vector particles preparation 
2.9.3.1 Preparation of HEK293T cells 
24 hours before transfection, HEK293T cells were passaged and 8 X 106   cells 
were plated in a T150 cm2 flask and incubated overnight at 37°C, 5 % CO2. A 
number of 6-8 flasks were prepared in the same way. HEK293T cell confluence 
was monitored before transfection and only flasks that had 80-85% confluence 
were used for virus generation. 
2.9.3.2 Preparation of the transfection solutions 
The following volumes are sufficient for one T150 cm2 flask. 
Recipe 1(Optimem PEI)  
1 µl of 10 mM PEI was added to 5 ml of Optimem in a 50 ml Falcon tube and 
mixed by inversion several times. The mixture was filtered and sterilized using a 
0.2 µm syringe-filter. 
Recipe 2 (Optimem DNA) 
Lentivirus-based vectors containing the gene of interest together with the 
packaging plasmids (table 2-19) were added to 5 ml of Optimem in a 50 ml 
Falcon tube (figure 2-2) and mixed by inversion. The mixture was filtered and 
sterilized by 0.2 µm syringe-filter. 
Table 2-19 Vectors concentration for Lentiviruses generation 
 
Plasmid name 
 
Concentration / T150 cm2 flask 
 
Lentiviral vector 40 µg 
Packaging plasmid(pMDLg/PRRE) 20 µg 
Envelope plasmid (pMD2G) 10 µg 
Rev plasmid (pRSV-Rev) 10 µg 
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To generate transfection precipitates, the PEI-containing Optimem (recipe 1) 
was added drop by drop to the DNA-containing Optimem (recipe 2). Both recipes 
were mixed by inversion and incubated for 20-30 minutes at room temperature 
in the fume hood to help formation of the transfection mix.  
 
Figure 2-2 Generation of lentivirus particles 
Schematic diagram showing the steps of lentivirus production. (1) shows the structural 
genes of the lentivirus (Gag, Pol, Rev and Env) located between both LTRs. (2) shows the 
structure of the lenti-vector backbone with all structural genes replaced by the gene of 
interest (e.g. ME1FlagRFP) between the two LTRs. (3) To generate lentivirus particles, all 
essential genes were supplied in-trans by 3 different vectors. (4) Transfection precipitates 
were carried out by mixing positively charged PEI with negatively charged DNA. (5) 
Transfection precipitate was added to HEK293T cells for 4 hours followed by 48 hours 
incubation. (6) Diagram of HEK293T cells showing the production of the virus RNA which is 
then packaged into viral proteins followed by viral assembly and release to the culture 
medium.  
 
2.9.3.3 Transfection of HEK293T cells 
To transfect HEK293T cells with the transfection mixture, the culture medium 
was replaced by 10 ml of the transfection mix. The flask was swirled gently to 
ensure that the transfection fluid covered all cells. The flask was then incubated 
at 37°C, 5% CO2 for 4 hours to allow transfection of HEK cells. To confirm the 
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presence of transfection precipitates, the cells were visualized under the 
microscope and the presence of small black dots on and in-between the cells 
was confirmed. Finally the transfection mix was replaced by 30 ml of pre-
conditioned complete DMEM medium and incubated at 37°C, 5% CO2 for 48 
hours. 
2.9.4 Collection of lentivirus particles 
Two batches of the virus containing media were collected; the first batch of 
lentivirus was collected after 48 hours. The culture medium containing the 
particles was transferred to a 50 ml falcon tube and replaced by 30 ml of pre-
warmed fresh complete DMEM medium and incubated for another 24 hours under 
the same conditions. To remove cellular debris, the virus containing medium was 
centrifuged at 4000 rpm for 5 minutes at 4°C. The supernatant was filtered-
sterilized by 0.2µm syringe-filter and stored at 4°C for further processing. The 
second batch of the virus was collected 24 hours after the first batch and 
processed in the same way. HEK293T cells were treated with Virkon and 
discarded. 
  
2.9.5 Concentration of the Virus particles 
To concentrate the virus particles, virus containing medium from the first and 
second batch were mixed together followed by spinning at 27000 rpm for 2 hours 
at 4°C in the pre-cooled Beckman ultracentrifuge. The supernatant was carefully 
discarded and the virus pellets (yellow and sometime difficult to see) were re-
suspended in 5 ml of pre-chilled DMEM medium and incubated on ice for 20 
minutes before being vigorously dispersed by vortexing. The content of all six 
ultracentrifuge tubes were added together in one tube and re-centrifuged at 
27000 rpm for 2 hours at 4°C. The supernatant was discarded and the virus 
pellet was dispersed in 100 µl of pre-chilled PBS and incubated overnight at 4°C 
followed by final vigorous dispersion of the virus particles by vortex and 
pipetting up and down.10 µl Aliquots were then stored at -80°C in a cryo-
protective tubes. 
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2.9.6 Titration of lentivirus particles 
2.9.6.1 First method 
 0.5 X 105  of HEK293T cells/coverslip were plated on 6 poly-L-Lysine coated 
coverslips in 24 well tissue culture plates. After 24 hours one coverslip was used 
to estimate the total cell count per coverslip. One cover slip was used as a 
control (non-transduced) and the remaining four coverslips were transduced with 
a series of increasing amounts of virus particles (1, 2, 4 and 8 µl). After 72 hours 
the cells were fixed with 4% PFA and screened for RFP expression. The number 
of RFP expressing cells was counted and the titre was calculated according to 
the following formula; 
Number of HEK293T cells X percentage of RFP positive cells X1000 
                    Volume of virus (µl) used for transduction 
The resulting titre will be presented as (infection unit) IU/ml  
2.9.6.2 Second method 
HEK293T cells were prepared as described above. On the day of transduction, 
the complete DMEM medium was discarded and replaced by 1ml of fresh 
complete DMEM containing a serial dilution of the virus particles in 102 to 1010. 
After 72 hours the numbers of RFP-positive cells were counted in each dilution 
and the titre was calculated according to the following formula; 
Virus titre (IU/ml) = virus dilution X number of RFP-positive cells. 
2.10 Adeno-associated virus production 
Adeno-associated virus particles (AAV9) has been generated, titrated and 
supplied by Dr. Steven Gray, Jude Samulski Lab UNC Gene Therapy Center, USA. 
Recombinant AAV vectors were generated using HEK293 cells grown in serum-
free suspension conditions in shaker flasks, using proprietary methods developed 
at the UNC Gene Therapy Center Vector Core facility.  In brief, single-stranded 
or self-complementary AAV particles (AAV2 serotype vector backbone packaged 
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into AAV9 serotype coats) were produced from suspension HEK293 cells (ATCC# 
CRL 1573) transfected using polyethyleneimine (Polysciences) with the following 
helper plasmids (pXX6-80 (Xiao et al., 1998), pGSK2/9) plus the ITR-flanked 
transgene construct (pTR-CBA-GFP, pTR-CBA-hMeCP2, or pSJG-MeP-hMeCP2, 
respectively). The CBA constructs utilized a CMV enhancer, chicken beta actin 
promoter, shortened SV40 intron, and SV40 polyadenylation sequence (Gray et 
al., 2011b). The MeP construct used a truncated 229 bp murine MeCP2 promoter 
(Gray et al., 2011a) and the bovine growth hormone polyadenylation signal . All 
MECP2 constructs utilized the human MECP2_e1 minigene with a C-terminal Myc 
epitope tag. Forty-eight hours post-transfection, cell cultures were centrifuged 
and supernatant was discarded. The cells were resuspended and lysed by 
sonication, as described in (Grieger et al., 2006). DNase (550 U) was added to 
the lysate and incubated at 37°C for 45 minutes, followed by centrifugation at 
9400 x g to pellet the cell debris and the clarified lysate was loaded onto a 
modified discontinuous iodixanol gradient followed by column chromatography, 
or purified by a step CsCl gradient centrifugation followed by a discontinuous 
CsCl gradient centrifugation.  Both purification methods provide equivalent high 
levels of purity and in vivo transduction efficiency (Gray et al., 2011c).  Purified 
vectors were dialyzed in 1x PBS with 5% D-sorbitol and a final NaCl concentration 
of 350 mM. Titer was obtained by both dot blot (Grieger et al., 2006) and qPCR. 
2.11 Stereotaxic brain injection 
To drive expression of exogenous Mecp2flagRFP in the hippocampus of the  
Mecp2stop/y mouse, animals were anaesthetized with inhalational anaesthesia 
(Halothane) and after full loss of consciousness, their head was shaved and 
cleaned with 70% alcohol-soaked gauze. The mice were fixed on the stereotaxic 
frame using ear and mouth bars. Body temperature was monitored by insertion 
of a rectal probe. The skin was cut by scissors and the skull bone was softened 
using a bone drill followed by removal of the vault bone that covers the 
injection coordinates. An Injection glass pipette 25-30 µm in diameter was used, 
under the dissection microscope, to inject 0.3-0.6 µl of the virus/sit very slowly 
(over 5 minutes) using pressure pump. The injection pipette was kept in place 
for 2-3 minutes to minimize virus reflux. The skin was sutured and the mouse 
was injected intramuscularly with analgesic and was given a soft diet and kept in 
a 37°C incubator overnight to help the post-operative recovery.  
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2.12 Neonatal injection  
For neonatal delivery of AAV9/MECP2, male littermates were sexed at birth 
(post-natal day 0-2) and received either facial vein injection of 30 µl of 
scAAV9/MECP2 or direct bilateral brain injections of sc/ssAAV9/MECP2 virus (3 
µl/site) into the neuropil via a 33 g needle (Finescience) connected to10 µl 
Hamilton syringe by a very thin tube. The brain injection sites were over the 
temporal cortex, approximately 1-2 mm lateral from the midline, anterior to 
lambda and 2mm in depth. Injection was carried out slowly (over approximately 
30 second) and the injection needle was kept in place for 30-60 seconds to 
minimize virus reflux. Immediately after injection, the pups were wrapped in 
the home cage bedding materials to prevent mother rejection. Non-injected 
female pups were also kept in the same cage to prevent mother distress. Three 
weeks after injection mice were weaned and ear-tagged for genotype 
verification and were then weekly phenotyped as previously described.  
2.13 Immunohistochemistry (IHC)  
To detect /study protein expression in different tissue sections, mice were 
deeply anaesthetised with sodium pentobarbital (Euthatal) at a dose of 100 
mg/kg body weight (Merial Animal Health Ltd., Harlow, UK). After the animals 
were fully anaesthetised, the chest was opened immediately and the heart was 
explored. The perfusion needle was inserted in the left ventricle and a small cut 
to the right atrium was made to allow washing out of the blood and the excess 
fixative. Mice were first perfused with mammalian ringer or 0.1M PBS until their 
livers were cleared followed by perfusion with 300 ml of 4% paraformaldehyde 
(PFA) in 0.1M PBS. After complete fixation (evidenced by tail and limb rigidity) 
brains and other organs were dissected. All organs were then post-fixed in the 
same fixative for 5 hours before being transferred to 30% sucrose in 0.1M PBS 
and stored overnight at 4°C. Brain, spinal cord and other organs were embedded 
in 3% agar in water (w/v) and subsequently sectioned at 40-70 µm using a 
vibrating microtome (Leica VT1200, Leica UK). Sections were washed three 
times in 0.3 M PBS followed by blocking using 15% normal goat serum in 0.3 M 
PBS with 0.3% Triton X100 for one hour at room temperature. Sections were 
incubated with primary antibody (table 2-20a) for 48 hours on a shaker at 4°C.  
The primary antibodies were then washed off (3 x 0.3 M PBS) followed by an 
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overnight incubation with the secondary antibodies (table 2-20b) at 4°C. Finally 
sections were incubated with DAPI (Sigma, 1/1000) dilution (v/v) in o.3 M PBS 
for 30 minutes at room temperature and mounted with Vectashield (Vector labs, 
UK). 
Table 2-20 Primary and secondary antibodies used in IHC 
 
Antibody 
 
Dilution 
 
Supplier 
   
(a) Primary antibodies 
Mouse anti-Flag tag 1/500 Abcam 
Mouse anti–Mecp2 1/500 Sigma 
 
Rabbit anti-Mecp2 1/500 Millipore 
Rabbit anti-Myc tag 1/500 Abcam  
Mouse anti Neu-N 1/500 Sigma 
Rabbit Anti-GFAP 1/200 Abcam 
Rabbit anti-Mecp2(S421) 1/10000 Greenberg lab 
Chicken Anti-MAP2 1/200 Millipore 
Rabbit anti-acetylated H4 1/1000 Millipore 
Mouse anti-H4 1/1000 Abcam 
Goat Anti-ChAT 1/100 Abcam 
Sheep anti-GFP 1/1000 Santa Cruz 
(b) Secondary antibodies 
Alexa fluor 488 goat anti-mouse 1/500 Invitrogen 
Alexa fluor 488 goat anti-rabbit 1/500 Invitrogen 
Alexa fluor 488 donkey anti-sheep 1/500 Santa-cruz 
Alexa fluor 546 goat anti-mouse 1/500 Invitrogen 
Alexa fluor 546 goat anti-rabbit 1/500 Invitrogen 
Alexa fluor 647 goat anti-mouse 1/500 Invitrogen 
Alexa fluor 647 goat anti-rabbit 1/500 Invitrogen 
Alexa fluor 647 goat anti-chicken 1/500 Invitrogen 
Alexa fluor 647 donkey anti-goat 1/500 Invitrogen 
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2.14 Image analysis  
Expression patterns, transduction efficiency and transgene level quantification 
(intensity measurements) were carried out on image stacks captured using a 
Zeiss LSM710 laser confocal microscope. Z-series were taken at 0.6-1.3 μm 
intervals through the section of interest using a 40x or 60x objectives.   
To estimate transduction efficiency, the ratio of Myc-positive nuclei relative to 
DAPI-stained nuclei in random fields was obtained from the hippocampus (CA3 
region), layer 5 of primary motor cortex, thalamus, hypothalamus, brainstem 
and striatum. To assess the percentage of transgenic expression in neurons, the 
ratio of Myc-immunopositive to NeuN-immunopositive cells were determined. To 
quantify the amount of transgene product WT mice were injected with virus 
particles (lenti or AAV9) and at the end of the experiment these mice were 
perfused and their brains were sectioned as described above. RFP fluorescence 
or anti-Myc antibodies were used to identify the transduced cells whereas anti-
Mecp2 immunofluorescence was used for intensity measures of the cellular 
Mecp2 level. ImageJ software (http://rsbweb.nih.gov/ij/) was used to 
determine mean MeCP2-channel fluorescence intensity within transduced and 
non-transduced cells within a 15 micron optical section. 
Nuclear volume estimation was made by serial reconstruction of nuclei in a Z-
series (0.6 μm) using ImageJ. The DAPI channel was used to define the nuclear 
boundary and the transduction status of cells discriminated by the presence or 
absence of anti-Myc immunolabelling for AAV9-based experiment and with RFP 
fluorescence expression in Lentivirus-based experiments.  
2.15 Treadmill motor challenge test 
Treadmill motor test was carried out using the DigiGait imaging system (Mouse 
Specifics, Boston, MA) as described (Kale et al., 2004). Digital videos were 
captured as mice were challenged to run at varying speeds (10 and 25cm/s) on a 
transparent treadmill. Mice were contained within a plexiglass chamber (figure 
2-3), with front and rear bumpers, that was placed on top of the treadmill to 
ensure the animals remained visible to the camera at all times. Mice were given 
1-2 minutes to accommodate before starting the test. The treadmill belt was 
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cleaned with 70 % EtOH after each run. A run was considered as successful if the 
animals could run at the set speed for 10 consecutive steps (~ 2 seconds) without 
sliding back and hitting the rear bumper with their hindquarters. 
 
Figure 2-3 DigiGait apparatus 
An image showing the DigiGait apparatus that was used for the treadmill test. Mice were 
challenged to run on a transparent treadmill belt (white arrow) and their movement were 
captured by a camera fixed underneath the belt. Mice were kept in the view of the camera by 
front and rear bumpers (black arrows). 
2.16 Open Field Testing 
Motor function and anxiety were evaluated using the well-established open field 
test (Choleris et al., 2001). Mice were placed in the centre of a 60 cm diameter 
arena (with opaque wall that the mouse cannot see outside, figure 2-4) and 
allowed to ambulate freely for 40 minutes during which time the experimenter 
left the room. The arena was filmed using an overhead digital camera and the 
mouse was tracked using Ethovision 3.1 tracking software (Noldus Inc,. Leesburg, 
VA). The digital track produced by the animal was then analysed by the software 
and various motor and anxiety parameters were calculated. All animals tested 
were between 9-11 weeks old.  
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Figure 2-4 Open field test 
Images showing the open field test. (1and 2) show The open field arena. (3) Camera fixed on 
the top of the arena to trace mice movement. (4 and 5) the movement was tracked and 
analysed by Ethovision 3.1 tracking software. 
2.17 Whole body plethysmograph 
Respiratory phenotype was determined in a conscious and unrestrained animal 
using whole body plethysmography (EMMS, Bordon, U.K.). Animals were placed 
inside a plexiglass chamber (figure 2-5) for 20 minutes to become adapted to the 
environment after which their breathing was monitored for 30 minutes. A 
continuous bias airflow supply allowed the animal to be kept in the chamber for 
extended periods of time. Pressure changes caused by alterations in the 
temperature and humidity of the air as it enters and leaves the subjects lungs 
were detected by a pressure transducer. This analogue signal was amplified and 
converted to a digital display by the custom software to produce a waveform 
representing the breathing pattern of the animal. This waveform was then 
exported and analysed using pClamp 10.2 (Molecular Devices inc., California, 
USA). Pressure changes were calibrated by injecting 1ml of air via syringe. 
Respiratory waveforms were analysed for frequency, frequency variability and 
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the presence of abnormal breaths /apnoeas (expiratory pauses >3 breaths (Lioy 
et al., 2011). 
 
Figure 2-5 Whole body plethysmograph apparatus 
Images of the whole body plethysmograph used for assessment of the breathing 
phenotype. (1 and 2) plexiglass chambers. (3) Source for air supply. (4 and 5) changes in the 
chambers transmitted by pressure transducer to be analysed by (EMMS, Bordon, U.K.) 
software. 
2.18 Statistical analysis 
Differences between treatment groups were analysed using 2-way ANOVA, 
repeated measures ANOVA, one way ANOVA, Fisher‟s exact test, or Student‟s T-
test where appropriate. p < 0.05 was used to define statistical significance. 
 
 
Chapter 3 
Generation of Lentivirus vector-based approach to 
deliver exogenous Mecp2 in vitro and in vivo 
  
3.1 Introduction  
The characteristic neurological phenotype in RTT patients (Neul et al., 2010) and 
in Mecp2 knockout mouse models (Chen et al., 2001) in addition to the rescue of 
RTT-like phenotypes in mouse models by delayed activation of endogenous 
Mecp2 in the brain suggests that RTT can be potentially treated at the gene level 
by introducing a functional copy of Mecp2 into the brain. Therefore the 
availability of functional copy of Mecp2 and suitable viral vector that can 
transfer Mecp2 into brain cells (neurons and glia) is important to test this 
approach. 
Lentiviral vectors are useful tools for transgene delivery to the brain as it can 
transduce neurons with enduring gene expression (Trowbridge et al., 1980, 
Blomer et al., 1996). Lentiviral vectors contain only the cis elements required 
for nuclear targeting and integration to the host genome whereas all viral genes 
responsible for viral infection and assembly are supplied in trans by number of 
plasmids to generate replication incompetent virus. 
Mecp2_e1 is the most abundant Mecp2 isoform throughout the brain (Dragich et 
al., 2007) and is translated more efficiently in vivo compared to Mecp2_e2 
(Kriaucionis and Bird, 2004). Mutations in exon1 (only translated in Mecp2_e1) 
cause neurological manifestation and affect Mecp2_e2 translation (Mnatzakanian 
et al., 2004, Saxena et al., 2006). A recent report showed that Mecp2_e2 is more 
up regulated during neuron-induced toxicity and its forced overexpression 
enhanced apoptosis in healthy neurons, moreover knocking down Mecp2_e2 
achieved a neuron-protective effect (Dastidar et al., 2012). Therefore I decided 
to focus on using Mecp2_e1 minigene in this study.  
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Fluorescent proteins (FPs) are widely used to study cell dynamics and as a 
marker for fusion proteins to help identify their cellular location, expression 
level and interactions. Red fluorescent proteins (RFP), used in conjunction with 
the well-established green fluorescent protein (GFP), broadens the spectrum of 
protein labelling and permits protein-protein interaction studies, however a 
wide range of FP variants has now been generated that covers nearly the entire 
visible spectrum (Rizzo et al., 2009) .  RFP  has a maximum of fluorescence 
emission above 558 nm and absorption maximum at 583 nm (Wachter et al., 
2010). RFP has been used, through recombinant DNA technology, to visualize 
many proteins in vitro (Park et al., 2007) and in vivo (Brolund et al., 2011) 
without reports of altered dynamic changes (e.g. misfolding or abnormal 
conformational changes). The RFP induced fluorescence allows rapid 
visualization and characterization of the fused protein in the real time and in 
fixed material without the need for immunolabelling reaction.  
Several epitopes have been used for labelling recombinant proteins to reveal 
their cellular location, expression level and posttranslational alterations. Flag-
tag was the first generated 8 amino acid polypeptide to be used for protein 
tagging. It helps protein localization and can be employed for 
immunocytochemistry and for western blot analysis. The FLAG tag is more 
hydrophilic than other common epitope tags and is therefore not likely to cause 
abnormal folding of the tagged proteins (Braun, 1995).  
3.2 Study aims 
The main aim of the work described in this chapter was to develop a lentiviral 
vector system with various promoters to enable delivery of tagged Mecp2_e1 
encoding sequences into the brain of Mecp2 knockout mice. The specific 
objectives of this study are: 
I. To generate a fusion construct in which Mecp2_e1 (ME1) minigene is tagged at 
the C-terminal with Flag-epitope and RFP. This construct should permit 
tracing exogenous Mecp2 expression in real time and in fixed tissues. 
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II. Cloning of ME1FlagRFP fusion construct into lentiviral vectors with various 
promoters including; the synapsin1 (syn1), neuron specific, or the 
phosphoglycerate kinase (PGK), ubiquitous, promoter. 
III. Generation of Lentivirus particles to enable exogenous Mecp2_e1 delivery into 
Mecp2 deficient cells in vitro and in vivo. 
3.3 Generation of lenti-syn1/PGK-ME1FlagRFP vectors 
3.3.1 Creation of ME1FlagRFP fusion construct 
pCDNA3.1 Zeo(+) RFP (pCDNARFP) is a mammalian expression vector  (5.678 kb) 
that contains the red fluorescence protein (RFP) gene (678 bp) cloned between 
BamH1 and EcoR1 restriction sites under the control of CMV promoter (figure3-
1). Analysis of the multiple cloning sites of this vector showed the presence of 
Nhe1 restriction site upstream to the RFP encoding sequences. On the same 
time, mapping the restriction sites in ME1Flag sequences showed that Nhe1 and 
bamh1 sequences are not present in this construct. Therefore Nhe1 and EcoR1 
are suitable restriction enzymes to create sticky ends of both ME1Flag and 
pCDNARFP vector for future cloning. 
To create ME1 with C-terminal FlagRFP (figure 3-1), a polymerase chain reaction 
(PCR)  was used to amplify ME1 (1.5 kb) minigene from pRSV40- ME1 vector using 
Forward primer (Fpr), 5`TTT GCTAGC ATG GCC GCC GCT GCC 3`, that contains 
an Nhe1 restriction site (underlined) and reverse primer (Rpr), 5`AAA GGA TCC 
GC CTT GTC ATC GTC GTC CTT GTA GTC GCT AAC TCT CTC GGT`3, that contains 
Flag-tag coding sequences (double underline) and BamH1 restriction site (single 
underline). Two base pairs (grey colour) were added to this primer to keep the 
downstream RFP on frame. This primer also precludes the ME1 stop codon to 
allow read-through the downstream flag-tag and RFP encoding sequences (figure 
3-1). Gel electrophoresis of the PCR product resulted from this reaction showed 
a band size of approximately 1.5 kb which is corresponding to the expected ME1 
band-size (figure 3-2).  
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Figure 3-1 Cloning strategy of ME1FlagRFP fusion construct 
Simplified cartoon showing the cloning steps of Mecp2 encoding sequences into 
pCDNARFP vector (1) ME1 minigene with C-terminal Flag-tag coding sequences (ME1Flag) 
was amplified by PCR. (2) ME1Flag construct and pCDNARFP vector were cut by EcoR1 and 
BamH1 restriction enzymes. (3) Ligation reaction was performed to insert ME1Flag fusion 
construct at the N-terminal end of the RFP to generate pCDNAME1FlagRFP plasmid. Amp; 
Ampicillin resistance gene, CMV; Cytomegalovirus promoter. 
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In order to clone the ME1Flag fusion construct to the N-terminal end of the RFP, 
both the PCR product and the pCDNARFP vector were cut by Nhe1 and BamH1 
restriction enzymes to create compatible sticky ends. The PCR product was then 
cleaned to remove residual primers and buffers using PCR cleaning kits (Qiagen). 
The pCDNARFP vector was cut from the gel and purified using gel extraction kits 
(Qiagen). Both doubly cut insert and vector (molar ratio of 3:1 respectively) 
were ligated together using T4 DNA ligase enzyme. 
 
Figure 3-2 PCR amplification of ME1Flag fusion construct. 
Gel image showing the resulting PCR product after amplification of ME1Flag fusion 
construct. The PCR product size is 1.5 kb which is equivalent to the size of ME1Flag coding 
sequence. M; 1 KB DNA ladder. 
3.3.2 Validation of the pCDNAME1FlagRFP construct 
The ligation reaction was transformed and plated onto ampicillin plates (50 
µg/ml, see chapter 2). The Plasmid DNA preparation was then carried out for all 
resulting colonies (N = 9). In order to identify plasmids that contain the new 
construct (ME1Flag), 0.1-1ng of each plasmid was used as a template for a PCR 
reaction using the same Fpr and Rpr primers that were used to amplify ME1Flag 
sequences. A parallel PCR reaction using the pRSV-40ME1 plasmid as a template 
was carried out (positive control). Six of the plasmids generated PCR products of 
1.5 kb band size; this was comparable to the positive control band size, 
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suggesting that ME1Flag encoding sequences were successfully cloned into 
pCDNARFP vector (figure3-3).  
 
 
Figure 3-3 PCR verification of pCDNARFP vectors for successful cloning of ME1Flag fusion 
construct. 
Gel image showing PCR amplification of ME1 minigene from plasmid DNA preparations 
obtained after the transformation with the ligation mix of ME1Flag and pCDNARFP vector. 
Lane 1 shows the positive control reaction with band size of 1.5kb (ME1 minigene). Lanes 2, 
4 and 9 show no PCR band suggesting failed cloning process. Lanes 3, 5-8 and 10 show 
PCR bands (1.5kb) that are equal to the ME1 minigene band size and similar to the positive 
control band, indicating successful cloning of ME1Flag fusion construct into pCDNARFP 
vector. M; 1 kb DNA ladder.  
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To further confirm the structure of the new pCDNARFP vector after successful 
cloning of ME1Flag fusion construct (henceforth referred to as 
pCDNAME1FlagRFP) 1 µg of this plasmid was examined by restriction digest using 
restriction enzymes (Nhe1, BamH1 and EcoR1) that flank the fusion construct 
(figure3-4A). BamH1 and EcoR1 double restriction digest gave rise to two bands, 
sized 0.6 and 6.5 kb (figure3-4B), which are corresponding to the size of the RFP 
gene and pCDNAME1Flag vector respectively. Nhe1 and BamH1 double restriction 
digest resulted in two bands sized 1.5 and 5.6 kb, which are equivalent to the 
ME1 gene and to pCDNARFP vector respectively. Finally, Nhe1 and EcoR1 double 
restriction digest produced two bands, sized 2.1 and 5.0 kb which are equal to 
the size of the MR1FlagRFP and pCDNA vector respectively. These results, 
together with the previous PCR data indicate the successful generation of a new 
vector construct (figure 3-5) that contains the ME1 minigene with a C-terminal 
flag-tag and RFP under the control of the CMV promoter in the pCDNA vector. 
The new plasmid pCDNAME1FlagRFP was also sequenced used primers that 
anneal to specific sequences on the vector backbone and flank ME1FlagRFP 
fusion construct confirmed the presence of ME1FlagRFP construct with 100% 
sequence identity to that of ME1 (GenBank accession No. NM_001081979.1) and 
RFP (GenBank accession No. EF212309.1) sequences.  
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Figure 3-4 Restriction digest validation of pCDNAME1FlagRFP. 
(A) Diagram showing the expected band-sizes after restriction digestion of 
pCDNAME1FlagRFP with Nhe1, EcoR1 and BamH1. (B) Gel image showing the bands size 
after restriction digest (RD). Lane 1 shows undigested vector. Lane 2 shows RD with BamH1 
and EcoR1 that gives 2 bands sized 6.5 and 0.687 kb which represents the pCDNAME1Flag 
vector and the RFP gene respectively. Lane 3 shows RD with Nhe1 and BamH1 that 
produced bands sized 5.7 and 1.5 kb representing pCDNARFP vector and ME1Flag fusion 
construct respectively. Lane 4 shows RD with Nhe1 and EcoR1 that resulted in generation 
of bands sized 5 and 2.1 kb corresponding to pCDNA vector and ME1FlagRFP fusion 
construct respectively. M; 1 kb DNA ladder. 
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Figure 3-5 pCDNA(+)ZeoME1FlagRFP vector map. 
A simplified plasmid map of the pCDNAME1FlagRFP vector showing the C-terminal flag-
tagged ME1 minigene that was incorporated in frame with the N-terminal end of the RFP 
gene between Nhe1 and BamH1 restriction sites. This fusion construct is under the control 
of CMV (ubiquitous) promoter. Amp, ampicillin resistance gene, expressed under EM7 and 
SV40 promoters. F1 and PUC are the origins of replication in E-Coli. 
3.3.3 Cloning of ME1FlagRFP fusion construct into Lentivirus 
vector backbone 
To enable Mecp2 delivery into Mecp2 deficient cells, I decided to clone 
ME1FlagRFP fusion construct into lentiviral backbone which is known to produce 
high transduction efficiency in vitro and in vivo. Two lentiviral vectors were 
used in this study; one contains the synapsin1 promoter (neuron- specific) and 
the second one contains the PGK (ubiquitous) promoter. Restriction mapping of 
the lentiviral vectors showed the presence of two unique restriction sites; Nhe1 
and EcoR1 flanking the EGFP encoding sequences (figure 3-6). The same 
restriction sites are also flanking the ME1FlagRFP fusion construct in the 
pCDNAME1FlagRFP vector. Therefore to clone ME1FlagRFP fusion construct into 
lentiviral vectors, both pCDNAME1FlagRFP and lentiviral vectors were restriction 
digested with Nhe1 and EcoR1 restriction enzymes to generate compatible sticky 
ends. Lentiviral vectors and ME1FlagRFP bands were cut from the gel and gel 
extracted using gel extraction kits and ligated together using T4 DNA ligase.  
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Figure 3-6 Cloning strategy for ME1FlagRFP fusion construct insertion into lentiviral vector 
backbones. 
ME1FlagRFP fusion construct was cloned using EcoR1 and Nhe1 restriction enzymes. 
EGFP gene was cloned into lentiviral vectors using the same restriction enzymes. (1) 
Compatible sticky ends were generated in lentiviral vectors and ME1FlagRFP fusion 
construct by double RD with Nhe1 and EcoR1. (2) DNA gel extraction was followed by 
ligation of the linearized lentiviral vectors and ME1FlagRFP construct to create new plenti-
PGK/Syn1-ME1FlagRFP vectors. 
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3.3.4 Confirmation of lenti-PGK/syn1-ME1FlagRFP constructs 
To verify the cloning of the ME1FlagRFP fusion construct into the lentiviral 
vectors, all the bacterial colonies grown on the transformation plates were sub 
cultured and the plasmid DNA was extracted. PCR reactions using primers 
specific for ME1Flag sequences were used to confirm the presence of ME1Flag 
sequences in the lentiviral vectors. Analysis of the electrophoresis gel showed 
PCR product size of 1.5kb (figure 3-7) which are equivalent to the size of 
ME1Flag sequences, suggesting that ME1FlagRFP sequences are successfully 
cloned into both lenti-PGK and Lenti-syn1 vectors (these constructs hereafter 
referred to as plenti-PGK-ME1flagRFP and plenti-syn1-ME1FlagRFP). 
For additional confirmation of successful ME1FlagRFP insertion into the lentiviral 
vectors, both plenti-PGK-ME1FlagRFP and plenti-syn1-ME1FlagRFP were 
restriction digested with Nhe1 and EcoR1 restriction enzymes (figure 3-8A). Both 
vectors showed two bands; one is equal to ~ 2.2kb (figure 3-8B) which is 
equivalent to the ME1FlagRFP band size and the other band is 7.0 kb which is 
equal to lentiviral vector backbones. Final validation of the plenti-PGK/syn1-
ME1FlagRFP Vector constructs (figure 3-9) was carried out by plasmid DNA 
sequencing (figure 3-10). Alignment of the fusion construct sequence and mouse 
Mecp2_e1 (Gen Bank accession No. NM_011081979.1) and RFP (Gen Bank 
accession No. EF212309.1) nucleotide sequences revealed complete identity 
between the sequences  
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Figure 3-7 PCR validation of lenti-PGK-ME1FlagRFP 
Gel image shows PCR amplification of ME1 minigene to validate the creation of the plenti-
ME1FlagRFP constructs. Lane 1 shows the positive control. Lane2-5 show reactions based 
on the proposed plenti-PGK-ME1FlagRFP plasmids, presence of ME1 equivalent bands size 
indicates successful cloning. Lane 6-9 show PCR reactions based on the proposed plenti-
Syn1-ME1FlagRFP plasmid templates, presence of bands size equal to ME1 band (1.5kb) 
denotes positive cloning. M; 1 kb ladder.  
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Figure 3-8 Restriction digest confirmation of plenti-PGK/syn1-ME1FlagRFP. 
(a) Diagram showing the expected band sizes after restriction digest of lentiviral vectors. (b) 
Gel image showing restriction digest of lenti-vectors by Nhe1 and EcoR1 enzymes. Lane 1 
shows the undigested vector plenty-PGK-ME1FlagRFP. Lane 2 shows restriction digest of 
plenty-PGK-ME1FlagRFP that show; one band at 2.1 kb (ME1FlagRFP) and another band at 
7kb that represents plenti-PGK vector. The extra band at 7 kb could possibly be an open 
circular uncut vector. Lane 3 shows restriction digest of plenti-syn1-ME1FlagRFP that 
shows 2 bands; one at 2.1kb that represents ME1FlagRFP and the other at 7kb that 
represents plenti-syn1 vector. M; I kb DNA ladder.  
a 
b 
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Figure 3-9 plenti-PGK/syn1-ME1FlagRFP vector map. 
Plasmid map showing the main components of Lentivirus based-vectors. ME1 with a C-
terminal FlagRFP fusion was inserted downstream to either the PGK (ubiquitous) or the 
synapsin1 (neuron specific) promoter. Both the transgene and the promoter are 
incorporated between both LTRs (essential for integration into the host genome). 
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plenti-ME1FlagRFP      CCGGGGCTAGCATGGCCGCCGCTGCCGCCACCGCCGCCGCCGCCGCCGCGCCGAGCGGAG 180 
Mecp2                  -----------ATGGCCGCCGCTGCCGCCACCGCCGCCGCCGCCGCCGCGCCGAGCGGAG 49 
                                  ************************************************* 
plenti-ME1FlagRFP      GAGGAGGAGGAGGCGAGGAGGAGAGACTGGAGGAAAAGTCAGAAGACCAGGATCTCCAGG 240 
Mecp2                  GAGGAGGAGGAGGCGAGGAGGAGAGACTGGAGGAAAAGTCAGAAGACCAGGATCTCCAGG 109 
                       ************************************************************ 
plenti-ME1FlagRFP      GCCTCAGAGACAAGCCACTGAAGTTTAAGAAGGCGAAGAAAGACAAGAAGGAGGACAAAG 300 
Mecp2                  GCCTCAGAGACAAGCCACTGAAGTTTAAGAAGGCGAAGAAAGACAAGAAGGAGGACAAAG 169 
                       ************************************************************ 
plenti-ME1FlagRFP      AAGGCAAGCATGAGCCACTACAACCTTCAGCCCACCATTCTGCAGAGCCAGCAGAGGCAG 360 
Mecp2                  AAGGCAAGCATGAGCCACTACAACCTTCAGCCCACCATTCTGCAGAGCCAGCAGAGGCAG 229 
                       ************************************************************ 
plenti-ME1FlagRFP      GCAAAGCAGAAACATCAGAAAGCTCAGGCTCTGCCCCAGCAGTGCCAGAAGCCTCGGCTT 420 
Mecp2                  GCAAAGCAGAAACATCAGAAAGCTCAGGCTCTGCCCCAGCAGTGCCAGAAGCCTCGGCTT 289 
                       ************************************************************ 
plenti-ME1FlagRFP      CCCCCAAACAGCGGCGCTCCATTATCCGTGACCGGGGACCTATGTATGATGACCCCACCT 480 
Mecp2                  CCCCCAAACAGCGGCGCTCCATTATCCGTGACCGGGGACCTATGTATGATGACCCCACCT 349 
                       ************************************************************ 
plenti-ME1FlagRFP      TGCCTGAAGGTTGGACACGAAAGCTTAAACAAAGGAAGTCTGGCCGATCTGCTGGAAAGT 540 
Mecp2                  TGCCTGAAGGTTGGACACGAAAGCTTAAACAAAGGAAGTCTGGCCGATCTGCTGGAAAGT 409 
                       ************************************************************ 
plenti-ME1FlagRFP      ATGATGTATATTTGATCAATCCCCAGGGAAAAGCTTTTCGCTCTAAAGTAGAATTGATTG 600 
Mecp2                  ATGATGTATATTTGATCAATCCCCAGGGAAAAGCTTTTCGCTCTAAAGTAGAATTGATTG 469 
                       ************************************************************ 
plenti-ME1FlagRFP      CATACTTTGAAAAGGTGGGAGACACCTCCTTGGACCCTAATGATTTTGACTTCACGGTAA 660 
Mecp2                  CATACTTTGAAAAGGTGGGAGACACCTCCTTGGACCCTAATGATTTTGACTTCACGGTAA 529 
                       ************************************************************ 
plenti-ME1FlagRFP      CTGGGAGAGGGAGCCCCTCCAGGAGAGAGCAGAAACCACCTAAGAAGCCCAAATCTCCCA 720 
Mecp2                  CTGGGAGAGGGAGCCCCTCCAGGAGAGAGCAGAAACCACCTAAGAAGCCCAAATCTCCCA 589 
                       ************************************************************ 
plenti-ME1FlagRFP      AAGCTCCAGGAACTGGCAGGGGTCGGGGACGCCCCAAAGGGAGCGGCACTGGGAGACCAA 780 
Mecp2                  AAGCTCCAGGAACTGGCAGGGGTCGGGGACGCCCCAAAGGGAGCGGCACTGGGAGACCAA 649 
                       ************************************************************ 
plenti-ME1FlagRFP      AGGCAGCAGCATCAGAAGGTGTTCAGGTGAAAAGGGTCCTGGAGAAGAGCCCTGGGAAAC 840 
Mecp2                  AGGCAGCAGCATCAGAAGGTGTTCAGGTGAAAAGGGTCCTGGAGAAGAGCCCTGGGAAAC 709 
                       ************************************************************ 
plenti-ME1FlagRFP      TTGTTGTCAAGATGCCTTTCCAAGCATCGCCTGGGGGTAAGGGTGAGGGAGGTGGGGCTA 900 
Mecp2                  TTGTTGTCAAGATGCCTTTCCAAGCATCGCCTGGGGGTAAGGGTGAGGGAGGTGGGGCTA 769 
                       ************************************************************ 
plenti-ME1FlagRFP      CCACATCTGCCCAGGTCATGGTGATCAAACGCCCTGGCAGAAAGCGAAAAGCTGAAGCTG 960 
Mecp2                  CCACATCTGCCCAGGTCATGGTGATCAAACGCCCTGGCAGAAAGCGAAAAGCTGAAGCTG 829 
                       ************************************************************ 
plenti-ME1FlagRFP      ACCCCCAGGCCATTCCTAAGAAACGGGGTAGAAAGCCTGGGAGTGTGGTGGCAGCTGCTG 1020 
Mecp2                  ACCCCCAGGCCATTCCTAAGAAACGGGGTAGAAAGCCTGGGAGTGTGGTGGCAGCTGCTG 889 
                       ************************************************************ 
plenti-ME1FlagRFP      CAGCTGAGGCCAAAAAGAAAGCCGTGAAGGAGTCTTCCATACGGTCTGTGCATGAGACTG 1080 
Mecp2                  CAGCTGAGGCCAAAAAGAAAGCCGTGAAGGAGTCTTCCATACGGTCTGTGCATGAGACTG 949 
                       ************************************************************ 
plenti-ME1FlagRFP      TGCTCCCCATCAAGAAGCGCAAGACCCGGGAGACGGTCAGCATCGAGGTCAAGGAAGTGG 1140 
Mecp2                  TGCTCCCCATCAAGAAGCGCAAGACCCGGGAGACGGTCAGCATCGAGGTCAAGGAAGTGG 1009 
                       ************************************************************ 
plenti-ME1FlagRFP      TGAAGCCCCTGCTGGTGTCCACCCTTGGTGAGAAAAGCGGGAAGGGACTGAAGACCTGCA 1200 
Mecp2                  TGAAGCCCCTGCTGGTGTCCACCCTTGGTGAGAAAAGCGGGAAGGGACTGAAGACCTGCA 1069 
                       ************************************************************ 
plenti-ME1FlagRFP      AGAGCCCTGGGCGTAAAAGCAAGGAGAGCAGCCCCAAGGGGCGCAGCAGCAGTGCCTCCT 1260 
Mecp2                  AGAGCCCTGGGCGTAAAAGCAAGGAGAGCAGCCCCAAGGGGCGCAGCAGCAGTGCCTCCT 1129 
                       ************************************************************ 
plenti-ME1FlagRFP      CCCCACCTAAGAAGGAGCACCATCATCACCACCATCACTCAGAGTCCACAAAGGCCCCCA 1320 
Mecp2                  CCCCACCTAAGAAGGAGCACCATCATCACCACCATCACTCAGAGTCCACAAAGGCCCCCA 1189 
                       ************************************************************ 
plenti-ME1FlagRFP      TGCCACTGCTCCCATCCCCACCCCCACCTGAGCCTGAGAGCTCTGAGGACCCCATCAGCC 1380 
Mecp2                  TGCCACTGCTCCCATCCCCACCCCCACCTGAGCCTGAGAGCTCTGAGGACCCCATCAGCC 1249 
                       ************************************************************ 
plenti-ME1FlagRFP      CCCCTGAGCCTCAGGACTTGAGCAGCAGCATCTGCAAAGAAGAGAAGATGCCCCGAGGAG 1440 
Mecp2                  CCCCTGAGCCTCAGGACTTGAGCAGCAGCATCTGCAAAGAAGAGAAGATGCCCCGAGGAG 1309 
                       ************************************************************ 
plenti-ME1FlagRFP      GCTCACTGGAAAGCGATGGCTGCCCCAAGGAGCCAGCTAAGACTCAGCCTATGGTCGCCA 1500 
Mecp2                  GCTCACTGGAAAGCGATGGCTGCCCCAAGGAGCCAGCTAAGACTCAGCCTATGGTCGCCA 1369 
                       ************************************************************ 
plenti-ME1FlagRFP      CCACTACCACAGTTGCAGAAAAGTACAAACACCGAGGGGAGGGAGAGCGCAAAGACATTG 1560 
Mecp2                  CCACTACCACAGTTGCAGAAAAGTACAAACACCGAGGGGAGGGAGAGCGCAAAGACATTG 1429 
                       ************************************************************ 
plenti-ME1FlagRFP      TTTCATCTTCCATGCCAAGGCCAAACAGAGAGGAGCCTGTGGACAGCCGGACGCCCGTGA 1620 
Mecp2                  TTTCATCTTCCATGCCAAGGCCAAACAGAGAGGAGCCTGTGGACAGCCGGACGCCCGTGA 1489 
                       ************************************************************ 
plenti-ME1FlagRFP      CCGAGAGAGTTAGC--- 1634 
Mecp2                  CCGAGAGAGTTAGCTGA 1506 
                       **************    
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plenti-ME1FlagRFP      GACTACAAGGACGACGATGACAAGGCGGATCCGATGGCCTCCTCCGAGGACGTCATCAAG 60 
RFP                    ---------------------------------ATGGCCTCCTCCGAGGACGTCATCAAG 27 
                                                        *************************** 
plenti-ME1FlagRFP      GAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATC 120 
RFP                    GAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATC 87 
                       ************************************************************ 
plenti-ME1FlagRFP      GAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACC 180 
RFP                    GAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACC 147 
                       ************************************************************ 
plenti-ME1FlagRFP      AAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCCAGTACGGCTCC 240 
RFP                    AAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCCAGTACGGCTCC 207 
                       ************************************************************ 
plenti-ME1FlagRFP      AAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAG 300 
RFP                    AAGGCCTACGTGAAGCACCCCGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAG 267 
                       ************************************************************ 
plenti-ME1FlagRFP      GGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAG 360 
RFP                    GGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAG 327 
                       ************************************************************ 
plenti-ME1FlagRFP      GACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTC 420 
RFP                    GACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTC 387 
                       ************************************************************ 
plenti-ME1FlagRFP      CCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGG 480 
RFP                    CCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGG 447 
                       ************************************************************ 
plenti-ME1FlagRFP      ATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGATGAGGCTGAAGCTGAAGGAC 540 
RFP                    ATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGATGAGGCTGAAGCTGAAGGAC 507 
                       ************************************************************ 
plenti-ME1FlagRFP      GGCGGCCACTACGACGCCGAGGTCAAGACCACCTACATGGCCAAGAAGCCCGTGCAGCTG 600 
RFP                    GGCGGCCACTACGACGCCGAGGTCAAGACCACCTACATGGCCAAGAAGCCCGTGCAGCTG 567 
                       ************************************************************ 
plenti-ME1FlagRFP      CCCGGCGCCTACAAGACCGACATCAAGCTGGACATCACCTCCCACAACGAGGACTACACC 660 
RFP                    CCCGGCGCCTACAAGACCGACATCAAGCTGGACATCACCTCCCACAACGAGGACTACACC 627 
                       ************************************************************ 
plenti-ME1FlagRFP      ATCGTGGAACAGTACGAGCGCGCCGAGGGCCGCCACTCCACCGGCGCCTAAGAATTCGTC 720 
RFP                    ATCGTGGAACAGTACGAGCGCGCCGAGGGCCGCCACTCCACCGGCGCCTAA--------- 678 
                       ***************************************************          
                                                 
 
 
 
 
3.3.5 Delivery of exogenous Mecp2 into hippocampal cell culture 
using Ca2+ phosphate transfection method. 
To test the ability of plenti-ME1FlagRFP plasmids to express exogenous Mecp2 in 
vitro, dissociated rat hippocampal cell culture was transfected with either 
plenti-PGK-ME1FlagRFP or plenti-syn1-ME1FlagRFP plasmids using Ca2+ phosphate 
transfection method (chapter 2). Mecp2FlagRFP expression was investigated 17 
hours post-transfection. Live image analysis showed that the RFP fluorescence 
was localized to the nuclei of cultured cells (figure 3-11). To further confirm the 
nuclear localization of the transgene, cultured neuronal cells were fixed with 4% 
PFA and stained with DAPI. RFP fluorescence (indicator of exogenous Mecp2) was 
co-localized with DAPI-stained nuclei indicating nuclear targeting. These results 
confirmed that both lentiviral vectors are able to express exogenous Mecp2 and 
 
Figure 3-10 Sequence alignment of ME1FlagRFP to the mouse Mecp2_e1 and RFP encoding 
sequences. 
ME1 sequence was compared to mouse Mecp2_e1 sequence (NM_001081979.1, yellow 
colour). Whereas the cloned RFP gene sequence was compared to RFP sequences 
(EF212309.1, red colour). Flag sequence was confirmed upstream to the RFP gene (green 
colour). Two nucleotide bases (blue colour) were included to keep RFP in frame. Restriction 
endonuclease sites that were used for generating the fusion construct are underlined (Nhe1, 
BamH1 and EcoR1 respectively). The Mecp2 start codon (purple colour) is used to start 
translation whereas the stop codon (grey colour) of the RFP is used to stop translation. * 
indicates identical nucleotide 
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that this exogenous protein recapitulates similar expression pattern, in vitro, to 
that of the endogenous Mecp2.  
 
Figure 3-11 Lenti-PGK/syn1-ME1FlagRFP vectors express ME1FlagRFP fusion protein in 
hippocampal disscoiated culture. 
Micrographs showing exogenous ME1FlagRFP expression in the rat hippocampal 
dissociated culture. Culture was transfected with (a) plenti-PGK-ME1FlagRFP or (b) plenti-
syn1-ME1FlagRFP using Ca
2+
 phosphate transfection. (i-iii)  Live images showing the RFP 
fluorescence that is confined to the nuclei of the cultured hippocampal cells (White arrows). 
(iv-vi) cultured cells were fixed with 4% PFA and stained with DAPI. RFP fluorescence is co-
localised with DAPI-stained nuclei indicating nuclear targeting of the exogenous Mecp2 (red 
arrows). Scale bar = 20 µm. 
3.3.6 Generation and titration of Lentivirus particles 
To generate Lentivirus particles, human embryonic kidney cells (HEK293T) were 
transfected with plenti-ME1FlagRFP plasmids together with packaging plasmid to 
supply the essential viral proteins (chapter 2). To test the efficiency of the viral 
particles, HEK293T cells were transduced with 1 µl of the concentrated 
particles. After 72 hours the culture was fixed with 4% PFA and stained with 
DAPI. RFP fluorescence was observed in the nuclei of HEK cells; however, 
transduction efficiency was shown to be low (figure 3-11a) as indicated by the 
low percentage of cells expressing the transgene compared to DAPI-stained 
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nuclei. High virus titre is required to achieve high transduction efficiency, 
especially for the in vivo studies. Therefore I optimized the virus production 
protocol by increasing the quantity of virus containing media (through increasing 
the number of transfected culture flasks) with subsequent consecutive 
concentration using the ultracentrifuge. The virus particles generated by the 
adjusted protocol displayed high transduction efficiency (figure 3-11b) with virus 
titres between 107 and 108 IU/ml.
 
Figure 3-12 HEK293T cells transduced with lenti-PGK-ME1FlagRFP virus particles. 
Micrograph showing the transduction efficiency of lentivirus particles in HEK cells.1 µl of 
the concentrated virus was used for transducing HEK cells. (a) Low viral titre displayed 
lower transduction efficiency (as indicated by low number of transgene expressing (red) 
cells (i) compared to DAPI-stained nuclei (blue) (ii). (b) Increased transduction efficiency (i) 
after the production of high titre viruses with the majority of DAPI-stained nuclei showing 
transgene expression (ii). Note some cells are brighter than others probably as a result of 
differences in the multiplicity of infection. Scale bar = 20 µm. 
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3.3.7 Time course expression analysis of lenti-mediated delivery 
of Mecp2 
To study the expression time course of the Lentivirus-derived products in vitro, 
dissociated hippocampal neuron cultures (N = 2) were transduced with 1µl of 107 
IU/ml (104 IU) of lenti-syn1-ME1FlagRFP. Cover slips were fixed with 4% PFA at 
24, 84, 72, 96 and 120 hours post-transduction and stained with DAPI. Images of 
6-8 random fields were captured and the percentage of transduced cells counted 
as a proportion of the number of DAPI-stained nuclei at each time point (figure 
3-12). ME1flagRFP expression was detectable as early as 24 hours after lenti-
transduction (3.4 ± 1.3%). The number of transgene expressing cells increased 
steadily but not linearly with time to 25.3 ± 2.4% after 120 hours of transfection.  
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Figure 3-13 Time course expression analysis of exogenous Mecp2. 
Plot showing transduction efficiency over time of lenti-syn1-ME1FlagRFP in neuronal cell 
culture. Note that transgene expression was observed after 24 hours with marked increase 
in the transduction efficiency after 5 days. Data are presented as mean ± SEM. 
3.4 Discussion  
The monogenic nature of RTT combined with studies showing phenotypic 
reversal after delayed reactivation of the Mecp2 gene (Giacometti et al., 2007, 
Guy et al., 2007) makes RTT an attractive target for gene therapy. However, in 
order to study potential therapeutic applications, cloning of the Mecp2 minigene 
into viral vectors was essential to achieve high transduction efficiency and to 
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allow in vivo studies. MeCP2 protein has two isoforms; MeCP2_e1 and MeCP2_e2 
that result from alternative splicing of exon one (Kriaucionis and Bird, 2004). 
Both isoform were previously thought to have identical function, however a 
recent report has shown that overexpression of Mecp2_e2 but not Mecp2_e1 
induces neuronal apoptosis and death in cultured cells (Dastidar et al., 
2012).Therefore I generated a fusion construct containing  Mecp2_e1 encoding 
sequences combined with a Flag-epitope tag and RFP gene. 
The importance of the ME1FlagRFP fusion construct is that it enables tracking of 
exogenous Mecp2 expression in real time (by RFP fluorescence) so that studies 
addressing electrophysiological properties can be conducted on transduced (RFP-
positive) and non-transduced cells (RFP-negative) to test the effect of exogenous 
Mecp2 on the electrical properties of null cells. It also helps in discriminating 
exogenous and endogenous Mecp2 in WT cells thus helping to measure and 
adjust the amount of exogenous Mecp2 expression in transduced cells. This is 
important to avoid overexpression related toxicity. These tags also allow 
immunolabelling detection of exogenous Mecp2 in fixed tissues by using anti-Flag 
or anti-RFP antibodies. 
The rescue of RTT-like phenotype after delayed activation of Mecp2 in mouse 
brain (Giacometti et al., 2007) indicates that any attempt at treating RTT at the 
gene level should utilise delivery methods capable of transferring Mecp2 into the 
brain.  Rastegar and colleagues have shown the ability of retrovirus- and 
lentivirus- based vectors to drive expression of Mecp2 in neuronal stem cells and 
dissociated neuronal culture, respectively (Rastegar et al., 2009). However this 
study was confined to dissociated neuronal culture with no data regarding in 
vivo expression or levels of exogenous Mecp2 in transduced cells. Therefore I 
decided to clone a ME1FLAgRFP fusion construct into Lentiviral vectors under the 
control of either the syn1 or the PGK promoter. Syn1, which drives neuron-
specific expression of Mecp2, was chosen as a previous report has shown that 
neuron-specific expression of Mecp2 was able to rescue RTT-like phenotypes in 
Mecp2 knockout mice (Luikenhuis et al., 2004). The PGK promoter, which drives 
expression in both neurons and glia, was chosen based on the growing evidence 
for the role of glia in RTT pathogenesis (Ballas et al., 2009) and the reported 
rescue of RTT-like phenotype after glia-specific activation of Mecp2 in Mecp2 
knockout mice (Lioy et al., 2011).  
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Ca2+ phosphate transfection of rat neuronal dissociated culture using lenti-
syn1/PGK-ME1FlagRFP plasmids showed that the Mecp2FlagRFP fusion protein 
recapitulates the same expression pattern of the endogenous  Mecp2 in rats 
(nuclear targeting with diffuse localization to the euchromatic chromosome 
without tendency to concentrate in distinct areas of the genome) (Lewis et al., 
1992, Nan et al., 1996) without ectopic expression.  Mouse neuronal cultures 
transfected with the same vectors produced an exogenous Mecp2FlagRFP fusion 
protein that followed the same pattern as the endogenous  Mecp2 expression in 
mouse cells (nuclear localization with characteristic heterochromatin 
localization, chapter 4) (Lewis et al., 1992, Nan et al., 1996, Nan et al., 1997) 
indicating that the expression of the fusion product follows the same expression 
pattern and sub-nuclear localization as the endogenous  Mecp2 in different 
species. This data also confirms that cloning of the RFP in the C-terminal end of 
Mecp2 does not interfere with the regular cellular and subcellular localization of 
the transgene.  
Ca2+ phosphate transfection has been reported to display low transfection 
efficiency in vitro (Goetze et al., 2004, Karra and Dahm, 2010) and is not 
applicable for in vivo studies, therefore production of Lentivirus particles was 
necessary for conducting in vivo studies in the animal model of RTT syndrome. 
Initial attempts to generate lentivirus particles showed relatively low titre as 
indicated by low transduction efficiency in HEK cells. These virus particles were 
generated by harvesting virus containing medium obtained from a single 150 cm2 
flask and spinning it down by the ultracentrifuge to precipitate the virus pellet 
which was then re-suspended in 600 µl of PBS. To increase the titre, I modified 
this protocol by scaling up the number of transfected HEK cells to 8 times the 
number used in the initial protocol and re-suspending the final pellet in a 
smaller volume of PBS. This modification increased the virus titre from 104 to 
107-108 IU/ml.  
Time course experiments were also conducted to study the onset and expression 
course of lenti-mediated Mecp2 expression. RFP fluorescence was detected 24 
hours post-transduction with gradual increases in the percentage of 
Mecp2FlagRFP expressing cells over time. Previous report showed that lenti-
mediated transgene expression in cell culture shows peaks after both 6 hours 
and 3 days of transduction (Wang et al., 2005). However very early expression of 
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the transgene could be due to pseudo-transduction (the protein is transferred 
passively within the viral particles) and is not  true transduction (Nash and 
Lever, 2004). Technical issues precluded monitoring of early expressing cells 
over time to discriminate true transduction (persistent expression) from pseudo-
transduction (fading of expression with time due to limited half-life of the 
passively transferred protein). The delayed detection of Mecp2RFP expression in 
some cells could be explained by; (1) reduced viral uptake into the cells 
(electrostatic repulsion between lentivirus and neuron cell surface as both of 
them are negatively charged)(Swaney et al., 1997, Jensen et al., 2003, Denning 
et al., 2012), (2) difference in the transcription machinery in the transduced 
cells, (3) the variability in the onset of neuronal cell recovery (cells were 
transduced 24 hours after culture) (4) the variability in the multiplicity of 
infection (MOI) i.e. number of virus copies per cell. Cells with low MOI require 
more time to produce a detectable level of Mecp2RFP(Wanisch and Yanez-
Munoz, 2009).  
The fact that even after 5 days the maximum transduction efficiency was around 
30% of DAPI-stained nuclei can be explained partially by the low virus titre that 
was used in this experiment and also to the fact that syn1 is a relatively weak 
promoter (require more time to build up detectable protein level (Glover et al., 
2002) and drives expression only in neurons thus excluding glia that might be 
transduced but not expressing the transgene. 
In this chapter I have generated a Lentivirus-based vector to drive expression of 
exogenous Mecp2 in Mecp2 knockout as well as WT cells to help investigate the 
potential therapeutic effects of this approach in both in vitro and in vivo models 
of Rett syndrome.  
 
 
 
 
 
 
Chapter 4 
Lentivirus-mediated delivery of Mecp2 in vitro and 
in vivo in a mouse model of Rett syndrome 
  
4.1 Introduction 
Previous studies have shown that rescue of RTT-like phenotypes in the Mecp2 
knockout mouse model at the gene level is achievable by delayed activation of a 
conditionally silenced endogenous Mecp2 (Giacometti et al., 2007, Guy et al., 
2007).Thus introducing a functional copy of Mecp2 through viral vectors to 
neurons or glia or both of them could be a potential therapeutic avenue for RTT. 
In the last few years huge progress has been made in the field of gene therapy 
through improving vector design and discovering/optimizing many tissue-specific 
promoters (Boulos et al., 2006, Gray et al., 2011b). Previous report, based on a 
published abstract, showed improvement in the locomotor activity after local 
delivery of exogenous Mecp2 in the striatum of Mecp2-null mice (Kosai, 2005), 
however this work has never been published as a full study paper. In addition, 
neurons that have been differentiated from Mecp2-transduced neuronal stem 
cells taken from a Mecp2-/+ heterozygous female mouse, displayed improvement 
in dendritic arborization and spine density (Rastegar et al., 2009).  
As described in chapter 3, I have generated lentivirus-based vectors to drive 
expression of Mecp2-e1 isoform as a fusion construct with RFP and Flag-epitope.  
These vectors were designed to enable exogenous Mecp2 expression under the 
synapsin1 promoter to drive neuron-specific expression (Boulos et al., 2006) of 
Mecp2 because it has been shown that lacking Mecp2 in neurons only resulted in 
RTT-like phenotypes (Chen et al., 2001) whereas delayed activation of Mecp2 
only in neurons rescued RTT-like phenotypes (Luikenhuis et al., 2004) in Mecp2 
knockout mouse model. Recently it has been reported that absence of Mecp2 in 
glia negatively affects normal neuronal growth (Ballas et al., 2009) and 
interestingly delayed activation of Mecp2 in glia only rescued RTT-like 
phenotype in Mecp2 knockout mouse model (Lioy et al., 2011). Therefore I 
generated lentivirus-based vector to drive expression of Mecp2 in both neurons 
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and glia under the control of the PGK (housekeeping) promoter (Hannan et al., 
1993, Wang et al., 2008). In this chapter I utilised these constructs to investigate 
the potentials benefits of exogenous Mecp2 expression in Mecp2 knockout mice 
in vitro and in vivo.  
Many theoretical obstacles impede considering gene therapy as a real highly 
potential approach for RTT therapy; firstly, the transduction efficiency should 
be high enough to compensate for the global absence of Mecp2. Secondly the 
expression pattern of exogenous Mecp2 should be similar to that of the 
endogenous Mecp2 (Nan et al., 1996).Thirdly, the cellular levels of exogenous 
Mecp2 protein should be crucially maintained at a near physiological level to 
minimize the overexpression-related toxicity (Collins et al., 2004, Luikenhuis et 
al., 2004, Na et al., 2012). Finally, the exogenous Mecp2 should be able to 
recapitulate the molecular characteristics of the endogenous Mecp2 protein e.g. 
site-specific phosphorylation at S421 (Zhou et al., 2006). 
Another possible application of lenti-mediated Mecp2 expression is to provide a 
Mecp2-overexpression model. Such a model will enable investigation of the 
effect of Mecp2 overexpression on cellular morphology and function. Moreover it 
helps investigating the effect of Mecp2-overexpression on other nuclear 
proteins. Mecp2 is one of the most abundant nuclear proteins in post-mitotic 
neurons and its absence is associated with alteration in the expression pattern of 
other nuclear proteins (Skene et al., 2010). Previous reports showed that the 
total level of histone1 (H1) protein is elevated in Mecp2-null mice (Nan et al., 
1997) whereas other studies reported changes in the chromatin remodelling  
through changes in the acetylation state of H3 (Shahbazian et al., 2002a, Skene 
et al., 2010) and H4 (Wan et al., 2001) in Mecp2-null cells. In this study I tested 
the potential effect of Mecp2 overexpression in the WT brain on cellular levels 
and acetylation state of histone 4 protein that could provide more understanding 
of protein dynamic changes in the nucleus in the presence of abnormally high 
level of Mecp2.   
In this chapter I examined the efficiency of lentivirus-mediated delivery of 
Mecp2 as a potential therapeutic tool. This work includes initial validation of 
transgene expression in vitro and the phenotypic consequences of the in vivo 
transgene delivery to the CNS of Mecp2 knockout mice.  
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4.2 Study aims 
The main aim of the work described here was to examine the ability of lentiviral 
vectors to deliver Mecp2 into neurons and glia in vitro and in vivo. This work was 
further extended to study the effect of delivering exogenous Mecp2 into the 
brain of Mecp2stop/y mice on RTT-like phenotypes at the cellular and organismal 
levels. The specific objectives of this study are:  
1. To investigate the ability of the lentivirus-based vectors described in 
chapter 3 to drive exogenous Mecp2 expression in neurons in vitro and in 
vivo. 
2. To determine the transduction efficiency and cellular levels of protein 
expression after in vitro and in vivo administration. 
3. To evaluate the effect of brain-specific delivery of exogenous Mecp2 on 
the organismal and cellular RTT-like phenotype in Mecp2stop/y mice. 
4. To establish a model of Mecp2 overexpression at the cellular level and to 
study the effect of overexpressing Mecp2 on the level of other nuclear 
proteins, particularly Histone 4. 
4.3 Methods 
To study the potential of lenti-mediated Mecp2 expression in vitro and in vivo in 
Mecp2 knockout mice, Mecp2_e1 minigene was tagged at its C-terminal with 
Flag-tag epitope and RFP gene. This fusion construct was then cloned into 
lentivirus-based vector backbones under either, neuron-specific synapsin1 or 
generic PGK promoter (figure 4-1). Lentivirus particles were generated as 
described in chapter 2.  
Hippocampal dissociated neuronal cultures were prepared from P0-3 pups from 
Mecp2
stop/y
 mice. The mouse was decapitated and the hippocampus was 
removed, chopped into small pieces, incubated in papain for 20 minutes before 
being cell dispersal by pipetting. The dissociated neurons were then plated on 
poly-L-lysine coated cover slips and maintained in a 5% CO2 incubator at 37
o
C. 
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The culture was fixed with 4% paraformaldehyde followed by 
immunocytochemistry staining. 
Stereotaxic brain injection of Mecp2stop/y and WT mice was carried out at the age 
of 8 weeks (mildly symptomatic Mecp2stop/y mice). The details of the injection 
coordinates and the volume of injected viruses will be discussed later in this 
chapter. Brain coronal sections were prepared using a vibratome then 
immunolabelled with varies antibodies to confirm transgenic expression. Images 
were taken using a confocal microscope and analysed by Image J software (see 
chapter 2). 
 
Figure 4-1  Lentivirus-based vector constructs 
Representative figure showing designs of lentivirus-based vectors utilized in this study. (a) 
Mecp2_e1 (ME1) FlagRFP fusions construct was cloned into Lentiviral vector under neuron-
specific synapsin1 promoter. (b) GFP gene was cloned in the same vector backbone to be 
used as a control vector. (c) and (d) are similar vectors to (a) and (b) respectively, however 
synapsin1 is replaced by the housekeeping PGK promoter. LTR; long terminal repeat, syn1; 
synapsin1 promoter, PGK; phosphoglycerate kinase promoter, RFP; red fluorescent protein, 
GFP; green fluorescent protein. 
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4.4 Results  
4.4.1 Lenti-mediated delivery of ME1FlagRFP to cultured neuronal 
cells 
4.4.1.1 Neuron-specific expression of Mecp2 in the hippocampal dissociated 
cell culture 
Primary hippocampal dissociated neuronal cultures were prepared from Mecp2-
stop mice (Guy et al., 2007). Cultured hippocampal cells prepared from 
Mecp2stop/y (hemizygous male) and Mecp2-/+ (heterozygous female) mice were 
transduced with 104 IU of lenti-syn1-ME1FlagRFP. Seven days later, the cultures 
were fixed with 4% PFA and immunolabelled with anti-Flag, anti-Mecp2 and anti-
MAP2 (neuronal specific marker) antibodies and stained with DAPI. The results 
show that the Flag-tagged Mecp2 protein was localised to the nucleus, as 
indicated by co-localization with DAPI (figure 4-2), and displayed discrete 
punctate heterochromatin targeting with no evidence of ectopic (non-nuclear) 
cellular expression (figure 4-2). Anti-Mecp2 labelling further confirms the 
exogenous Mecp2 expression and showed that the transgene is the only source of 
detectable Mecp2 in Mecp2stop/y mice as indicated by the presence of detectable 
Mecp2 immunofluorescence only in Flag-immunopositive nuclei. Co-
immunolabelling with a neuronal marker MAP2 showed that exogenous Mecp2 is 
only expressed in neurons as evidenced by expression of the transgene in MAP2- 
positive cells and not in MAP2-immunonegative cells (figure 4-2). 
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Figure 4-2 Synapsin1 promoter drove neuron-specific expression of exogenous Mecp2. 
Micrograph of primary hippocampal dissociated cell culture prepared from Mecp2
stop/y
 
neonatal mouse. The culture was transduced after 24 hours with lenti-syn1-ME1FlagRFP. (i-
iii) show labelling for nuclei (DAPI), anti-Mecp2 and anti-Flag antibodies respectively. (iv) 
Showed merge of i-iii together with immunolabelling for the neuronal marker MAP2.  Arrows 
show examples of Flag-tagged Mecp2 expressed in neuronal nuclei and showing discrete 
heterochromatin-like punctate expression with no evidence of ectopic, non-nuclear, 
expression. Arrowheads indicate MAP2-immunonegative cells (presumed to be glia). Scale 
bar = 20 µm.  
4.4.1.2 Delivery of exogenous Mecp2 in Mecp2+/stop female mosaic 
hippocampal cell culture  
In Mecp2+/Stop heterozygous female mice insertion of a stop cassette leads to 
silencing of one of the Mecp2 alleles (Guy et al., 2007). This leads to mosaic 
expression of the endogenous Mecp2 due to random X-chromosome inactivation. 
The mosaic pattern of Mecp2 expression was indicated by the presence of a 
population of DAPI-positive cells showing absence of detectable Mecp2 
expression (figure 4-3). Anti-Flag immunolabelling enables discrimination of cells 
expressing endogenous Mecp2 (Flag negative) from those expressing recombinant 
Mecp2 (Flag-immunopositive, figure 4-3). Anti-Mecp2 antibody is unable to 
distinguish between endogenous and exogenous Mecp2 in the transduced cells 
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and thus anti-Mecp2 immunofluorescence in transduced cells either represents 
exogenous Mecp2 alone (if the transduced cells are lacking endogenous Mecp2) 
or exogenous plus endogenous Mecp2 (if the transduced cells are expressing 
endogenous Mecp2).  
 
 
Figure 4-3 Neuron-specific expression of exogenous Mecp2 in Mecp2
+/stop
 hippocampal cell 
culture. 
Micrograph of primary hippocampal dissociated cell culture from Mecp2
+/stop
 heterozygous 
female neonatal mice. The culture was transduced after 24 hours with lenti-syn1-
ME1FlagRFP and stained with (i) DAPI, (ii) anti-Mecp2 antibody and (iii) anti-Flag antibodies 
to discriminate transduced cells. (iv) Merge of i-iii together with MAP2 immunolabelling. 
Note the mosaic expression pattern of endogenous Mecp2 as indicated by the presence of 
DAPI stained nuclei with a mixture of Mecp2 positive (arrows) and negative cells (arrows 
with double heads). Arrowhead points to cell expressing endogenous Mecp2 only. The 
arrows indicate transduced cells. Scale bars = 20 μm. 
 
4.4.1.3 Lenti-mediated delivery of Mecp2 in neurons and glia under 
ubiquitous, PGK, promoter in hippocampal dissociated cell culture 
Recent reports have suggested that glia may be an important factor in the RTT 
etiology (Ballas et al., 2009, Maezawa et al., 2009) and a more recent study has 
shown phenotypic rescue in a RTT mouse model after delayed activation of 
Mecp2 in astrocytes only (Lioy et al., 2011). To deliver exogenous Mecp2 into 
  125 
 
neurons and glia, dissociated hippocampal cell culture was prepared from  
Mecp2stop/y neonatal mice and transduced with 105 IU of lenti-PGK-ME1FlagRFP. 
Seven days after transduction, the culture was fixed with 4% PFA and 
immunolabelled with anti-neuronal nuclear antigen (NeuN) antibody and DAPI. 
RFP fluorescence was used to discriminate transduced cells. The result of this 
experiment shows that lenti-PGK-ME1FlagRFP drove exogenous Mecp2 expression 
both in neuronal (NeuN-immunopositive) and non-neuronal populations (NeuN-
immunonegative, figure 4-4 A). The transduction efficiency of lenti-PGK-
ME1FlagRFP was measured by counting the RFP positive cells, NeuN positive and 
DAPI stained nuclei in 12 random fields taken from 4 cover slips (N = 2 mice). 
The average percentage of cells transduced (ME1RFP expressing) was 75 ± 2.7% 
(mean ± SEM, N = 459 transduced cells of 614 DAPI-stained cells). NeuN-
immunopositive cells represent 62 ± 2.5% whereas NeuN-immunonegative cells 
(presumed to be glia) constitute 38 ± 2.5 % of total Mecp2RFP expressing cells 
(figure 4-4b). 
4.4.1.4 PGK promoter drove expression of high level of exogenous Mecp2 in 
neurons in dissociated hippocampal cell culture 
Mecp2 is one of the most abundant nuclear proteins with neurons expressing high 
level of Mecp2 compared to glia (Skene et al., 2010). To determine exogenous 
Mecp2 level expressed from the lenti-PGK-ME1FlagRFP construct in neurons and 
glia, intensity measures of Mecp2RFP fluorescence were measured (chapter 2) in 
NeuN-immunopositive cells and NeuN-immunonegative cell taken from 6 cover 
slips (N = 2 mice). The average fluorescence intensity of Mecp2RFP in NeuN-
immunopositive cells was 116.1 ± 9.9 AU (mean ± SEM, N = 236 sampled cells) 
which is significantly (p < 0.001, unpaired t test) higher than the average 
Mecp2RFP intensity in NeuN-negative cells 46.9 ± 5.0 AU (N = 106 sampled cells, 
figure 4-4c). 
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Figure 4-4 Lentivirus-based vector mediated high neuronal transduction of Mecp2 in 
hippocampal dissociated cell culture.  
(a) Micrograph of primary hippocampus neuronal culture from Mecp2
stop/y
 neonatal mice. 
The culture was transduced with 10
5
 IU of lenti-PGK-ME1FlagRFP. (i) RFP fluorescence was 
used to discriminate the transduced cells. DAPI stain (ii) was used to determine the 
transduction efficiency (red arrows indicate transduced cells while blue arrows indicate 
non-transduced cells). Anti-NeuN antibody (iii) was used to show neuronal transduction 
(green arrows indicate neuronal expression whereas white arrows indicate glia expression). 
(b) Plot showing the total transduction efficiency (percentage of transgene-expressing cells 
relative to DAPI-stained cells) in dissociated cell culture and illustrates the relative 
proportion of exogenous Mecp2 expression in neurons and glia (6 cover slips from 2 
separate cultures). (c) Plot showing RFP fluorescence intensity as an indicator of 
exogenous Mecp2 expression level, in neurons and presumed glia. Numbers on the 
columns indicate the numbers of sampled cells / group (6 cover slips. N = 2 mice). *** = p < 
0.001, unpaired t test. Scale bar in (a) = 20 µm.  
 
 
a 
b c 
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4.4.2 In vivo injection of lenti-ME1FlagRFP viruses into the mouse 
brain 
4.4.2.1 In vivo Neuron-specific delivery of exogenous Mecp2 into the mouse 
brain 
Brain-specific Mecp2 knock out resulted in RTT-like phenotypes similar to that 
resulted from global  Mecp2 knockout (Chen et al., 2001, Guy et al., 2001) 
indicating the importance of this organ in RTT. Therefore it is clear that any 
attempt for gene therapy application in RTT should involve transgene delivery to 
the brain. To examine the ability of lentivirus to drive expression of exogenous 
Mecp2 into the brain, 2 month old WT and Mecp2stop/y male mice were injected 
with lenti-syn1-ME1FlagRFP to target the hippocampus (well-defined structure 
and easy to target) in one hemisphere and with lenti-syn1-GFP in the contra-
lateral hemisphere as a control (figure 4-5a). 0.9µl of 107 IU/ml (~104 IU) were 
injected by stereotaxic brain injection (was kindly performed by Dr John Riddell, 
University of Glasgow, UK) into 3 different sites in each hemisphere (0.3 µl/site, 
table 4.1).  
Table 4-1 Injection coordinates for the hippocampus stereotaxic brain injection  
 
Injection sites 
 
 
Bregma 
 
Lateral 
 
Depth 
 
 
 
First  -1.5mm 1.08mm 2.2mm 
Second  -1.25mm 1.56mm 2.2mm 
Third  -1.75mm 2.08mm 2.1mm 
 
 
To validate transgene expression, mice were transcardially perfused one week 
post-injection with 4% PFA in 0.1 M PBS. Coronal sections from the brain were 
immunolabelled with anti-Flag, anti-Mecp2 and anti-GFP antibodies together 
with DAPI stain. Analysis of transgene expression showed that the majority of 
Flag-immunopositive or RFP fluorescent cells (left hemisphere) and GFP-
immunopositive cells (right hemisphere) were located within the granule cell 
layer of the dentate gyrus (figure 4-5) with limited spread to the CA3 region of 
the hippocampus. Exogenous Mecp2 expression was targeted to the nucleus and 
recapitulated the characteristic heterochromatin localization of endogenous 
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Mecp2 as indicated by nuclear co-localization with DAPI (figure 4-6a). Anti-
Mecp2 staining of the WT sections showed two populations of cells, cells 
expressing the endogenous Mecp2 only (normal fluorescence intensity) and cells 
expressing endogenous and exogenous Mecp2 (relative greater fluorescence 
intensity, figure 4-5b). As expected anti-Mecp2 immunofluorescence in the GFP 
injected hemisphere of Mecp2stop/y males showed absence of detectable 
endogenous Mecp2. In the lenti-PGK-ME1FlagRFP injected hemisphere however, 
immunolabelling for anti-Mecp2 was positive and co-localized with the Flag 
immunofluorescence, indicating that the presence of Mecp2 expression was due 
to exclusively exogenously delivered Mecp2 (figure 4-5c). 
4.4.2.2 Syn1 promoter drove expression of exogenous Mecp2 at near-
physiological levels in vivo. 
MeCP2 over-expression in patients (Meins et al., 2005, Van Esch et al., 2005) and 
mouse models (Collins et al., 2004, Luikenhuis et al., 2004) leads to a wide 
range of neurological deficits. In this study I quantified the cellular levels of 
exogenous Mecp2 expressed under the control of syn1 promoter in WT mice 
(based on the fluorescence intensity after immunolabelling with an anti-Mecp2 
antibody). RFP fluorescence was used to discriminate between non-transduced 
(RFP-negative) cells that express the endogenous protein and the transduced 
(RFP-positive) cells that express endogenous and exogenous Mecp2, figure 4-6a). 
Transduced cells displayed Mecp2 levels that were 1.8 ± 0.07AU (mean ± SEM, N 
= 115 sampled cells from 9 brain sections, figure 4-6b) times greater than 
endogenous levels (p< 0.001, unpaired t test) in non-transduced cells (1.0 ± 0.02 
AU, N = 130 sampled cells) which means that the levels of exogenous Mecp2 are 
about 85 % of the endogenous protein. Frequency distribution analysis of total 
Mecp2 levels showed that the non-transduced cells have tight endogenous Mecp2 
expression (narrow peak, SD = 0.3 AU, figure 4-6c), whereas Mecp2 transduced 
cells displayed a broader range (wide peak, SD = 0.8 AU) of exogenous Mecp2 
expression indicating modest variability in the expression levels. 
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Figure 4-5  Lentivirus-based vector mediated exogenous Mecp2 delivery into the 
hippocampus of Mecp2
stop/y
 and WT adult mice. 
(a) Representative diagram showing the injection strategy. Lenti-syn1-ME1FlagRFP was 
injected into the left (L) hemisphere and lenti-syn1-GFP into the contra-lateral side (R). (b) 
Micrograph showing the expression of exogenous Mecp2 (i-iii) and GFP (iv-vi) in the  WT 
brain section. Transduced cells (co-localized with anti-Flag immunofluorescence) display 
high levels of anti-Mecp2 immunofluorescence indicating presence of an extra protein that 
has been added by (exogenous) Mecp2 expression (white arrows). (c) Micrograph showing 
exogenous Mecp2 (vii-ix) and GFP (x-xii) expression in Mecp2
stop/y
 mouse brain. Note the 
absence of anti-Mecp2 immunofluorescence in the GFP injected hemisphere whereas the 
exogenous Mecp2 is the only source of anti-Mecp2 immunofluorescence (yellow arrows). 
Scale bar = 100 µm. 
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Figure 4-6 Syn1 promoter drove near-endogenous levels of exogenous Mecp2 in vivo. 
(a) Micrograph showing WT brain section after lenti-syn1-ME1FlagRFP injection. (i) RFP 
fluorescence discriminates between transduced (purple arrows) and non-transduced (white 
arrows) cells. (ii) Intensity of anti-Mecp2 immunofluorescence in transduced (red circles) 
and non-transduced (white circle) was used as a relative estimate for Mecp2 levels. (b) Plot 
showing Mecp2 immunofluorescence in non-transduced (endogenous level) and transduced 
cells (endogenous + exogenous Mecp2). Numbers on the columns indicate the numbers of 
sampled cells / group.  Data was standardized to the average of the endogenous values and 
presented as mean ± SEM. *** = p < 0.001, unpaired t test. (C) Frequency distribution of 
Mecp2 levels in transduced and non-transduced cells. Note the tight control of endogenous 
Mecp2 levels in the non-transduced cells (narrow peak). In contrast Mecp2 levels in 
transduced cells displayed wide peak, indicating variability in the expression level. Scale 
bar in (a) = 20 µm. 
To exclude the possible effect of Lentivirus transduction on the endogenous 
Mecp2 level, quantification of anti-Mecp2 fluorescence intensity in the GFP- 
transduced and non-transduced cells (figure 4-7a) showed cellular levels of 
Mecp2 expression in GFP-transduced cells equal to 0.94 ± 0.03 AU (N = 78 
a 
b c 
Mecp2+RFP Mecp2 
i ii 
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sampled cells from 9 brain sections, figure 4-7b) fold of the endogenous levels in 
GFP non-transduced cells (1.0 ± 0.02 AU, N = 140 sampled cells). Frequency 
distribution of Mecp2 level showed that the GFP-transduced cells (SD = 0.3 AU) 
as well as the GFP non-transduced (SD = 0.3 AU) displayed a similar narrow range 
of endogenous Mecp2 expression (figure 4-7c) indicating that lentivirus-based 
vector transduction has no detectable effect on the levels of endogenous Mecp2 
expression. 
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Figure 4-7 Lentivirus-mediated GFP expression showed no effect on the cellular levels of 
endogenous Mecp2. 
(a) Micrograph showing WT brain section after lenti-syn1-GFP injection. (i) Anti-GFP 
antibody was used to discriminate transduced (green arrows) from non-transduced (white 
arrows) cells. (ii) Immunofluorescence intensity was used to quantify relative Mecp2 levels 
in transduced (green circles) and non-transduced (white circle) was used as a measure for 
Mecp2 level. (b) Plot showing the difference in Mecp2 level between non-transduced 
(endogenous level) and GFP-transduced. Numbers on the columns indicate number of 
sampled cells / group.  Data was standardized to the average of the endogenous values and 
presented as mean ± SEM. ns; non-significant, En in (b); endogenous protein. (c) Frequency 
distribution plot of Mecp2 level in the GFP-transduced and non-transduced cells showing 
similar distribution pattern with tightly controlled Mecp2 expression levels. Scale bar in (a) = 
20 µm. 
Mecp2 
a 
b c 
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4.4.3 Transgenic expression of ME1FlagRFP in the CA1 region of 
the hippocampus under the control of the PGK promoter 
The hippocampus constitutes a key part of the limbic system in the brain of 
humans and vertebrates. Studies of the hippocampus in Mecp2 knockout mice 
have shown altered synaptic plasticity (Asaka et al., 2006, Weng et al., 2011) 
that were reversible by delayed activation of Mecp2 (Guy et al., 2007). 
Alteration in the cellular morphology, such as decreased neuron nuclear-size, 
was also observed in the hippocampus of Mecp2 knockout mice (Giacometti et 
al., 2007). Recent work published during the course of my research highlighted 
the unexpected contribution of glia in the development of RTT syndrome. In 
particular, studies showed that glia from the Mecp2-null mice were able to 
negatively affect the function of WT neurons when co-cultured together in the 
same media (Ballas et al., 2009). I therefore decided to inject lenti-PGK-
ME1FlagRFP into the CA1 region of the hippocampus in order to test the 
potential rescue of the impaired synaptic plasticity and to investigate the effect 
of exogenous Mecp2 on the pyramidal cell morphology. Eight week old 
Mecp2stop/y (N = 4) mice were injected into the CA1 region of the hippocampus at 
the level of stratum pyramidale with lenti-PGK-ME1FlagRFP in one hemisphere 
and lenti-PGK-GFP viruses in the contra-lateral hemisphere as an internal 
control. 1.5 μl of 108 IU/ml (1.5X105 IU) of lentiviruses were injected into to each 
hemisphere (3 sites per hemisphere, 0.5 μl per site) according to the following 
coordinates (table 4-2).  
Table 4-2 Injection coordinates for CA1 region of the hippocampus 
 
Injection sites 
 
Bregma  
 
Lateral  
 
Depth  
    
First  -2mm 1.08mm 1.15mm 
Second  -1.75mm 1.56mm 1.15mm 
Third  -2mm 2.04mm 1.25mm 
 
To confirm exogenous Mecp2 delivery, one of the injected mice was 
transcardially perfused after one week with 4% PFA in 0.1M PBS and transverse 
coronal brain sections were immunolabelled with anti-Flag, anti-Mecp2 
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antibodies. Exogenous Mecp2 expression was evident in the CA1 region of the 
hippocampus (figure 4-8a) with nuclear targeting and characteristic localization 
to the heterochromatin (figure 4-8b). Lentivirus mediated high transduction 
efficiency around the injection sites. The percentage of cells expressing the 
transgene was 83.5 ± 4.2 % of DAPI-stained nuclei (1941 transgene-expressing 
cells of 2359 DAPI-stained nuclei. N = 4 mice). However, the spread was limited 
and only covered approximately 41% of the CA1 region.  
Whilst an original aim of the experiments was to compare synaptic plasticity in 
Mecp2stop/y mice, all injected mice (N = 4) developed a severe tail lesion that 
necessitated culling them before any functional rescue (LTP) could be 
investigated. Mice that needed to be culled were perfused ~13 days after 
injection (minimum 8 days and maximum 18 days post-injection) and their 
tissues were used for further cellular and morphological analysis. 
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Figure 4-8  Lentivirus-mediated delivery of exogenous Mecp2 to CA1 region of the 
hippocampus of Mecp2
stop/y
 mouse. 
(a) Micrograph showing low power image of a coronal brain section taken from Mecp2
stop/y
 
brain one week after lenti-PGK-ME1FlagRFP injection. Note the high transduction efficiency 
close to the injection site but limited spread. Box indicates high power image. (bi-iv) high 
power amplification image from the CA1 region shows; (i) staining with DAPI (ii) 
immunolabelling with anti-Flag antibody, (iii) immunolabelling with anti-Mecp2 antibody and 
(iv) is a merge of i-iii showing nuclear targeting of the transgene with characteristic 
localization to the heterochromatin. Scale bar = 200 µm in (a) and 20 µm in (b). 
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4.4.3.1 Lentiviruses with PGK promoter drove high neuronal expression of 
the exogenous Mecp2  
To test the in vivo neuronal transduction efficiency of lenti-PGK-ME1FlagRFP, 50 
µm thick sections from Mecp2stop/y mice were immunolabelled with anti-NeuN 
and anti-GFAP (Astrocyte specific marker) antibodies. RFP fluorescence was used 
as a marker for transduced cells (figure 4-9). This data shows that the majority 
of transduced cells are NeuN positive with few transduced Astrocytes. This result 
indicates high neuronal tropism of lentiviruses regardless of the promoter type 
(syn1 or PGK) when injected using these coordinate at this age. 
 
Figure 4-9 High neuronal tropism of Lentiviruses 
Micrograph showing flattened confocal stack image from Mecp2
stop/y
 brain after lenti-PGK-
ME1FlagRFP injection. (i) RFP fluorescence labels transduced cells. (ii-iii) show 
immunolabelling with anti-NeuN and anti-GFAP antibodies respectively. (v) is merge of (i-iii). 
Note the high neuronal transduction efficiency (yellow arrows) with very low glial 
expression (arrow). Scale bar = 20µm. 
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4.4.3.2 Exogenous Mecp2 rescued neuronal nuclear volume in Mecp2stop/y 
mice 
A characteristic hallmark of Mecp2 deficiency, at the cellular level, is a 
reduction in neuronal nuclear volume (Giacometti et al., 2007, Johnson et al., 
2011). In order to assess the potential changes of this cellular feature in cells in 
which Mecp2 is reintroduced by lentivirus transduction, 3D nuclear 
reconstruction was carried out in ME1FlagRFP transduced and non-transduced (as 
an internal control) pyramidal cells of the CA1 region of Mecp2stop/y mice. Non-
transduced neurons (N = 4 mice) in Mecp2stop/y mice showed significant (p < 
0.001, one way ANOVA with tukey`s posthoc pairwise comparison) reduction of 
the nuclear volume (0.86 ± o.o4 AU fold of WT values, mean ± SEM) compared to 
non-transduced cells in (N = 4) age-matched WT mice (1.0 ± 0.02 AU). 
ME1FlagRFP-transduced cells (N = 4 mice) displayed nuclear volumes of 1.0 ± 
0.04 AU fold of WT values that were significantly (p < 0.01) larger than non-
transduced cells (from the contra-lateral hemisphere as an internal control). In 
contrast there was no significant difference in the neuronal nuclear volume 
between Mecp2stop/y pyramidal cells expressing exogenous Mecp2 and that of WT 
age matched mice (Figure 4-10). 
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Figure 4-10  Exogenous Mecp2 rescued nuclear volume in Mecp2
stop/y
 mice. 
Plot showing 3D nuclear volume measures of pyramidal cell layer of the CA1 area of the 
hippocampus of the Mecp2
stop/y 
(injected with lenti-PGK-ME1FlagRFP) and age-matched WT. 
Data was standardized to the average of the WT values and presented as mean ± SEM. N = 4 
mice/group. Numbers on the column refer to the number of sampled cells/group. *** = p < 
0.001, ** = p < 0.01, one way ANOVA with tukey`s posthoc comparison.  
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4.4.3.3 Exogenous Mecp2 produced a modest increase in the nuclear 
volume of WT mice 
The previous experiment demonstrated that exogenous Mecp2 rescued neuronal 
nuclear volume in Mecp2stop/y mice to levels comparable to WT values. However 
it is not clear whether this change is due to expressing Mecp2 in cells lacking this 
protein or due to other downstream effect of the transgene. In order to test this 
effect, lenti–PGK-ME1FlagRFP was injected in the CA1 region of the hippocampus 
of 2 month old WT mice (N = 4) and the neuronal nuclear volume was examined 
two weeks later. 3D reconstruction of transduced CA1 pyramidal cell nuclei 
(RFP-positive) and non-transduced cells (RFP-negative) showed a modest, but 
significant (p = 0.045, unpaired t test), increase in the nuclear volume of 
transduced (1.1 ± 0.02 AU fold of WT non-transduced cells) compared to the 
non-transduced cells (1.0 ± 0.02 AU, figure 4-11).  
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Figure 4-11 Exogenous Mecp2 increased pyramidal cells nuclear volume in WT mice. 
Plot showing 3D nuclear volume measures of CA1 pyramidal cells of the hippocampus of 
WT mice (N = 4). Data was standardized to the average of the WT (non-transduced) values 
and represented as mean ± SEM. Numbers on the column refer to the number of sampled 
cells/group. * = p < 0.05, unpaired t test. 
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4.4.3.4 PGK promoter drove high levels of exogenous Mecp2 In vivo 
Maintaining the Level of Mecp2 within physiological levels is critical in order to 
avoid the overt neurological deficits associated with Mecp2 overexpression 
(Collins et al., 2004, Luikenhuis et al., 2004). I showed previously that synapsin1 
promoter leads to expression levels of exogenous Mecp2 approximately 85 % of 
the endogenous value in neurons (based on anti-Mecp2 immunofluorescence 
intensity). Here I used the same approach to quantify the exogenous Mecp2 
protein levels expressed under the control of the PGK promoter. Analysis of the 
fluorescence intensity measurements of the anti-Mecp2 immunofluorescence in 
transduced (RFP positive) and non-transduced (RFP negative) pyramidal cell 
nuclei in WT mice (figure 4-12a) revealed significantly (p < 0.001, unpaired t 
test) higher level of total Mecp2 expression in transduced cells (3.173 ± 0.12 AU, 
mean ± SEM, times the endogenous level) compared to non-transduced cells (1.0 
± 0.03 AU). This indicates that the PGK promoter drove expression of exogenous 
Mecp2 protein in Mecp2stop/y mice at a level approximately 2.1 fold higher than 
endogenous levels (figure 4-12b). Frequency distribution analysis of the total 
Mecp2 levels showed that the non-transduced cells maintain the tightly 
controlled levels of endogenous Mecp2 (SD = 0.38 AU), whereas Mecp2 
transduced cells displayed an extended range (SD = 1.37 AU) of Mecp2 cellular 
levels indicating variable high expression levels (figure 4-12c). 
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Figure 4-12 PGK promoter drove high levels of exogenous Mecp2 in vivo. 
(a) Micrograph showing coronal brain section taken from WT mouse 2 weeks after lenti-
PGK-ME1FlagRFP injection into the CA1 region. Section was immunolabelled with (i) anti-
Mecp2 antibody. (ii) RFP fluorescence was used to identify the transduced cells. (iii) Merge 
of (I & ii). Red arrows indicate high levels of anti-Mecp2 immunofluorescence in transduced 
cells whereas white arrows indicate normal anti-Mecp2 immunofluorescence in non-
transduced cells (express the endogenous Mecp2). (b) Plot showing Intensity 
measurements of anti-Mecp2 immunofluorescence in non-transduced (endogenous levels) 
cells and in transduced cells (N = 2 mice). (c) Frequency distribution of Mecp2 levels in 
transduced and non-transduced cells revealed extended levels of Mecp2 expression in 
transduced cells. Values are standardized to the average WT (non-transduced) values and 
presented as mean ± SEM. Numbers in the columns in (b) indicate the numbers of sampled 
cells / group.  *** indicates p < 0.001, unpaired t test. En; endogenous protein. Scale bar in 
(a) = 20 µm. 
 
 
4.4.4 Exogenous Mecp2 maintains phosphorylation at serine 421  
The exact mechanism of action of Mecp2 at the molecular level in not fully 
understood. Previous studies have linked Mecp2 activity and interaction to site-
specific phosphorylation particularly at serine 421(S421) and S424 (Cohen et al., 
2011). After neuronal activity-induced, Mecp2 was reported to be 
phosphorylated S421 with subsequent detachment from chromatin binding-sites 
to allow downstream expression of variety of genes (Chen et al., 2003b, 
Martinowich et al., 2003). However recent report has shown that proportion of 
a 
b c 
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Mecp2 become phosphorylated while still attached to the chromatin (Na et al., 
2012). I therefore decided to investigate whether exogenous Mecp2 is 
comparable, at the molecular level, to endogenous Mecp2, in terms of site-
specific phosphorylation. Brain sections from Mecp2stop/y mice (transduced into 
the CA1 region using lenti–PGK-ME1FlagRFP) were immunolabelled with anti-
Mecp2 and anti-phosphorylated Mecp2 at serine 421 (pS421) antibodies (generous 
gift from Dr. Michael Greenberg laboratory, Harvard Medical School, USA). RFP 
fluorescence was used to distinguish transduced cells. These results show that 
Mecp2 phosphorylation at S421 persevered in the exogenous Mecp2 protein as 
indicated by co-localization between RFP fluorescence, anti-Mecp2, and anti-
pS421 immunofluorescence (figure 4-13). However this phosphorylation in the 
exogenous Mecp2 was observed in the absence of induced neuronal activity.  
 
Figure 4-13 Exogenous Mecp2 maintains characteristic phosphorylation at S421 
Micrograph showing a flattened confocal stack taken from Mecp2
stop/y
 mice after lenti-PGK-
ME1FlagRFP injection. Section was immunolabelled with anti-Mecp2 (i) and anti-pS421 (iii)  
antibodies. RFP fluorescence (ii)  discriminate exogenous Mecp2 expression. Note that in 
the absence of neuron induced activity, exogenous Mecp2 becomes phosphorylated at S421 
(iv merge). Scale bar = 20 µm. 
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4.4.5 Exogenous Mecp2 is highly phosphorylated at S421 
Mecp2 phosphorylation at S421 is normally neuronal activity-dependent with 
endogenous Mecp2 showing low levels of phosphorylation at this site under basal 
conditions. Therefore I decided to quantify the phosphorylation level of 
exogenous (transgenic delivered) Mecp2 relative to the basal level of 
phosphorylation of endogenous Mecp2. Sections from WT brains transduced into 
the CA1 region with lenti–PGK-ME1FlagRFP were immunolabelled with Anti-pS421 
and anti-Mecp2 antibodies. RFP fluorescence was used to categorize transduced 
and non-transduced cells (figure 4-14). Fluorescence intensity measures of the 
anti-pS421 immunofluorescence were used to estimate cellular levels of pS421 
protein. This result shows that the cellular levels of pS421 protein in transduced 
cells (6.6 ± 0.44 AU fold of the endogenous levels) was significantly (p < 0.001, 
unpaired t test) higher than the endogenous level (1.0 ± 0.04 AU) in non-
transduced cells (figure 4-15a). Frequency distribution of pS421 levels in non-
transduced cells showed tight control (SD = 0.58 AU) whereas the levels varied in 
the transduced cells (SD = 5.2 AU), indicating variable and high expression levels 
(figure 4-15b). 
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Figure 4-14 Exogenous Mecp2 expression and Mecp2-pS421 in WT mice. 
Micrograph showing coronal brain section taken from WT mouse 2 weeks after lenti-PGK-
ME1FlagRFP injection into the CA1 region. Section was immunolabelled with (i) anti-Mecp2 
(green), (ii) RFP fluorescence (red) was used to identify transduced cells and (iii) anti-pS421 
(blue) antibodies. (iv) Merged (ii & iii) shows high anti-pS421 antibody signals in transduced 
cells (red arrows) relative to non-transduced cells (white arrows). Scale bar = 20 µm. 
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Figure 4-15  Exogenous Mecp2 expressing cells display high level of Mecp2-pS421 levels 
(a) Plot showing Quantitative immunofluorescence of anti-pS421 immunofluorescence in 
non-transduced and transduced cells of CA1 region of the hippocampus (N = 2 mice). (b) 
Frequency distribution of pS421 immunofluorescence in transduced and non-transduced 
cells revealed closely regulated endogenous protein and extended expression range in the 
transduced cells. Values were standardized to the average WT (non-transduced) values and 
presented as mean ± SEM. Numbers in the columns in (a) indicate the numbers of tested 
cells / group. *** indicates p < 0.001, unpaired t test. En; endogenous protein. 
 
 
 
4.4.6 Neuronal overexpression of exogenous Mecp2 alters 
nuclear levels of histone 4  
Previous studies have emphasized the potential interaction between Mecp2 and 
histones in the nucleus in both RTT patients (Wan et al., 2001) and Mecp2-null 
mice (Skene et al., 2010). In this study I investigated the effect of Mecp2 
overexpression on the level of histone 4 (H4) and acetylated H4 (AcH4) level in 
CA1 region of the hippocampus of WT mice. Sections from mouse brains 
previously transduced with lenti–PGK-ME1FlagRFP were immunolabelled with 
anti-H4 and anti-AcH4 (binds to acetylated lysine residues, 5 , 8, 12 and 16) 
antibodies. RFP fluorescence was used to identify transduced pyramidal cells. 
Cellular levels of AcH4 and H4 were estimated in the transduced and non-
transduced cells by quantitative immunofluorescence (figure 4-16). The results 
show that the amount of the total H4 was significantly (p < 0.001, 2 way ANOVA, 
tukey`s posthoc  pairwise comparison) reduced in the transduced cells (0.78 ± 
0.014 AU, mean± SEM, times the endogenous level) compared to the non-
a b 
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transduced cells, express endogenous level, (1.0 ± 0.01AU, figure 4-17a). In 
parallel, the level of AcH4 was also significantly (p < 0.001, 2 way ANOVA) 
reduced in the transduced cells (0.79 ± 0.014 AU times the endogenous level) 
compared to the non-transduced cells (1.0 ± 0.01 AU, figure 4-16a). There was a 
positive correlation between the reduction in the level of total H4 and the AcH4 
(figure 4-17b).  
 
 
Figure 4-16  H4 and AcH4 cellular levels after Lenti-PGK-ME1-FlagRFP transduction 
Micrograph showing sections from the CA1 region of the hippocampus of WT mice (N = 2 
mice) that were injected with lenti-PGK-ME1FlagRFP at the pyramidal cell layer. Section was 
immunolabelled with anti-AcH4 (ii) anti-H4 (iii) antibodies whereas RFP fluorescence (i) 
discriminates the transduced (red arrows) and non-transduced cells (white arrows). Scale 
bar = 20 µm. 
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Figure 4-17  Altered cellular levels of H4 and AcH4 in Mecp2 overexpressing pyramidal cells. 
(a) Plot showing the effect of exogenous Mecp2 expression on the cellular levels of H4 and 
AcH4. Values are normalized to the endogenous levels (in non-transduced cells and 
presented as mean ± SEM. Numbers on the columns indicate to the number of sampled 
cells / group. (b) Plot showing the correlation between cellular levels of H4 and AcH4 in the 
transduced cells. In (a) *** =  p< 0.001, 2 way ANOVA with tukey`s posthoc pairwise 
comparison.  
4.4.7 Neonatal brain delivery of lenti-PGK-ME1FlagRFP 
Mecp2 is globally expressed in the brain and peripheral tissue. However 
expression in the brain shows a special importance as brain-specific delayed 
activation of Mecp2 rescued RTT-like phenotype in mouse models (Luikenhuis et 
a 
b 
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al., 2004, Giacometti et al., 2007). Stereotaxic brain injection of lenti-PGK-
ME1FlagRFP in adult mice showed limited spread around the injection site 
indicating that lentivirus-mediated delivery has limited potential to deliver 
widespread expression of exogenous Mecp2 in the adult mouse brain. As young 
animals have relatively large extracellular spaces that could allow more spread 
of the viral particles (Cetin et al., 2006), I therefore tested the potential of 
neonatal brain injection to produce a wider transgene spread across the brain. 
Neonatal pups (P0-2) were intracranially injected (chapter 2) with 3µl of 108 
IU/ml of lenti-PGK-ME1FlagRFP in each hemisphere (6 x 105 IU / brain). Four 
weeks after injection, these mice were perfused with 4% PFA and brain sections 
were tested for the expression of the RFP. Serial coronal sections of the injected 
brains showed again that the majority of transduced cells were located very 
close to the ventricular wall with very limited parenchymal spread (figure 4-18). 
 
Figure 4-18  Neonatal intracranial injection of lenti-PGK-ME1FlagRFP resulted in limited 
transgene spread. 
Micrograph showing the spread of exogenous Mecp2 expression after direct brain injection 
in neonates. Section was stained with DAPI (i&iv) whereas RFP fluorescence was used to 
detect the extend of transgene expression (ii&v). (i-iii) low power image showing that the 
expression was confined to the wall of the ventricle with very limited parenchmal spread. 
box indicate high power image. (iv-vi) high power image showing the nuclear expression 
pattern of exogenous Mecp2 and confirm the low transduction efficiency. LV; lateral 
ventricle. Scale bar = 100 µm. 
 
LV 
LV 
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4.5 DISCUSSION  
The unclear understanding of the molecular mechanism of Mecp2 and its 
downstream effects make Mecp2 replacement by gene therapy a potential 
therapeutic approach for Rett syndrome. However gene delivery methods as well 
as dosage issues are a major hindrance to this approach. Lentivirus-based 
vectors are a well-established and widely used system for gene delivery (Blomer 
et al., 1996, Azzouz et al., 2004a). Lentiviruses are particularly used because of 
their ability to transfect terminally differentiated neurons and provide long term 
stable transduction with minimal immune response stimulation (Kay et al., 2001, 
Li et al., 2010). In this study I have generated Lentivirus-based vectors that can 
drive expression of exogenous Mecp2 in vivo and in vitro under two different 
promoters, the syn1 promoter (neuron-specific) and the PGK promoter 
(ubiquitous). In agreement with Rastegar and colleagues (Rastegar et al., 2009), 
I showed that lenti-mediated exogenous Mecp2  was targeted to the nucleus and 
showed a characteristic heterochromatin localization pattern similar to that of 
the endogenous Mecp2 in mice (Nan et al., 1996). Exogenous Mecp2 was mostly 
expressed in neurons in dissociated cell culture even under the control of the 
ubiquitously expressing PGK promoter. This could be explained by the natural 
neuronal tropism of Lentivirus (Lai and Brady, 2002) or due to a level of 
expression in transduced glia that was below the detectable limit (figure 4-4a). 
The transduced neurons expressed exogenous Mecp2 at a relatively high level 
(2.5 fold) compared to glia. This expression pattern is consistent with the fact 
that endogenous Mecp2 is mostly neuronal with ten times lower, however 
important, expression levels in glia (Ballas et al., 2009, Lioy et al., 2011) 
compared to neurons (Skene et al., 2010). The fact that the same vector drove 
different levels of exogenous Mecp2 in neurons and glia could be partially 
explained by the increased multiplicity of infection in neurons due to viral 
neuronal tropism and partially by the difference in the transcription machinery 
in both populations of cells.  
In vivo delivery of exogenous Mecp2 in the hippocampus revealed nuclear 
targeting of the transgene with characteristic heterochromatin condensation. 
The transduction efficiency was high around the injection sites, however as in 
agreement with previous report (Brooks et al., 2002), the transgene showed 
limited spread from the injection sites. Large lentivirus particles (100-120 nm, 
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(Fleury et al., 2003) relative to the narrow extracellular space (40-60 nm, 
(Thorne and Nicholson, 2006) partially explain the limited spread of the 
transgene. The PGK promoter drove expression of exogenous Mecp2 in neurons, 
mostly, and glial. Whereas, as reported before (Hioki et al., 2007), synapsin1 
promoter was efficient in driving neuron-specific expression. 
Endogenous Mecp2 expression is very tightly controlled (Collins et al., 2004, Na 
et al., 2012) at the cellular level. Overexpression of Mecp2 has been shown to 
lead to overt neurological deficits in Rett patients (Meins et al., 2005, Van Esch 
et al., 2005) as well as in the mouse model (Collins et al., 2004, Luikenhuis et 
al., 2004, Na et al., 2012). In this study I analysed the cellular expression level 
of exogenous Mecp2 driven by two different promoters in the hippocampus. 
Synapsin1 promoter led to exogenous Mecp2 expression levels that were very 
close to the physiological levels (0.8 fold of the endogenous level), whereas PGK 
promoter achieved a 2.2 fold of the endogenous levels. These results are 
particularly important in RTT females in which approximately half of the cells 
expressing the mutant allele (Mecp2-null cells) while the other half expressing 
the WT allele, therefore a transgene delivery strategy should be adopted to 
produce exogenous Mecp2 at a therapeutic levels in the null cells without 
inducing overexpression toxicity in the normal cells (Zhou et al., 2006, Rastegar 
et al., 2009, Gadalla et al., 2011). My results suggest that Mecp2 expression 
under PGK but not under synapsin1 promoter is more likely to produce an overt 
phenotype similar to the previously reported overexpression toxicity (Collins et 
al., 2004, Luikenhuis et al., 2004, Na et al., 2012). Optimizing the virus titre 
could help reduce the multiplicity of infection and, thus, expression levels 
(Wanisch and Yanez-Munoz, 2009). Combining segments from PGK promoter and 
syn1 promoter could help increase the expression power of syn1 promoter in a 
neuron-specific manner (Owens et al., 2002). Alternatively, Mecp2 endogenous 
promoter (Adachi et al., 2005, Rastegar et al., 2009) or its core segment (Gray 
et al., 2011b) that have previously shown to recapitulate the expression pattern 
of endogenous Mecp2 in neurons and glia, could potentially be used to achieve 
near physiological level of exogenous Mecp2.  
Several studies have reported deficits in both short- and long-term forms of 
synaptic plasticity, which increase in severity as the neurological phenotype 
progress in Mecp2 knockout mice (Asaka et al., 2006, Guy et al., 2007, Weng et 
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al., 2011). To test the ability of exogenous Mecp2 to rescue this plasticity 
deficit, early symptomatic Mecp2stop/y mice were injected with lentivirus-based 
vector to drive expression of Mecp2 in the CA1 region of the hippocampus, so 
that plasticity at the Schaffer-collateral to CA1 pyramidal synapse could be 
assessed with and without the reintroduction of Mecp2 in the postsynaptic 
neurons. Whilst the lenti-mediated delivery of Mecp2 was successful, 
unfortunately, the injected Mecp2stop/y mice developed a severe tail lesion and 
died/were culled before it was possible to investigate any functional rescue. The 
development of tail injury is not uncommon finding in Mecp2 knockout mice, 
however its incidence increased after the stereotaxic brain injection which could 
be explained by an oversensitivity of Mecp2 knockout mice to the anaesthetic or 
as a complication of the surgical procedures. Notably the WT mice injected with 
the same virus stock were normal, which indicates that virus particles are not 
likely to be involved in the etiology of this problem. 
Neuronal nuclear volume measures within the CA1 region of the hippocampus 
revealed clear cellular changes in Mecp2stop/y cells after exogenous Mecp2 
expression. The significant reduction in neuronal nuclear size has been reported 
previously (Giacometti et al., 2007, Johnson et al., 2011) and my results show 
that these morphological deficits are effectively normalized (comparable to WT) 
by reintroducing exogenous Mecp2. Interestingly the WT pyramidal cells 
transduced with exogenous Mecp2 showed a modest increase in the nuclear 
volume compared to the non-transduced cells. Nuclear volume deficit in the 
Mecp2stop/y cells could be explained by the fact that Mecp2 is one of the most 
abundant nuclear proteins (Nan et al., 1997, Skene et al., 2010) so its absence 
could lead to volume shrinkage of the nuclei. Another possibility is that absence 
of Mecp2 negatively affect normal cell growth and maturation which could be 
reflected as a smaller nuclear volume especially with the evidenced relationship 
between nuclear volume and overall soma size (Ledda et al., 2000). Exogenous 
Mecp2 probably rescued the nuclear volume deficits by replacing absent nuclear 
protein and by enhancing cellular growth and maturation of the transduced 
neurons. The functional consequences of this volume changes needs to be 
investigated. However a recent report suggests that restoration of neuronal 
soma size due to Mecp2 delayed activation is mirrored by changes in dendritic 
architectures and complexity (Robinson et al., 2012).  
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Mecp2 acts as a transcriptional repressor (Nan et al., 1997) and/or activator 
(Chahrour et al., 2008). The exact interaction of Mecp2 with the chromatin 
structures is not fully elucidated. Mecp2 is believed to bind specifically to the 
methylated CpG dinucleotide within the promoter regions of variety of genes 
(Nan et al., 1997, Skene et al., 2010). Upon neuronal induced activity Mecp2 was 
originally described to become phosphorylated at Serine 421 and subsequently 
detach from the promoter binding sites to allow downstream expression of genes 
(Chen et al., 2003a, Martinowich et al., 2003, Zhou et al., 2006). More recent 
studies from the same authors shows phosphorylation of Mecp2 at S421 rather 
acts as a global remodeling of the neuronal chromatin in response to neuronal 
activity (Cohen et al., 2011). Taken together with the fact that Mouse models 
with mutant S421 (A421) displayed cognitive impairments (Cohen et al., 2011), it 
was important to test the ability of the exogenous Mecp2 to maintain the 
appropriate phosphorylation regulation at S421. These results showed that the 
exogenous Mecp2 becomes phosphorylated at the S421 in the transduced cells in 
the Mecp2stop/y mice under basal conditions. Zhou and colleagues reported 
phosphorylation of exogenous Mecp2 in organotypic slice culture after lenti-
Mecp2 vector transfection, however this phosphorylation was induced either by 
membrane depolarization or glutamate application (Zhou et al., 2006). To 
validate the presence of basal level of S421 phosphorylation, lenti-PGK-
ME1FlagRFP transduced WT mice were used to estimate the S421 
phosphorylation level in non-transduced (basal) and transduced cells. My data 
shows that there is a detectable level of S421 phosphorylation at the basal level 
with the cells expressing exogenous Mecp2 displaying ~ 5.5 folds of the 
endogenous levels in non-transduced cells. The increased level of Mecp2 
phosphorylation at S421 in the transduced cells could be explained by;(1) an 
overall increase in cellular levels of Mecp2 (by exogenous Mecp2), (2) transduced 
cells might become electrically more active compared to the non-transduced 
cells which could lead to more activity induced phosphorylation, (3) altered 
sensitivity of exogenous Mecp2 to neuronal activity and Ca+2 signaling. However 
the effect of this increased phosphorylation on the neuronal morphology and 
function necessitates further investigation.  
Previous studies have highlighted the potential effect of lacking Mecp2 on other 
nuclear proteins, particularly histone deacetylase (HDAC)-containing complexes 
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(Nan et al., 1998). In vitro studies showed that Mecp2 and histone1(H1) have the 
same pattern of distribution across the neuronal  genome (Nan et al., 1997, 
Ghosh et al., 2010) with potential competition for the same binding sites as 
indicated by upregulated H1 levels (doubled) in the brain of Mecp2 knockout 
mice (Nan et al., 1997, Ghosh et al., 2010). Further effect of Mecp2 on the 
acetylation state of histone 3 (Shahbazian et al., 2002a, Skene et al., 2010) and 
histone 4 (Wan et al., 2001) has been reported. These data support the notion 
that Mecp2 is working as chromatin remodeling protein in addition to acting as a 
transcriptional regulator (Skene et al., 2010, Cohen et al., 2011). However the 
effect of Mecp2 was only investigated with regards to the acetylated forms of 
both H3 and H4 so it was unclear whether the increased acetylation status was 
due to an overall increase in the H3 and H4 levels or was a genuine increase in 
the acetylation process without affecting the total level of these proteins. I 
decided to address this question in the model of in vivo Mecp2 over-expression 
after lenti-PGK-ME1FlagRFP transduction in the CA1 region of the hippocampus 
of WT mice. My data shows that the cellular level of acetylated H4 (AcH4) was 
significantly decreased in cells over-expressing Mecp2 (transduced) which fits 
well with the previous report that showed hyperacetylation of H4 in the absence 
of Mecp2 in human (Wan et al., 2001), however quantification of the total H4 in 
the transduced cells displayed significant reduction in cellular level of H4 
compared to the non-transduced cells. The reduction in the level of AcH4 was 
positively correlated to the reduction in the level of total H4 level. The parallel 
reduction in the cellular level of AcH4 in transduced cells shows that this 
reduction could be due to reduction in the total H4 level without altering the 
acetylation status of H4 protein. It also argues that the previous report of 
hyperacetylated H4 in cells lacking Mecp2 is probably due to increased level of 
H4 rather a genuine change of the acetylation condition. Identification of Mecp2 
as a component/modulator of neuronal chromatin with various interactions with 
histone proteins highlights the potential benefits of chromatin modulator drugs 
in the treatment of RTT syndrome. 
Lenti-mediated exogenous Mecp2 delivery by stereotaxic injection in the adult 
mouse brain displayed a limited spread around the injection sites (Blomer et al., 
1997, Brooks et al., 2002). Mecp2 is globally expressed in the brain (Nan et al., 
1997) and any attempt to rescue the RTT-like phenotype should produce 
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exogenous Mecp2 in a reasonably high proportion of brain cells. Previous reports 
have described different methods to enhance lentivirus-mediated gene delivery 
to the CNS after peripheral administration, therefore I tried different methods 
to augment Mecp2 delivery to the CNS by using lentivirus-based vectors. Firstly I 
tried delivery of lenti-syn1-ME1FlagRFP by intravenous injection in the tail vein 
of adult mice after the BBB was distributed by Mannitol injection (Ikeda et al., 
2002, McCarty et al., 2009). Analysis of the brain tissue after 4 weeks of 
injection showed absence of RFP or anti-Flag immunofluorescence in different 
brain regions suggesting that lentivirus-based vector is not able to achieve brain 
transduction after peripheral injection. Secondly, lentivirus particles were 
pseudo-typed with rabies virus glycoprotein coat to enable retrograde transport 
to the CNS after peripheral intramuscular injection (Mentis et al., 2006, Federici 
et al., 2009). Despite achieving transgene expression in cultured neurons using 
lentivirus pseudotyped with the rabies coat, several attempts to deliver Mecp2 
under either syn1 or PGK promoter to the CNS via IM injection of this vector 
were not successful. Previous reports have  shown that extracellular space is 
relatively larger in young animals compared to the adults, which could allow a 
better spread of viral particles in the brain parenchyma (Cetin et al., 2006), 
therefore I finally injected neonatal mice intracranially with lentivirus particles 
to enhance transgene spread in the brain. RFP fluorescence was detected in the 
brain after 4 weeks of injection but the transgene showed a limited spread in 
the brain parenchyma.  
In this chapter I have provided an overview of the potentials of lentivirus-based 
vector approach in examining aspect of RTT pathology/rescue in Mecp2 knockout 
mice. Despite failure to investigate functional rescue, however, at the cellular 
level it helps study the molecular function of Mecp2 and its interaction with 
different nuclear proteins. Targeted expression of lenti-mediated exogenous 
Mecp2 expression in CA1 region of the hippocampus of Mecp2-null mice rescued 
neuron nuclear volume deficits to a WT level. Lentiviruses also provide an easy 
Mecp2 overexpression model to study the overexpression threshold without the 
need for generation of very sophisticated transgenic animal models. It could also 
be used to target Mecp2 to specific brain regions in the Mecp2 knockout mice 
(e.g. breathing centre and striatum (Kosai, 2005) in order to evaluate the 
potential for reversal of particular aspects of the RTT phenotype such as 
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respiratory or motor abnormalities. Thus whilst lentivirus-based vectors fulfil 
some of the necessary aspects of a viable gene therapy vector in RTT-gene 
therapy, the usefulness is restricted by the limited spread of Lentivirus in brain 
tissue compared to the global expression of Mecp2, makes Lentivirus based 
vectors inappropriate for seeking phenotype prevention/recovery which will 
require a vector with very high transduction efficiency and extended spread 
capabilities such as Adeno-associated virus-based vectors. The potential of these 
vectors in RTT-gene therapy will be addressed in detail in the next chapter. 
 
 
 
 
Chapter 5 
Improved Survival and Reduced Phenotypic 
Severity Following AAV9/MECP2 Gene Transfer to 
Neonatal Male Mecp2 Knockout Mice 
  
5.1 Introduction  
The genotype-phenotype pathway in RTT remains elusive and in the absence of a 
well-characterized set of downstream targets based on a known mechanism for 
MeCP2 action, a therapeutic strategy targeting the underlying causes of RTT 
more directly represents an attractive way forward. While there are multiple 
challenges facing its application in the clinical arena, gene-replacement therapy 
is a potential future treatment option for RTT patients, as postnatal activation 
of Mecp2 in mice has been shown to lead to an improved phenotype (Luikenhuis 
et al., 2004, Giacometti et al., 2007, Guy et al., 2007) thus demonstrating that 
aspects of the disorder may be reversible and potentially preventable if early 
treatment can be instigated (Cobb et al., 2010, Gadalla et al., 2011). 
MECP2 is expressed widely throughout the body but at particularly high levels in 
post-mitotic central nervous system (CNS) neurons postnatally (LaSalle et al., 
2001, Shahbazian et al., 2002b, Zhou et al., 2006), and it has been 
demonstrated that activation of conditionally silent Mecp2 only in specific 
populations of cells in the brain of Mecp2-null mice results in restoration of a 
broadly normal phenotype (Luikenhuis et al., 2004, Lioy et al., 2011). However, 
deletion of Mecp2 in adult mice produces RTT-like phenotypes suggesting a 
persistant role of MeCP2 in adult neuronal function and a requirement for 
enduring expression on any therapeutic transgene (McGraw et al., 2011). It will 
thus be necessary for gene therapy approaches in RTT both to achieve 
widespread CNS delivery of a functional copy of MECP2 and to maintain long-
term expression (McGraw et al., 2011). 
The lentivirus-based approach was able to drive expression of exogenous Mecp2 
in neurons (chapter 4), however the limited spread of the transgene observed 
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after in vivo injection of lentivirus in the brain of adult as well as neonatal mice 
impedes its application for global Mecp2 expression. In contrast recombinant 
adeno-associated virus (AAV) pseudotyped with capsid 9 (AAV serotype 9) is 
particularly important because of its ability to spread widely and to cross the 
blood brain barrier and its high neuronal tropism especially after neonatal 
injection (Foust et al., 2009). AAV has been used in research and clinical gene-
delivery studies primarily because it transduces non-dividing cells and confers 
stable gene expression (Arruda et al., 2005, Foust et al., 2009) without 
associated inflammation or toxicity.  
5.2  Study aims 
The main aim of the work described in the chapter was to assess the ability of 
ssAAV9-based vector to deliver MECP2 to the Mecp2-/y mouse brain. This work 
also extended to evaluate the effect of exogenous MeCP2 on RTT-like 
phenotypes at the cellular and organismal levels. The specific objectives of this 
study are:   
 To test the ability of AAV9/MECP2 virus particles to drive widespread 
expression of MeCP2 in the brain after direct brain injection in neonatal 
mice. 
 To test the cellular level of exogenous MeCP2 in the transduced cells. 
 To detect possible changes (improvement) in RTT-like phenotypes after 
early postnatal AAV9 mediated delivery of human MECP2 in Mecp2-null 
mice. 
5.3 Methods  
To test the potential of Adeno-associated virus to deliver MECP2 to the mouse 
brain, human MECP2_e1 isoform coding sequences carrying a C-terminal Myc-tag 
was cloned into an adeno-associated virus 2 vector backbone and produced AAV 
particles with capsid 9 (AAV2/9) under the chicken beta actin (CBA) promoter 
(this construct hereafter referred to as AAV9/MECP2; figure 5-1a). ssAAV9/GFP 
vector was also generated to be used as a control. 
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To achieve high neuronal transduction of exogenous MECP2 in mouse brain, a 
total of 6 µl of 8 X 1012 vector genome/ml was directly injected into the brain of 
male neonatal (P0-2) WT and Mecp2-/y mice. 
The effect of exogenous MECP2 on the organismal level was carried out by 
weekly (figure 5-1b) evaluating the disease progression using the RTT-like 
phenotype severity score. 
 Further assessment of motor (open field and treadmill test) and breathing 
(whole body plethysmograph) phenotypes were carried out between 8-11 weeks 
post injection (chapter 2).   
 
Figure 5-1 AAV vector-constrcuts and the experimenatal plan 
(a) MECP2_e1/Myc fusion and GFP (control) constructs were cloned into AAV2 backbones 
under the control of CBA promoter. (b) Experimental plan in which male WT or Mecp2
-/y
 
mice were injected intracranially with AAV9/MECP2 or AAV9/GFP at P0-2, scored for the 
progression of RTT-like signs from 3 weeks onwards and phenotyped quantitatively at 
weeks 8-11. PolyA; SV40 polyadenylation signal, CBA; chicken beta actin, ITR; inverted 
terminal repeat. 
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5.4 Results  
5.4.1 Confirmation of genotypes in Mecp2-null mouse colony by 
PCR 
To discriminate between Mecp2-null and WT allele, primers were used to 
amplify a 416 bp PCR product from WT allele (primers P5/P7) and a 470 bp 
product from Mecp2-null allele (primers P5/P6) (Guy et al., 2001). Ear samples 
from all mice were collected after weaning and genomic DNA was extracted and 
subjected to the previously described genotype protocol (chapter 2). Agarose gel 
electrophoreses (figure 5-3) was used to identify each mouse genotype (table 5-
1). Two set of PCR reactions were carried out for each genomic DNA sample; the 
first is to detect the Mecp2-WT allele and the second is to detect the Mecp2-null 
allele. WT (male and female) and Mecp2-null mice display only one band with 
their corresponding reaction whereas the heterozygous females display PCR 
products with both reactions because female mice have both Mecp2-WT and 
Mecp2-Null alleles. 
Table 5-1 Identification of mice genotype by PCR reaction 
 Genotype P5/P7 (WT allele) P5/P6 (null allele) 
Heterozygous female Mecp2
-/+
 Positive Positive 
WT female Mecp2
+/+
 Positive Negative 
Hemizygous male Mecp2
-/y
 Negative Positive 
WT male Mecp2
+/y
 Positive Negative 
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Figure 5-2 PCR identification of mice genotype 
Representative gel image showing the PCR verification of mouse genotypes. Genomic DNA 
from heterozygous female was used as a template for a positive control PCR reaction (no.1) 
whereas PCR reactions without DNA template were used as a negative control (no.2). Each 
mouse genomic DNA has two sets of PCR reactions; the first reaction detects the WT allele 
and the second reaction detects Mecp2-null allele. Samples showing PCR bands on their 
first reaction are either WT males, e.g. no. 3&6, or WT females, e.g. no. 14&18 (white colour). 
Samples showing PCR bands on their second reaction are hemizygous males (orange 
colour). Finally samples showing 2 PCR bands in both PCR reactions are heterozygous 
females (green colours). M; 100bp DNA ladder.  
5.4.2 Neonatal CNS injection of AAV9/MECP2 resulted in 
widespread brain expression of MeCP2  
To test the ability of AAV9 vector to deliver exogenous MECP2 into the mouse 
brain, a WT mouse was perfused 12 weeks post-injection of AAV9/MECP2 and 
brain parasagittal sections were immunolabelled with anti-Myc and anti-NeuN 
antibodies. Scanning different brain regions for exogenous MeCP2 expression 
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showed that the transgene (Myc-positive cells) was widely expressed across the 
brain (figure 5-3a). The expression of exogenous MeCP2 was mainly detected in 
NeuN –immunopositive cells in different brain regions suggesting putative 
neuronal expression (figure 5-3b-d). 
 
 
 
Figure 5-3 Widespread expression of exogenous MeCP2 across the brain following neonatal 
IC injection of ssAAV9/MECP2. 
Representative micrograph (whole brain, parasagittal section) showing the distribution of 
transgene expression in a 12 week old WT mouse following bilateral brain injection. White 
dashed arrow indicates approximate injection site. (b) Higher power micrographs 
corresponding to boxes in (a) showing anti-Myc (transduced cells) and NeuN-
immunolabelled cell populations. b; motor cortex, c; hypothalamus, d; hippocampus and e; 
striatum. Scale bars in (a) = 1mm and in (b) = 100 μm. NeuN; neuronal nuclei antigen 
(Rbfox3), OLF; olfactory bulb, TH; thalamus, HT; hypothalamus, CX; cortex, BS; brainstem. 
 
 
OLF 
TH 
HT 
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CX 
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To measure the transduction efficiency across the brain, mice were perfused and 
brain coronal sections were immunolabelled with anti-Myc and anti-NeuN 
antibodies and stained with DAPI. The number of Myc-immunopositive cells DAPI-
stained nuclei were counted in 18 random fields for each brain region (N = 4 
mice) in different brain regions (figure 5-4a). The transduction efficiency varied 
between brain areas with the highest transduction efficiency observed in the 
hypothalamus (41.5 ± 11.3 % of all cells) and in the thalamus (37.2 ± 6.3 % of 
cells) and with the lowest efficiency seen in the striatum (6.8 ± 2.3% of cells, 
figure 5-4b). High power images showed that the transgene was mostly 
expressed in neurons which represented 67 ± 11.8 % to 98 ± 0.8 % of all 
transduced cells indicating high transduction and/or expression in neuronal 
populations. In contrast, the proportion of transgene-expressing cells 
immunonegative for NeuN (presumed mostly to represent glia) was modest 
(range 0.5 – 6.0% of all transduced cells, figure 5-4b). 
5.4.3 Neonatal CNS injection of AAV9/MECP2 resulted in spinal 
cord and liver expression of the exogenous MeCP2 
I previously showed in (figure 5-4) the widespread transduction of AAV9/MECP2 
throughout the brain after direct intracranial injection in neonatal mice. To test 
the ability of this virus to spread to the spinal cord, transverse sections were 
prepared from the lumbar spine and immunolabelled with anti-Myc and anti- 
Choline acetyl transferase (ChAT), a lower motor neuron marker, antibodies. 
Myc-immunopositive cells were observed in the lumbar section indicating the 
ability of AAV9/MECP2 to deliver expression to the spinal cord after direct brain 
injection. Co-labelling with anti-ChAT showed that the transgene was expressed 
in the lower motor neurons (figure 5-5a). I also asked whether AAV9 virus has the 
ability to transduce peripheral organs after direct brain injection. To answer this 
question, frozen sections from the liver were prepared and immunolabelled with 
anti-Myc antibody and DAPI. Interestingly, Myc-immunopositive cells that co-
localized with DAPI were detected in the liver indicating extended spread 
properties of AAV9 to the peripheral organs after direct brain injection (figure 5-
5b).  
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Figure 5-4 IC injection of AAV9/MECP2 in neonatal mice produced high transduction 
efficiency across the brain. 
(a) Micrographs showing brain coronal sections, that were immunolabelled with (a-i) anti-
Myc antibody and (a-ii) anti-NeuN antibody. Exogenous MeCP2 expression was detected 
across the brain with high transduction efficiency in the NeuN-immunopositive cell 
population. (b) Quantification of the numbers of Myc-immunopositive cells (transduced) 
relative to the numbers of DAPI stained nuclei in different brain regions (N = 4 mice). The 
highest transduction efficiency was observed in the hypothalamus whereas the lowest 
transduction efficiency was observed in the striatum. Data is represented as mean ± SEM. 
Scale bar in (a) = 20 µm. 
 
a 
b 
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Figure 5-5  IC injection of AAV9/MECP2 into neonatal mice led to widespread spinal cord 
and liver transduction.  
(a) Representative images from the lumbar region of the spinal cord after direct brain 
injection of AAV9/MECP2 in neonatal mice. Sections were immunolabelled with (i) anti-ChAT 
and (ii) anti-Myc antibodies. (iii) Merge of (i) and (ii). Arrowheads indicate expression of 
exogenous MeCP2 in the lower motor neurons as shown by the co-localization between 
Myc-immunopositive and ChAT-immunopositive cells. (b) Micrograph of a liver section 
taken from a mouse that was injected with AAV9/MECP2 directly into the brain. Section was 
stained with (i) DAPI and (ii) anti-Myc antibody. (iii) Merge of (i) and (ii). Arrows indicate 
expression of exogenous MeCP2 in the liver. Scale bars = 10 µm. ChAT; Choline Acetyl 
Transferase.  
5.4.4 Neonatal brain injection of AAV9/MECP2 resulted in MeCP2 
expression at near-physiological cellular levels  
Maintaining the normal cellular level of MeCP2 has become considered to be 
crucial for normal function as overexpression of Mecp2 has a moderate 
phenotype in mice (Luikenhuis et al., 2004) and human chromosome Xq28 
duplications involving MECP2 result in a pronounced clinical phenotype (Meins et 
al., 2005, Van Esch et al., 2005). Therefore, to quantify the cellular level of the 
transgene product and relate this to endogenous MeCP2 levels, WT mice were 
injected postnatally (P0-2) with AAV9/MECP2 and the resultant transgene 
product assessed by quantitative immunofluorescence after 12 weeks. Brain (N = 
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4) coronal sections were immunolabelled with anti-Myc and anti-MeCP2 (detect 
both endogenous and exogenous MeCP2 protein) antibodies. Analysis of MeCP2 
immunofluorescence intensity in principal cells within hippocampal area CA3 
(figure 5-6a) showed that the cellular levels of MeCP2 in transduced cells was 
2.4 ± 0.08 AU (mean ± SEM, N = 220 sampled cells) times the endogenous levels 
in non-transduced cells (1 ± 0.01 AU, N = 285 sampled cells). In layer V of 
primary motor cortex, the cellular level of Mecp2 in transduced cells was 2.05 ± 
0.04 AU (N = 307 sampled cells) times the endogenous level in the non-
transduced cells (1 ± 0.01AU, N = 281 sampled cells). This data suggests that the 
exogenously-derived MeCP2 was being expressed at approximately 1-1.25 times 
the endogenous levels (figure 5-6b). Analysis of MeCP2 expression levels in the 
motor cortex (measured as immunofluorescence intensity) in transduced and 
non-transduced cells (N = 4 brains) revealed endogenous MeCP2 levels to be 
tightly regulated (narrow peak, SD = 0.1), while levels in transduced cells were 
higher and more broadly distributed (SD = 0.6, figure 5-6c). 
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Figure 5-6 IC injection of AAV9/MECP2 into neonatal mice produced exogenous MeCP2 
levels close to that of the endogenous protein. 
(a) Micrograph showing brain coronal section of 12 week old WT mouse that was injected at 
P0-2 with ssAAV9/MECP2. Section was immunolabelled with (i) anti-Mecp2 antibody and (ii) 
anti-Myc antibody. (iii) Merge of (i) and (ii). Arrows indicate transduced cells (express 
endogenous and exogenous Mecp2) whereas arrowheads indicate non-transduced cells 
(express endogenous Mecp2) in the CA3 region of the hippocampus. (b) Plot showing 
intensity measures of the anti-MeCP2 immunofluorescence in transduced and non-
transduced cells in the (CA3) region of the hippocampus and in the primary motor cortex. 
(c) Distribution of MeCP2 levels (immunofluorescence intensity) in transduced and non-
transduced cells of the primary motor cortex (N = 4 mice). Analysis revealed endogenous 
MeCP2 levels to be tightly regulated (narrow peak) while levels in transduced cells showed 
a broader and positively shifted distribution. Data is represented as mean ± SEM. Scale bar 
in (a) = 10 µm. AU; arbitrary units. 
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5.4.5 AAV9-mediated neonatal delivery of MECP2 improved RTT-
like phenotypes in Mecp2-null mice 
 To establish whether AAV-mediated gene delivery of MECP2 can improve and/or 
prevent development of the RTT-like phenotype, Mecp2-null and corresponding 
WT littermate mice were injected intracerebrally at an early postnatal time 
point (P0/P2) with either AAV9/MECP2 or AAV9/GFP (as a non-therapeutic 
control) and monitored over a 30 week experimental period. Weekly monitoring 
of these mice for overt RTT-like features using an established observational 
scoring system (Guy et al., 2007, Lioy et al., 2011, Weng et al., 2011) was 
carried out (figure 5-7). AAV9/GFP control-injected Mecp2-null mice showed the 
expected phenotype with motor/activity and other deficits apparent at 3 weeks 
and a steep increase in phenotype severity score over the subsequent weeks. In 
contrast AAV9/MECP2-treated null mice exhibited slower progression of the 
phenotype, whose mean severity reached a peak around 14 weeks and then 
decreased towards WT values. This decrease was in part due to sudden death in 
the most severely phenotypic mice, but also in part due to the lower and/or 
improving phenotype score in the longest-lived mice. There was no difference in 
severity score between WT mice injected with AAV9/MECP2 and those injected 
with AAV9/GFP and scores in these two groups did not change significantly over 
the course of the study. It should be noted that the downward trajectory of 
severity in the AAV9/GFP control-injected Mecp2-null mice at 12 weeks is largely 
a result of the death of the most severely affected animals reducing the mean 
severity in the survivors rather than a tendency for the phenotype severity to 
peak and then reduce. 
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Figure 5-7 AAV9/MECP2 neonatal injection reduced phenotype severity in Mecp2-null mice 
Plot showing aggregate phenotype severity score of Mecp2-null and WT mice treated either 
with AAV9/GFP or AAV9/MECP2. The rate of phenotype progression in AAV9/MECP2-treated 
null mice (N = 14) was significantly (p < 0.05, Repeated measures ANOVA between weeks 3-
12 with tukey`s posthoc pairwise comparison) reduced compared to the aggressive 
phenotype trajectory seen in AAV9/GFP-injected control mice (N = 11). In contrast, WT mice 
injected with AAV9/MECP2 (N = 12) or AAV9/GFP (N = 12) showed no difference between 
groups.  Indicates that in the null untreated group, insufficient mice were still alive to plot 
the mean score after 12 weeks. Data is presented as mean ± SEM. 
5.4.6 AAV9-mediated neonatal delivery of MECP2 prolonged life 
span in Mecp2-null mice 
The reduced survival of Mecp2-null mice is one of the cardinal features of the 
RTT-like phenotype. Monitoring of the AAV9/MECP2 and GFP treatment mice 
revealed that AAV9/GFP-treated null mice displayed markedly reduced survival, 
as expected for this model (Guy et al., 2001) (figure 5-8; median survival 9.3 
weeks, range 5-19 weeks) whereas AAV9/MECP2-treated null mice showed 
significantly extended survival (median survival 16.6 weeks; range 7 to >30 
weeks; p < 0.0001, Gehan-Breslow-Wilcoxon  test).  In the AAV9/MECP2-treated 
WT cohort, included to investigate the effect of overexpressing exogenously-
derived MeCP2 in the brain, no mortality was observed. Two of 12 AAV9/GFP-
treated WT mice died suddenly before the end of the study. 
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Figure 5-8 Prolonged survival of Mecp2-null mice after neonatal IC injection of AAV9/MECP2 
Survival plot showing extended lifespan of Mecp2
-/y
 mice injected with AAV9/MECP2 (n = 14) 
compared to AAV9/GFP injected controls (n =11). The median survival period was 
significantly increased from 9.3 weeks to 16.6 weeks (P<0.0001 Gehan-Breslow-Wilcoxon 
test). The plot also shows absence of lethality associated with overexpression of MeCP2 in 
AAV9/MECP2 treated WT mice (n = 12). AAV9/GFP-treated WT mice (n = 12) showed 2 
unexplained sudden death at the age of 16 weeks.  # indicates two AAV9/MECP2-treated 
Mecp2-null mice that survived to the end of the 30 week study. 
5.4.7 Growth deficit persists after AAV9/MECP2 injection however 
stabilizes   
As growth deficits are commonly observed in RTT (Neul et al., 2010) and low 
bodyweight is a prominent characteristic of Mecp2-null mice(Chen et al., 2001, 
Guy et al., 2001), growth was also monitored weekly in these mice, but the 
difference in bodyweight between AAV9/GFP control-injected Mecp2-null mice 
and AAV9/MECP2-treated Mecp2-null mice was not significant (p > 0.05 repeated 
measures ANOVA) despite a trend towards improved growth in the AAV9/MECP2-
treated mice. 
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Figure 5-9 Persistent bodyweight deficit in Mecp2-null mice after AAV9/MECP2 injection  
Plot showing bodyweight changes over time in WT and Mecp2-null mice after neonatal 
injection with either AAV9/GFP or AAV9/MECP2. There was a genotype effect (repeated 
measures ANOVA, p < 0.05) but no significant treatment effect. 
5.4.8 AAV9-mediated neonatal delivery of MECP2 improved motor 
phenotypes in Mecp2-null mice 
5.4.8.1 Tread-mill test 
Movement-related deficits constitute 3 of the 4 main criteria for RTT diagnosis  
(Neul et al., 2010) and represent a major feature of the syndrome in girls. 
Similarly, mobility and movement-dependent behaviour deficits constitute 
prominent characteristics of Mecp2-null mice (Chen et al., 2001, Guy et al., 
2001). To explore the effect of AAV9/MECP2 treatment on movement-related 
phenotypes, mice were subjected to analysis of their locomotory behaviour at 8-
9 weeks using a treadmill device (chapter 2). Mice were challenged to perform 
on a treadmill at two different speeds (figure 5-10). There was a significant 
overall difference in performance between groups (10 cm/s, p = 0.0013; 25cm/s, 
p < 0.0001; Fisher‟s exact test). Challenged at the lower speed (10 cm/s), there 
was no significant difference between AAV9/GFP-treated and AAV9/MECP2-
treated Mecp2-null mice (4/8 and 10/12 mice, respectively, could manage the 
task; Fisher‟s exact test, p = 0.14) in their ability to perform to criteria 
(achieving run for approximately 2 seconds, without sliding back on the running 
belt) . When challenged using the more demanding high speed test (25 cm/s), 
none of the AAV9/GFP-treated Mecp2-null mice could perform to criteria 
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whereas 50% of AAV9/MECP2-treated Mecp2-null mice were still able to 
successfully complete the task, a significant difference in ability to perform in 
this test (0/8 vs 6/12 mice, respectively; Fisher‟s exact test, p = 0.024). All WT 
mice (both AAV9/MECP2 and AAV9/GFP treatment groups) could perform at both 
speeds. 
 
Figure 5-10 Treadmill motor test of Mecp2-null mice after neonatal injection of AAV9/MECP2. 
Plot showing the proportion of mice that were able to perform at two different speeds on a 
motorized treadmill. Numbers on the columns represent the number of mice included in 
each group. * p < 0.05, Fisher’s exact test.  
5.4.8.2 Open field test 
To further study the motor behaviours in AAV9/MECP2-treated Mecp2-null mice 
and their AAV9/GFP treated control, an open field test was carried out at 9 
weeks after injection. AAV9/GFP-treated Mecp2-null mice (n = 6) showed a 
significant deficit in locomotion-related parameters including; movement 
duration, total distance moved and mean velocity, compared to AAV9/GFP-
treated WT controls (figure 5-11a-c; n = 9; all  p < 0.01). In contrast, 
AAV9/MECP2-treated Mecp2-null mice (n = 11) were not significantly different 
from AAV9/GFP-treated WT controls (n = 9), while post hoc comparisons 
revealed significantly higher mean velocity and total distance moved parameters 
in the AAV9/MECP2-treated Mecp2-null mice than in the AAV9/GFP-treated 
Mecp2-null cohort (both p < 0.05).  
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Figure 5-11 Motor-related measures of the open field test 
Plots showing the motor related parameters of the open field test that was performed at 9-11 
weeks following AAV9 injection. (a) Plot showing movement total duration (time during 
which the mice were producing detectable movement). (b) Plot showing mean velocity and 
(c) Plot showing the total distance moved. Numbers of animals per genotype/treatment 
group are shown within each bar. Open field measures were assessed by 2-way ANOVA 
with Tukey’s post hoc comparisons. * p < 0.05, ** p < 0.01, ns = not significant.  
5.4.8.3 Improved exploratory behaviours with no effect on the anxiety-
related measures 
In addition to ambulatory movement, we tested exploration and anxiety-related 
behaviour by assessing rearing frequency and time spent in the outer and central 
zones of the open field. AAV9/GFP-treated Mecp2-null mice showed a 
significantly reduced rearing frequency (figure 5-12a) compared to AAV9/GFP-
treated WT mice (p < 0.01), while AAV9/MECP2-treated Mecp2-null mice showed 
increased rearing frequency relative to AAV9/GFP-treated Mecp2-null mice (p < 
0.05). As with ambulatory movements, there was no difference between the WT 
treatment groups. There was no genotype or treatment significant difference 
between the studied groups in the anxiety related parameters by 2 way ANOVA 
(p > 0.05, figure 5-12b-c). 
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Figure 5-12 Exploratory and anxiety related measures of the open field test. 
Plots showing the exploratory and anxiety related parameters of the open field test that was 
performed at 9-11 weeks following AAV9/MECP2 or GFP injection. (a) Plot showing the 
rearing frequency which is an indicator of the exploratory behaviours. (b&c) plots showing 
the time spend in the outer zone and inner zone respectively which are indicators of anxiety. 
Numbers of animals per genotype/treatment group are shown within each bar. Open field 
measures were assessed by 2-way ANOVA with Tukey’s post hoc comparisons. * p < 0.05, 
**p < 0.01, ns; not significant.  
5.4.9 AAV9/MECP2-treated Long-lived mice displayed consistent 
phenotype improvement. 
As I showed before, AAV9/MECP2 treated Mecp2-null mice displayed extended 
survival compared to AAV9/GFP treated mice. Analysis of RTT-like phenotype 
severity score of the long-lived mice (> 22 weeks old) showed a gradual increase 
in the severity score, which achieved maximum value at the age of 14 weeks 
followed by steady reduction in the phenotype severity score, finally reaching 
levels comparable to WT. However these severity scores were less than the 
average phenotype severity score of Mecp2-null mice treated with AAV9/GFP at 
all-time points) (figure 5-13a). For further confirmation of this phenotype 
improvement, open field testing was carried out at the age of 22 weeks for the 
three survivors and the data was compared to their own data at the age of 
11weeks. The data showed that the performances in the open field were very 
similar in motor and exploratory behaviour-related parameters at both ages 
which indicate persistent treatment effects (figure 5-13b-d).   
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Figure 5-13 Phenotypic analysis of AAV9/MECP2-treated long-lived Mecp2-null mice.  
(a) Plot showing individual aggregate phenotype severity scores for the longest surviving 
mice (No. 15, 23 and 30). Numbers 15 and 23 survived to the end of the study (30 weeks; ie. 
12 weeks beyond longest surviving AAV9/GFP–treated Mecp2
-/y
 mouse) whilst number 30 
died suddenly at 22 weeks. Black arrow indicates the peak mean severity score (around 14 
weeks of age). (b-d) plots showing the performance of these mice on the open field test at 
two time points (11 and 22 weeks). Plots show data as mean ± SEM. Statistical analysis was 
carried out by paired t test.  
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5.5 Overt respiratory phenotypes persist following AAV9-
mediated neonatal delivery of MECP2 to Mecp2-null 
mice 
Apnoeas and abnormal breathing patterns were investigated using whole body 
plethysmography at 9 weeks following neonatal delivery of AAV9/MECP2 or 
AAV9/GFP. Mecp2-null mice displayed a characteristic erratic breathing pattern 
with frequent apnoeas (figure 5-14a), in contrast to the regular baseline 
breathing pattern seen in both WT treatment groups. Overall, there was no 
difference in baseline respiratory frequency between genotypes or treatments 
(figure 5-14b; 2-way ANOVA, p > 0.05). An increased incidence of apnoeas 
(figure 5-15a) was observed in the Mecp2-null mice compared to the WT mice (2-
way ANOVA, genotype main effect p < 0.05), but the AAV9/MECP2- and 
AAV9/GFP-treated mice did not differ. Similarly, higher breathing frequency 
variability (CV%; figure 5-15b) was observed in the Mecp2-null mice compared to 
the WT mice, but again the AAV9/MECP2- and AAV9/GFP-treated mice did not 
differ (2-way ANOVA, genotype main effect p < 0.05, treatment main effect p = 
> 0.05, n = 7-12 mice per group).  
 
Figure 5-14 Persistent breathing phenotype in Mecp2-null mice after AAV9/MECP2 injection 
(a) Representative whole-body plethysmograph traces showing regular and erratic 
breathing patterns/apnoeas (arrows) in WT and Mecp2
-/y 
mice respectively. (b) Baseline 
breathing frequency. Respiratory frequency was assessed by 2-way ANOVA with Tukey’s 
post hoc comparisons. ns = not significant. Numbers of animals per genotype/treatment 
group are shown within each bar.  
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Figure 5-15 Breathing phenotype in Mecp2-null mice after AAV9/MECP2 injection 
(a) Plot showing the coefficient variability of the breathing frequency. (b) Plot showing the 
number of aponeas/minutes (breath hold for more than 1 second). Numbers of animals per 
genotype/treatment group are shown within each bar. Breathing frequency variability and 
Apnoea frequency were assessed by 2-way ANOVA with Tukey’s post hoc comparisons. * p 
< 0.05, ** p < 0.01, ns = not significant.  
5.5.1 AAV9-mediated delivery of MECP2 rescued the Mecp2-null 
nuclear volume phenotype 
A consistent feature of MeCP2 deficiency at the cellular level is a reduction in 
nucleus volume (Giacometti et al., 2007, Johnson et al., 2011). In order to 
assess potential changes in this parameter, 3D nuclear volume measures were 
obtained for AAV9/MECP2-transduced and non-transduced granule cells of the 
dentate gyrus (figure 5-16a-b). Consistent with previous reports, non-transduced 
neurons in Mecp2-null mice showed nuclear volumes that were on average 69% of 
volumes in age-matched WT mice (figure 5-16c). In Mecp2-null mice 
AAV9/MECP2-transduced cells displayed nuclear volumes that were significantly 
larger (by 29% on average) than those of neighbouring non-transduced cells in 
the same brains, and the AAV9/MECP2-transduced cells showed no significant 
difference from values observed in non-transduced WT mice. Interestingly, in 
WT mice, AAV9/MECP2-transduced cells showed a modest (approx. 1.2-fold on 
average) but significant increase in nuclear volume relative to neighbouring non-
transduced cells (figure 5-16d). 
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Figure 5-16 Increased nuclear volume in Mecp2
-/y
 and WT mice after AAV9/MECP2 injection.  
(a&b) Representative images from the dentate gyrus of (a) WT and (b) Mecp2-null mouse at 
12 weeks following AAV9/MECP2 injection. Sections were stained with DAPI (blue) and anti-
Myc antibody (red). Arrows indicate transduced cells (purple). (c) Neuronal nuclear volume 
measurements of transduced and non-transduced cells of Mecp2-null mice (N = 3 mice)and 
age matched WT (N = 4 mice). (d) Neuronal nuclear volume measurements of transduced 
and non-transduced granular cells of WT mice (n = 4). Data was normalized to the mean 
volume in non-transduced WT cells and is represented as mean ± SEM. Statistical analysis 
was carried out by 2-way ANOVA and Tukey's post hoc pairwise comparison. ***= p < 0.001. 
Scale bar = 10 µm.  
 
 
 
 
c d 
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5.6 Discussion  
Incomplete understanding of the precise molecular actions of MeCP2 continues 
to impede the development of rational therapeutic strategies for Rett syndrome. 
MECP2 gene delivery is an obvious theoretical approach to overcoming the 
consequences of functional MeCP2 deficiency. I showed that early postnatal 
delivery of exogenous MECP2 directly to the brain at transduction efficiencies in 
the range of ~7- 42%, depending on brain region, results in a substantial 
prolongation of lifespan (~80% increase in median survival) and a less aggressive 
trajectory of RTT-like phenotypes severity. Interestingly, a small number of mice 
survived to the end of the 30 week study period, well in excess of the average 
lifespan of the control Mecp2-null mice (lifespan was >3 fold greater for some 
AAV9/MECP2- treated mice). Furthermore, the longest-lived mice treated with 
the therapeutic vector also displayed a stabilization of the phenotype in terms 
of aggregate severity score and objective locomotor measures. 
 Male mice lacking MeCP2 in all cells display the most severe phenotype 
observable in any mouse model of RTT and thus provide an especially 
challenging system for assessing the potential of novel therapeutic approaches. 
Nevertheless, these data show that treatment with the AAV9/MECP2 vector can 
influence phenotype progression and lifespan. In contrast to the observed 
beneficial impact on the RTT-like signs, AAV9/MECP2-treatment resulted in only 
a modest, non-significant increase in bodyweight of Mecp2-null mice compared 
to control-treated Mecp2-null mice, even for the most long-lived animals. This 
raises the possibility that the levels of transgene in relevant areas of the brain 
did not reach a threshold for affecting bodyweight or that reduced bodyweight 
in Mecp2-null mice is at least in part due to MeCP2 deficiency in peripheral 
organs rather than solely the brain.  
An especially robust impact of treatment on the phenotype was observed in the 
motor behaviors measured, where exogenously-derived MeCP2 produced a 
substantial improvement in open field activity/locomotion and performance on a 
forced motor task in the Mecp2-null mice. The impaired locomotor activity 
observed in the control-treated Mecp2-null mice in the open field experiments 
can be explained by genuine motor disability, by an anxiety phenotype or by a 
lack of motivation. The complete inability of AAV9/GFP-treated mice to perform 
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when tested at the high speed on the treadmill and their partial ability to 
perform at low speed suggest the presence of a true motor defect in this forced 
challenge rather than inertia purely due to lack of motivation. This genuine 
motor impairment was ameliorated by AAV9/MECP2 treatment. This effect was 
mirrored in the open field test whereby AAV9/MECP2-treated mice displayed 
significantly enhanced ambulatory activity. Locomotor improvement was 
accompanied by an increase in rearing frequency in AAV9/MECP2-treated mice 
suggesting additional improvement in exploration-related behaviours.  Analysis 
of open field data from the long-term survivors collected on multiple occasions 
suggests that the locomotor phenotypes are not progressive throughout life in 
AAV9/MECP2-treated null mice (figure 5-13 a-d). Reports by other groups as to 
whether anxiety phenotypes, measured by open field test, are visible in young 
Mecp2-null mice have not revealed consistent observations (Pelka et al., 2006, 
Stearns et al., 2007, Lioy et al., 2011). We found no genotype or treatment 
differences in the proportion of time spent in the central zone of the open field.  
The analysis of breathing was consistent with other reports that Mecp2-null mice 
exhibit a range of breathing phenotypes (Viemari et al., 2005) and mirrors the 
clinical picture where apneas and other breathing irregularities are 
characteristic and highly prevalent features of RTT (Neul et al., 2010). Previous 
studies have shown that postnatal activation of Mecp2 globally (Robinson et al., 
2012) or in glial cells (Lioy et al., 2011) can rescue abnormal breathing and this 
suggests that the respiratory phenotype is not solely the result of an earlier 
developmental deficit and is amenable to treatment at the level of causative 
gene function. The absence of any impact of AAV9/MECP2-treatment on 
breathing irregularity or on the incidence of apneas in the mutant mice in this 
study could be explained if, despite the widespread expression of exogenous 
MeCP2, the cells responsible for breathing rhythmogenesis or otherwise 
contributing to breathing regulation were transduced at very low levels.  
MeCP2-deficiency is known to be associated with a wide variety of morphological 
and neurochemical changes in the brain (Gadalla et al., 2011). To examine the 
consequences of exogenous MECP2 delivery, simple measures of cellular 
phenotype, including neuronal nuclear volumes within the dentate gyrus, were 
investigated. The significant reduction in neuronal nuclear volume in MeCP2-
deficient cells has been reported previously (Giacometti et al., 2007, Johnson et 
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al., 2011) and my results show that this cell morphological measure can be 
effectively rescued by the expression of exogenously-derived MeCP2 at close to 
WT levels within the nucleus. Furthermore, the comparison within individual 
brains of neighbouring MeCP2-containing and MeCP2-deficient cells suggests that 
these changes represent a cell-autonomous effect. This would be consistent with 
the differences in nuclear volume and soma size in neurons containing MeCP2 
and those lacking MeCP2 in the female heterozygote (Mecp2+/-) mouse brain (Ho 
et al., 2008). The fact that nuclear volume was rescued after expression of 
exogenously-derived MeCP2 provides evidence for structural remodelling of 
neurons. Whether this remodelling also extends to changes in dendritic/axonal 
size and complexity, as shown for exogenously-derived MeCP2 in neuronal 
culture (Rastegar et al., 2009) and upon delayed activation of Mecp2 in mature 
brains (Robinson et al., 2012), remains to be established.  
Potentially serious complications have been attributed to MeCP2 overexpression 
(Luikenhuis et al., 2004, Van Esch et al., 2005, Friez et al., 2006).  The present 
studies demonstrate the potential for delivering the MeCP2 protein trans-
genetically without overt overexpression-related toxicity, at least with the 
vector designs utilized in this study and with the delivery efficiencies achieved.  
This is demonstrated by the lack of any phenotypic deficits in WT mice injected 
as neonates with the ssAAV9/CBA-MECP2 vector, which had approximately 
double normal levels of MeCP2 in transduced cells. The treated WT mice 
overexpressing MeCP2 displayed no difference from AAV9/GFP-treated WT 
controls in terms of survival, locomotor activity and breathing. However, these 
results cannot rule out the possibility of subtle or very delayed overexpression 
toxicity (Collins et al., 2004). Nevertheless, the same dose (conferring 1- to 
1.25-fold of WT levels in null cells) in male RTT mice provided a significant 
behaviour and survival benefit. The implications of these findings are 
particularly important when considering this approach for RTT females (that 
have a mosaic network of cells expressing either normal or mutant Mecp2 
allele). Here, there is a concern that overexpression toxicity might result from 
an introduction of MeCP2 to cells expressing the WT endogenous gene while 
trying to achieve therapeutic levels of MeCP2 in the cells expressing the mutant 
allele. Our data shows that it may be possible to achieve a therapeutic outcome 
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without the associated overexpression toxicity using an appropriate vector and 
promoter system.  
This work shows, at „proof-of-concept‟ level, that exogenous MeCP2 can be 
delivered at a physiologically tolerable level via AAV2/9 vectors to the brain of 
Mecp2-null mice. Provision of MeCP2 from exogenous source has achieved a 
partial amelioration of the RTT-like phenotype and has prolonged the survival in 
Mecp2-null mouse model. Importantly, overexpressing exogenous MeCP2 was 
without apparent toxicity when injected into the WT mice providing a broader-
than-anticipated window of therapeutic MeCP2 expression in the treatment of 
Rett syndrome. 
 
 
 
 
Chapter 6 
Self-complementary AAV9-mediated delivery of 
exogenous MECP2 into neonatal male Mecp2 
knockout mice  
  
6.1 Introduction  
In light of the ability of a single-stranded AAV9/CBA-MECP2 vector to enhance  
survival and reduce phenotype severity of Mecp2 knockout  mice injected at P0-
2 (chapter 5), I would suggest that greater therapeutic gain could be achieved by 
utilising a vector with increased transduction efficiency. This is supported by a 
previous report that showed that the degree of phenotype rescue achieved in 
delayed activation studies is directly correlated with the level of newly-
activated endogenous Mecp2 (Robinson et al., 2012). A recent advance in AAV 
vector technology has been the development of self-complementary (sc) vectors, 
whose genome is comprised of complementary copies of the DNA insert linked in 
cis through a mutated AAV inverted terminal repeat (McCarty et al., 2001). 
Therefore unlike ssAAV, scAAV vectors are not limited by the ability of the host 
cell to convert single-stranded genome to duplex that is a rate limiting step in 
the vector transduction (Fu et al., 2003). These scAAV vectors have been 
reported to have 10-100 fold higher transduction efficiency than traditional 
ssAAV9 vectors (McCarty et al., 2003). In addition, delivery of scAAV9 through 
intravenous (IV) injection in neonates has been reported to produce widespread 
transgene expression in the brain (Foust et al., 2009) and has been shown to 
rescue the phenotype in the animal model of Spinal Muscular Atrophy (Valori et 
al., 2010).  
The reduced cloning capacity of scAAV vector precludes the cloning of MECP2 
minigene under the control CBA promoter as used in chapter 5. An alternative 
promoter would be the Mecp2 endogenous promoter (~677bp) that has been 
reported to recapitulate the expression pattern of endogenous Mecp2 in neurons 
(Adachi et al., 2005). However, this segment is still too large to fit into the 
reduced capacity scAAV9 along with the MECP2 minigene. Recently a more 
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defined short segment (229bp) of Mecp2 endogenous promoter was proven to 
drive neuronal specific expression in the brain (Gray et al., 2011b). This short 
Mecp2 promoter segment allows concomitant cloning with MECP2 minigene in 
the scAAV9 vector which represents a potential tool to drive exogenous MeCP2 
expression in post mitotic neurons with high transduction efficiency following 
peripheral administration.  
6.2 Aims  
The main aim of the work described in this chapter was to examine the potential 
of delivering exogenous MECP2 using the more efficient scAAV9 vector and 
Mecp2 endogenous core promoter (MeP). I aimed to establish the effect of this 
vector on RTT-like phenotypes in Mecp2stop/y mice. The specific objectives of this 
study are:      
 To test the efficiency of scAAV9/MeP-MECP2 vector to deliver exogenous 
MECP2 in vivo by intravenous and direct brain injection in neonatal mice. 
 To evaluate the transduction efficiency in the brain and to quantify 
cellular levels of exogenous MeCP2 after both methods of injection. 
 To investigate the effect of IV and IC injections of scAAV9/MeP-MECP2 on 
the trajectory of RTT-like phenotype in Mecp2 knockout mice. 
  To test for potential overexpression-related toxicity after introducing 
exogenous MeCP2 to WT neonatal mice. 
 
6.3 Methods  
To test the ability of scAAV2 vector with capsid 9 (AAV2/9, from now I will refer 
to this vector as scAAV9) to globally deliver exogenous MECP2 with high 
transduction efficiency, human or mouse MECP2_e1 isoform coding sequences 
carrying a C-terminal Myc-tag fusion was cloned into a AAV9 vector-backbone 
under the control of murine Mecp2 endogenous core promoter (MeP, 229bp, this 
construct, scAAV9/MeP-hMECP2, henceforth referred to as scAAV9/MECP2; 
figure 6-1a). To compare the effect of global MeCP2 expression versus brain-
specific MeCP2 expression on the trajectory of RTT-like phenotypes, two 
delivery methods were adopted (figure 6-1b); the first was IV (for global 
expression) injection of 30 µl of 3.1X1011 vector genome (vg) / ml (9.3 X 109 vg / 
mouse) through the facial vein and the second was direct brain injection (for 
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brain-specific expression) of 6 µl of the same titre (1.8 X 109 vg / mouse). A 
scAAV9 / MeP-GFP vector was used as a control vector in all experiments.  Male 
neonatal (P0-2) WT and Mecp2stop/y mice were included in this study. Monitoring 
of RTT-like phenotype trajectory (described in chapter 2 and 5) was carried out 
weekly to evaluate the therapeutic benefits of the transgene.
 
Figure 6-1 scAAV9 vector-constructs and the experimental plan. 
(a) MECP2_e1/Myc fusion and GFP (control) constructs were cloned into AAV2/9 backbones 
under the control of Mecp2 endogenous core promoter. (b) Experimental plan in which male 
WT and Mecp2
stop/y
 mice were injected either intravenously or intracranially with 
scAAV9/MECP2 at P0-2 and scored for signs of  RTT-like phenotypes from 3 weeks 
onwards. sc; self-complementary, MeP; Murine Mecp2 endogenous core promoter, ITR; 
inverted terminal repeat. 
6.4 Results 
6.4.1 Intravenous injection of scAAV9/MECP2 in neonatal mice 
resulted in widespread expression of exogenous MeCP2  
To test for exogenous MeCP2 expression in the peripheral organs as well as in the 
CNS, WT mouse was transcardially perfused with 4% PFA 8 weeks after injection 
and sections were taken from different organs for immunohistochemical 
detection of the transgene. Immunolabelling of frozen sections taken from liver, 
kidney and heart with anti-Myc antibody showed that exogenous MeCP2 
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expression was targeted to the nucleus as indicated by co-localization with DAPI 
nuclear stain and recapitulated the characteristic heterochromatin localization 
with no detectable ectopic expression (figure 6-2). 
 
Figure 6-2  IV injection of scAAV9/MECP2 in neonatal mice produced widespread 
expression of exogenous MeCP2 in the peripheral tissues.  
Micrographs showing IV injection of scAAV9/MECP2 in mice neonates. (a-c); sections were 
prepared from the liver, kidney and the heart then; (i) stained with DAPI and (ii)  immuno-
labeled with anti-Myc antibody. (iii) Co-localization between anti-Myc immunofluorescence 
and DAPI fluorescence indicates nuclear targeting of exogenous MeCP2 and confirms 
peripheral expression of the transgene. Scale bar = 10 µm. 
To confirm transgene expression in the brain after IV injection of scAAV9/MECP2 
in neonatal mice, brain coronal sections were immunolabelled with anti-Myc and 
anti-NeuN antibodies and stained with DAPI. The results showed that the 
transgene has been delivered to all brain regions and the exogenous Mecp2 was 
allocated to the nucleus with pattern of expression resemble that of the 
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endogenous protein (heterochromatin targeting) with no obvious ectopic 
(cytoplasmic) expression. The results also show that exogenous Mecp2 expressing 
cells (Myc-immunopositive) are putatively neurons as indicated by co-localization 
between anti-Myc and anti-NeuN immunofluorescences. However, exogenous 
Mecp2 expression was observed in NeuN-immunonegative nuclei indicating that 
the non-neuronal population of cells (presumed to be glia) were also transduced 
(figure 6-3).  
 
Figure 6-3  IV injection of scAAV9/MECP2 into neonatal mice resulted in high neuronal 
transduction in the brain. 
Micrographs showing sections from striatum, thalamus, motor cortex and hypothalamus 
that were immunolabelled with (i) anti-NeuN and (ii) anti-Myc antibodies. The transduction 
efficiency varied across different brain regions with high neuronal transduction. Arrows 
label Myc-positive, NeuN-negative nuclei (proposed to be glia). Scale bar = 50 µm. 
The transduction efficiency of IV injected scAAV9/MECP2 varied across brain 
regions. To measure the transduction efficiency, brain coronal sections prepared 
from injected mice (11 weeks post-injection) were immunolabelled with anti-
Myc antibody and stained with DAPI. The transduction efficiency was calculated 
by dividing numbers of Myc-immunopositive nuclei by numbers of DAPI stained 
nuclei in 12 optical sections (N = 3 mice). The results showed that the 
transduction efficiency in the hippocampus was 12.2 ± 1.6 %, mean ± SEM, of all 
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counted cells (N = 140 Myc- immunopositive nuclei of 1160 DAPI-stained nuclei, 
figure 6-4) whereas the transduction efficiency in the motor cortex was 8.2 ± 0.8 
% of all counted cells (N = 146 Myc-immunopositive nuclei of 1811 DAPI-stained 
nuclei).  
Transduction effeciency
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Figure 6-4 Transduction efficiency of scAAV9/MECP2 in the brain after IV injection in 
neonatal mice. 
Plot showing the transduction efficiency of scAAV9/MECP2 in the motor cortex and 
hippocampus. Data is presented as mean ± SEM, N = 3 mice).  
In order to test the extent of transgene expression in the CNS after IV injection 
of scAAV9/MECP2, transverse sections were prepared from the lumbar segment 
of the spinal cord and immunolabelled with anti-Myc and anti-ChAT (choline 
acetyltransferase, lower motor neuron-specific marker) antibodies. Exogenous 
MeCP2 expression (Myc-immunopositive) was widely expressed through the 
lumbar sections especially in the gray matter (figure 6-5a). There was a co-
localization between anti-Myc and anti-ChAT immunofluorescences indicating 
transgene expression in the lower motor neurons. However, Myc- 
immunopositive nuclei were also observed in ChAT-immunonegative cells 
suggesting transgene expression in other cell populations (neurons or glia). High 
power images further confirm transgene expression in lower motor neurons 
(figure 6-5b).  
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Figure 6-5 IV injection of scAAV9/MECP2 into neonatal mice produces widespread 
transgene expression in the spinal cord. 
Micrograph showing sections from the lumbar segment of the spinal cord that were 
immunolabelled with; (i) anti-ChAT (lower motor neuron specific marker) and (ii) anti-Myc 
antibodies. (a) Low power images showing widespread expression of the transgene 
throughout the spinal cord section. Dotted boxes in (ai-iii) indicate high power images in (bi-
iii).  (b) High power images showing transgene expression in the lower motor neurons. 
Arrows indicate the ChAT-positive, Myc-positive lower motor neurons. Scale bar = 50 µm. 
ChAT; choline acetyltransferase, cc; central canal, GM; gray matter, WM; white matter. 
6.4.2 IV injection of scAAV9/MECP2 in neonatal mice resulted in 
MeCP2 expression at near-physiological cellular levels  
Maintaining cellular levels of MeCP2 within a narrow physiological window is 
crucial for normal function and to avoid overexpression-related toxicity 
(Luikenhuis et al., 2004, Na et al., 2012). To quantify the cellular levels of the 
transgene product and relate this to endogenous Mecp2 levels, WT neonatal 
mice were injected intravenously (N = 3) with scAAV9/MECP2. Injected mice 
were perfused 11 weeks post-injection and their coronal brain sections were 
immunolabelled with anti-Myc and anti-MeCP2 antibodies. Myc-
immunofluorescence used to discriminate transduced cells (figure 6-6a) whereas 
the intensity of MeCP2-immunofluorescence used to quantify the cellular levels 
of MeCP2 in transduced and non-transduced cells (discussed in chapter 2). 
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Transduced cells showed cellular levels of exogenous MeCP2 equal to 1.5 ± 0.1, 
mean ± SEM, times the endogenous levels in the CA3 region of the hippocampus 
and 1.1 ± 0.1 times the endogenous levels in layer V of the primary motor cortex 
(figure 6-6b). Analysis of MeCP2 expression levels (measured as 
immunofluorescence intensity) in transduced and non-transduced cells (N = 3 
brains) showed endogenous MeCP2 levels to be tightly regulated (narrow peak SD 
= 0.1 AU, figure 6-6c), while levels in transduced cells showed increase and 
varied expression levels (SD = 0.6 AU). 
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Figure 6-6 IV injection of scAAV9/MECP2 produced near-normal cellular levels of MeCP2. 
(a) Micrographs showing sections prepared from WT mouse brain 11 weeks after neonatal 
IV injection. Sections were immunolabelled with (i) anti-Myc and (ii) anti-Mecp2 antibodies. 
Arrows indicate transduced cells whereas arrowheads indicate non-transduced cells in the 
CA3 pyramidal cells layer of the hippocampus. Myc immunofluorescence used to 
discriminate transduced and non-transduced cells (iii). (b) Plot showing the cellular levels of 
Mecp2 in non-transduced cells (endogenous) and in transduced cells (endogenous + 
exogenous MeCP2) in the CA3 region of the hippocampus of WT (N = 3). (c) Distribution of 
MeCP2 levels in transduced and non-transduced CA3 pyramidal cells of the hippocampus 
(N = 3 brains) after IV injection of scAAV9/MECP2. Immunofluorescence intensity of the 
endogenous + exogenous MeCP2 showed wide range of expression (N = 46 cells). All data 
are standardized to the average of endogenous values. Results presented as mean ± SEM.  
Scale bar = 20 µm. AU; arbitrary units. 
a 
b 
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6.4.3 CNS injection of scAAV9/MECP2 in neonatal mice produced 
high transduction efficiency of exogenous MeCP2 
throughout the brain 
In the previous experiment, IV injection of scAAV9/MECP2 produced global 
expression of exogenous MeCP2, but the transduction efficiency in the brain was 
relatively low. The limited brain transduction after IV injection is probably due 
to viral spread into the peripheral organs. In order to avoid/minimize peripheral 
spread of the transgene and to augment transduction efficiency in the brain, 
scAAV9/MECP2 was injected directly into the brain of neonatal mice. To test 
brain transduction after direct intracranial injection, WT and Mecp2stop/y 
neonatal mice (P0-2) were injected directly to the brain with scAAV9/MECP2 (6 
ul of 3.1 X 1011 vg / ml, 1.8 X 109   vg / mouse). A cohort of neonatal mice were 
injected with equal dose scAAV9/GFP and used as a control. Brain coronal 
sections were prepared from IC injected mice (N = 3) and immunolabelled with 
anti-Myc antibody and stained with DAPI. The results showed that exogenous 
MeCP2 was broadly expressed throughout the brain (figure 6-7) and 
recapitulated the same nuclear distribution pattern of endogenous Mecp2.  
To test the extent of exogenous MeCP2 expression in the spinal cord and 
peripheral organs, sections from the lumbar segment of the spinal cord and from 
the liver were immunolabelled with anti-Myc antibody and stained with DAPI. 
Myc-immunopositive cells were observed in the spinal cord, especially in the 
lower motor neurons, as indicated by co-localization with anti-ChAT antibody. 
Anti-Myc immunopositive cells were also observed in the liver indicating broad 
transduction efficiency in the peripheral organ after direct brain injection of 
scAAV9/MECP2 (data not shown). 
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Figure 6-7 IC injection of scAAV9/MECP2 produced higher brain transduction than IV 
injection in neonatal mice. 
Micrograph showing sections prepared from the hippocampus and motor cortex and 
immunolabelled with anti-Myc antibody and stained with DAPI. (a&d) Low power images 
showing transgene expression in the hippocampus after IV and IC injection of 
scAAV9/MECP2. Dotted boxes in (a&d) indicate high power images in (b-f). (b-c) and (e-f) 
High power images showing transgene expression in the CA3 area of the hippocampus. 
(g&j) low power images showing exogenous MeCP2 expression in the motor cortex after IV 
and IC injection of scAAV9/MECP2. Dotted boxes in (g&j) indicate high power images in (h-
l). (h-I) and (k-l) High power images showing transgene expression in the deep cortical layer 
of the motor cortex. Note the increased number of cells expressing exogenous MeCP2 in 
the hippocampus and the motor cortex after IC injection compared to that after IV injection. 
Scale bar in a, d, g and j = 100 µm and in b, e, h and k = 20 µm. 
To confirm the expression of GFP in the control group, brain coronal sections 
prepared from mice injected IC with scAAV9/GFP were immunolabelled with 
anti-GFP and anti-NeuN antibodies. Co-localization between GFP and NeuN 
immunofluorescence indicated that the transgene is putatively expressed in 
neurons (figure 6-8). 
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Figure 6-8  IC injection of scAAV9/GFP in neonatal mice produced a broad GFP expression 
in the brain.  
Micrograph showing section prepared from the hippocampus 8 weeks after IC injection and 
immunolabelled with anti-GFP and anti-NeuN antibodies. (i) Low power image showing co-
labelling between GFP (green) and NeuN (red) immunofluorescence in the hippocampal 
regions. Note the widespread expression of the GFP across the hippocampus. Dotted box in 
(i) refers to high power images in (ii-iv). (ii-iv) High power micrographs of the CA3 region of 
the hippocampus showing; (ii) anti-GFP, (iii) anti-NeuN immunofluorescence and (iv) merge 
of (ii & iii).  Arrows refer to cells co-labelled with GFP and NeuN immunofluorescence 
indicating neuronal transduction. Scale bar = 50 µm. 
To measure the transduction efficiency, the number of Myc-immunopositive 
nuclei were counted in 18 optical sections (N = 3 mice) and divided by the 
number of DAPI stained nuclei in the same field. The results showed that the 
transduction efficiency in the hippocampus was 68 ± 3.5 %, mean ± SEM, of all 
counted cells (N = 854 Myc-immunopositive nuclei of 1245 DAPI stained nuclei, 
figure 6-9) whereas in the motor cortex, the transduction efficiency was 49.5 ± 
4.5 % of all cells (N = 820 Myc-immunopositive cells of 1675 DAPI stained nuclei). 
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Figure 6-9  IC injection of scAAV9/MECP2 produced high transduction efficiency in neonatal 
mice. 
Plot showing the transduction efficiency in the motor cortex and hippocampus of 11 week 
old mouse after IC injection of scAAV9/MECP2 (N = 3 mice). Data presented as mean ± SEM.  
6.4.4 IC injection of scAAV9/MECP2 in neonatal mice resulted in 
high cellular levels of MeCP2 expression  
To test whether the high brain transduction efficiency obtained after IC 
injection of scAAV9/MECP2 is coupled with an increase in Mecp2 expression 
levels, brain coronal section from WT neonatal mice ( N = 3) injected with 
scAAV9/MECP2 were immunolabelled with anti-Myc and anti-MeCP2 antibodies. 
Myc-immunofluorescence used to distinguish transduced cells (figure 6-10a) 
whereas the intensity of MeCP2-immunofluorescence used to quantify cellular 
levels of MeCP2 in transduced and non-transduced cells. The results show that 
cellular levels of MeCP2 in transduced cells were 1.8 ± 0.1 AU and 1.5 ± 0.1 AU 
times the endogenous level in the CA3 and layer V of the motor cortex 
respectively (figure 6-10b). These results suggest that the exogenous MeCP2 was 
being expressed in Mecp2stop/y mice at approximately 1.5 - 1.8 times the 
endogenous levels after IC injection. Analysis of MeCP2 expression levels 
(measured as immunofluorescence intensity) in transduced and non-transduced 
cells after IC (N = 3 brains) injection showed endogenous MeCP2 levels to be 
tightly regulated (narrow peak SD = 0.1 AU), while levels in transduced cells 
showed a wide variability in the expression levels (SD = 0.9 AU, figure 6-10c). 
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Figure 6-10 scAAV9/MECP2  expressed high cellular levels of exogenous MeCP2 after IC 
injection in neonatal mice. 
(a) Micrographs showing sections prepared from WT mice brain after IV injection. Sections 
were immunolabelled with (i) anti-Myc and (ii) anti-Mecp2 antibodies. Arrows indicate 
transduced cells whereas arrowheads indicate non-transduced cells in the CA3 pyramidal 
cells layer of the hippocampus. Myc-immunofluorescence used to discriminate transduced 
and non-transduced cells (iii). (b) Plot showing the cellular levels of Mecp2 in non-
transduced cells (endogenous) and in transduced cells (endogenous + exogenous MeCP2) 
in the CA3 region of the hippocampus of WT (N = 3) mice. (c) Distribution of MeCP2 levels in 
transduced and non-transduced CA3 pyramidal cells of the hippocampus (N = 3 brains) after 
IC injection and of scAAV9/MECP2. Immunofluorescence intensity of the endogenous + 
exogenous MeCP2 showed wide range of expression (N = 52 cells). All data are 
standardized to the average of endogenous values. Results presented as mean ± SEM.  
Scale bar = 20 µm. AU; arbitrary units 
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6.4.5 scAAV9/MECP2 injection in neonatal mice resulted in 
hindlimb motor dysfunction. 
To establish whether scAAV9-mediated gene delivery of MECP2 can improve 
and/or prevent development of the RTT-like phenotype, Mecp2stop/y and 
corresponding WT littermate mice were injected intravenously (9.3 x 109 vg) or 
intracerebrally (1.86 x 109 vg) at an early postnatal time point (P1/P2) with 
either scAAV9/MECP2 or scAAV9/GFP (as a non-therapeutic control). Weekly 
blind monitoring of these mice for overt RTT-like features using the established 
observational scoring system (Guy et al., 2007, Lioy et al., 2011, Weng et al., 
2011) was carried out. scAAV9/GFP control-injected Mecp2stop/y mice (N = 5) 
showed widespread GFP expression across the brain (figure 6-8) and displayed 
the expected phenotype severity score that started at 4 weeks with a steep 
increase in the severity score over subsequent weeks. Mecp2stop/y mice injected 
with scAAV9/MECP2 (N = 7) developed severe hindlimb motor dysfunction as 
early as 3 weeks post-injection. The phenotype consists of widely separated 
hindlimb while standing or moving (figure 6-11a) with frequent twitching 
uncoordinated paddling movements of the hindlimbs. The affected mice were 
capable of locomotion by dragging their bodies using their forelimbs. The wide 
separation of the hindlimbs led to very low Pelvic girdle that partially 
participate in development/ progression of a severe tail lesion in scAAV9/MECP2 
injected mice (figure 6-11b). Tail lesion is not uncommon feature in Mecp2 
knockout mice and it usually starts as small ulcer at the base of the tail then 
progresses to involve the entire tail. Unfortunately this tail lesion eventually 
resulted in complete tail necrosis and an anal infection (figure 6-11b) that 
necessitated culling these mice as early as 6 weeks after injection. Six of nine 
WT mice injected intravenously with scAAV9/MECP2 displayed similar hindlimb 
motor dysfunction and clasping, whereas scAAV9/GFP injected WT mice (N = 5) 
showed no obvious motor deficits.  
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Figure 6-11 scAAV9/MECP2 injection in neonatal mice resulted in Hindlimb motor 
dysfunction. 
(a) A still image of MECP2
stop/y 
mouse 5 month after IV injection with scAAV9/MECP2, red 
arrows indicate abnormal hindlimb dysfunction whereas white arrow indicates an early 
stage of the tail lesion. (b) A micrograph  of Mecp2
stop/y
 mouse 6 weeks after IV injection of 
scAAV9/MECP2, arrow indicates advanced tail lesion whereas arrowhead indicates the 
development of infection at the perianal area that necessitate culling the mouse once 
reached this stage. 
 
weekly assessment of injected mice using RTT-like phenotype severity score 
showed that Mecp2stop/y mice injected with scAAV9/MECP2 displayed a 
significantly (p < 0.01, repeated measures ANOVA, tukey`s posthoc pairwise 
comparison between weeks 3-6) higher phenotype severity score than Mecp2stop/y   
and WT (p < 0.01) mice injected with scAAV9/GFP (figure 6-12a). The aggregate 
severity score of the WT mice-injected with scAAV9/MECP2 was higher than that 
of the WT mice-injected with AAV9/GFP, but not significant so. The bodyweight 
of scAAV9/MECP2 treated Mecp2stop/y mice was significantly lower than 
scAAV9/GFP-treated Mecp2stop/y mice (p < 0.01, repeated measures ANOVA, 
tukey`s posthoc pairwise comparison) and scAAV9/GFP-treated WT mice (p < 
0.001). No significant difference was observed in the WT groups treated either 
with scAAV9/MECP2 or scAAV9/GFP.  
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Figure 6-12 Phenotype severity and bodyweight measures after IV injection of 
scAAV9/MECP2 in neonatal mice. 
(a) Plot showing the trajectory of the RTT-like phenotype severity score after IV injection of 
scAAV9/MECP2 or scAAV9/GFP in neonatal mice. (b) Plot showing the bodyweight of 
scAAV9/MECP2 and scAAV9/GFP treated mice. Groups that share the same letter are 
significantly different. Values presented as means ± SEM. Statistical analysis was carried 
out with (repeated measure ANOVA with tukey`s posthoc pairwise comparison between 
weeks 3-6). 
Mecp2stop/y mice injected with scAAV9/MECP2 intracranially displayed similar, 
though later onset, hindlimb motor dysfunction with onset at ~5 weeks post-
treatment). A number of these mice also displayed stunted growth, eye 
problems (opacity, figure 6-13a,b) and hindlimb clasping (figure 6-13d). WT mice 
treated with IC injection of scAAV9/MECP2 (N = 4) showed a significantly (p < 
0.01, repeated measures ANOVA, tukey`s posthoc pairwise comparison between 
weeks 3-8) higher phenotype severity score than WT mice treated with 
scAAV9/GFP (N = 5) (figure 6-14a). Mecp2stop/y showed significantly (p < 0.05) 
higher phenotype severity score than WT mice injected with scAAV9/GFP  
Bodyweight measurements showed that WT mice treated with scAAV9/GFP was 
significantly (p < 0.001, repeated measures ANOVA, tukey`s posthoc pairwise 
comparison between weeks 3-8) higher than that of both Mecp2stop/y mice- 
treated either with scAAV9/GFP or scAAV9/MECP2 and WT mice treated with 
scAAV9/MECP2 (figure 6-14b). The bodyweight of WT and Mecp2stop/y mice 
treated with scAAV9/MECP2 was significantly (p < 0.01) lower than the 
bodyweight of Mecp2stop/y mice treated with scAAV9/GFP.  
a b 
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Figure 6-13 IC injection of scAAV9/MECP2 results in abnormal phenotypes in WT mice 
(a) A micrograph showing stunted growth of a WT mouse (arrow head) treated with IC 
AAV9/hMECP2 compared to the WT littermate injected by the same virus (arrow) indicating 
mouse to mouse variability. (b) A micrograph showing eye abnormality (corneal opacity,  
(arrow) that developed in few WT mice after IC injection with scAAV9/MECP2.  (c) A still 
image showing normal hindlimb reflex (arrow) in WT mouse treated with AAV9/GFP. (d) A 
still image showing development of hindlimb clasping (arrow) in WT mouse after IC 
injection of AAV9/MECP2.  
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Figure 6-14 Phenotype severity score and bodyweight analysis after IC injection of 
scAAV9/MECP2 in neonatal mice. 
(a) Plot showing the aggregate phenotype severity score of WT mice injected with 
scAAV9/GFP (N= 5) and scAAV9/MECP2 (n = 4) and Mecp2
stop/y
 mice injected with 
scAAV9/GFP (N = 5) and scAAV9/MECP2 (N = 6). (b) Plot showing the bodyweight of 
scAAV9/MECP2 and scAAV9/GFP treated mice. Groups that share the same letter are 
significantly different. Values are presented as mean ± SEM. Statistical analysis was carried 
out with repeated measure ANOVA (between weeks 3-8) with tukey`s post-hoc pairwise 
comparison. 
6.4.5.1 Hindlimb motor dysfunction is associated with axonal degeneration 
of the dorsal column of the lumbar spine in scAAV9/MECP2-injected 
mice. 
To investigate the potential underlying causes of the hindlimb motor dysfunction 
observed in Mecp2stop/y and WT mice after neonatal injection of scAAV9/MECP2, 
four mice (with or without the hindlimb problem) were transcardially perfused 
using hard fixative (2% glutaldehyde and 4% PFA in 0.1 M ca codylate buffer). 
Semi-thin (0.5µm) sections were made from different regions of the spinal cord 
(cervical, thoracic and lumbar regions) and stained with toluidine blue dye to 
show the structure of the axons and their myelin sheath (this experiment was 
kindly carried out blindly by Dr. Julia Edgar, Institute of Infection, Immunity and 
Inflammation, University of Glasgow). Light microscopic analysis of these 
sections showed evidence of axonal degeneration in the dorsal columns of the 
lumbar region of the spinal cord as indicated by the presence of myelin sheath 
devoid of axons (figure 6-15). There were no detectable anatomical 
abnormalities in other regions of the spinal cord in the tested mice (N = 3). 
 
 
a b 
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Figure 6-15 Axonal degeneration of the dorsal columns of the lumbar spine 
(a) Low power magnification of the lumbar region of the spinal cord showing the dorsal 
columns (dashed line). Dotted box indicates high power image. (b) High power image of the 
dorsal columns showing white myelin sheath with black axon inside (arrows) and empty 
myelin sheath (arrowheads) denoting axonal degeneration. Scale bar = 10 µm.  
6.4.5.2  CD3 immuno-reactivity in the spinal cord of scAAV9/MECP2 injected 
mice 
Adeno-associated viruses are currently used in several clinical trials because of 
their ability to transduce a wide variety of tissues with sustained long term 
expression (Mingozzi and High, 2007). No immune reactivity was reported in 
animal studies; however, minimal immune stimulation was reported after AAV 
injection in clinical trials (Manno et al., 2006, Mingozzi et al., 2007). To exclude 
the possibility of immune system involvement in the pathogenesis of axonal 
a 
b 
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degeneration of the dorsal columns, 10 µm frozen section from the lumbar spine 
of scAAV9/MECP2 injected-Mecp2stop/y mice which displayed hindlimb motor 
dysfunction and from control non-injected mice, were stained with mouse anti-
CD3 antibodies (CD3 is expressed in natural killer T cells), anti-Myc and anti-
NeuN antibodies (figure 6-16). A section from the spleen was included as a 
positive control for the anti-CD3 antibody. Spleen sections showed the usual 
pattern of anti-CD3 antibody staining with no evidence of anti-NeuN or anti-Myc 
positive cells. However in the spinal cord of scAAV9/MECP2- injected and non-
injected mice, there was co-localization at the cellular level between anti-CD3 
and anti-NeuN antibodies (both label neurons with anti NeuN predominantly 
nuclear and anti-CD3 predominantly cytosolic. In light of this unexpected 
finding, a second batch of anti-CD3 antibody was tested. However, this produced 
the same immunolabelling pattern in spinal cord sections which made 
interpretation of this data difficult.  
 
Figure 6-16  Anti-CD3 antibody immunolabelling in the lumbar spine. 
(a) Micrograph showing section from the spleen (as a positive control) immunolabelled with 
(i) anti-CD3, (ii) anti-NeuN and (iii) anti-Myc antibodies. Arrows indicate CD3 expressing T 
cells in the spleen. (b) Micrograph showing section from the lumbar region of the spinal 
cord immunolabelled with (i) anti-CD3, (ii) anti-NeuN and (iii) anti-Myc antibodies. 
Arrowheads indicate exogenous MeCP2 expression in CD3-immunopositive, NeuN-
immunopositive cells. Scale bar = 10 µm.  
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6.4.5.3 Neonatal IV injection of scAAV9/MECP2 produced hindlimb motor 
dysfunction in RAG knockout mice. 
I showed in the previous experiment that anti-CD3 immunolabelling of the spinal 
cord was not conclusive due to the fact that anti-CD3 antibody additionally 
labelled NeuN immunopositive cells (putative neurons). To further investigate 
the involvement of the immune system in the development of the hindlimb 
motor dysfunction, three RAG-/- (Recombination Activation Gene) knockout mice 
were injected IV at P0-2 with scAAV9/MECP2 at a dose of 30 µl of 3.1 x 1011 vg / 
ml (9.3 X109 vg). These mice lack mature B and T lymophocytes (Mombaerts et 
al., 1992) (generous gift from DR. Alison Michie, Institute of Cancer Sciences, 
University of Glasgow). Two of these mice were found dead one week after 
injection and thus could not be investigated further. Weekly monitoring of the 
remaining mouse showed that it developed hindlimb motor dysfunction at 5 
weeks post-injection similar to previous animals injected with scAAV9/MECP2. 
Sections from the brain of this mouse showed transduction efficiency 
comparable to that of Mecp2stop/y mice injected with the same virus (figure 6-
17). These results suggest that a T and B cell-mediated immune response is not 
likely to be responsible for the hindlimb motor dysfunction seen in 
scAAV9/MECP2-treated mice, however the possible role of the innate immune 
response remains to be investigated. 
 
Figure 6-17 Exogenous MeCP2 expression in RAG
-/- 
knockout mouse brain 
Micrographs showing exogenous MeCP2 expression in the brain of RAG
-/-
 mouse 8 weeks 
after neonatal IV injection of scAAV9/MECP2. Different brain regions were immunolabelled 
with (i) anti-Myc and (ii) anti-NeuN. Scale bar = 50 µm. 
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6.4.5.4 Neonatal IV injection of scAAV9/mMecp2 led to a similar motor deficit 
in Mecp2-null mice. 
Human and mouse MeCP2 are 96% identical with just 19 amino acids different. 
Genetic studies have shown human MeCP2 to replace the function of the mouse 
protein and prevent the onset of RTT-like phenotypes in transgenic nice without 
overt drawbacks (Collins et al., 2004). However, to further exclude the 
possibility that using human MeCP2 in a murine model was a potential cause of 
the motor deficits, a mouse Mecp2 minigene was cloned in AAV2/9 backbone to 
generate scAAV9/mMecp2 virus particles. In addition, I decided to exclude the 
possibility that the mouse strain was a contributing factor by using Mecp2-null 
mice on a C57BL/6 background.  ScAAV9/mMecp2 (9.3 X 109 vg) was 
intravenously injected into the facial vein of Mecp2-/y (N = 1) and WT (N = 3) 
mice at P0-2.  Hindlimb motor deficit was observed in the WT and Mecp2-/y mice 
3-4 weeks post-injection (figure 6-18) indicating consistent adverse effect when 
either the human or mouse MECP2_e1 encoding sequences are delivered by 
scAAV9 vector in mice neonates. 
 
Figure 6-18 IV injection of scAAV9/mMecp2 into neonatal Mecp2
-/y
 mice resulted in hindlimb 
motor dysfunction. 
A still image showing Mecp2
-/y
 mice 7 weeks after IV injection of scAAV9/mMecp2. Blue 
arrows indicate abnormal paddling movements characteristic of the hindlimb motor 
dysfunction whereas white arrow indicates tail lesion that has progressed to tail necrosis. 
6.4.5.5  IC injection of scAAV9/MeP-MECP2 produced higher transduction 
efficiency and cellular protein levels than the ssAAV9/CBA-MECP2 in 
neonatal mice 
Due to the discrepancy in the results obtained after IV and IC injection of 
scAAV9/MeP-MECP2 construct compared to that obtained after IC injection of 
ssAAV9/CBA-MECP2 in neonatal mice I therefore decided to compare the 
transduction efficiency and cellular levels of Mecp2 expressed by these vectors 
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in the hippocampus and motor cortex of the injected mice. The transduction 
efficiency after IC injection of self-complementary AAV9/MeP-MECP2 was 
significantly (p < 0.001, one way ANOVA with tukey`s posthoc pairwise 
comparison) higher than both IV injection of the same vector (scAAV9/MeP-
MECP2) and IC injection of single-stranded AAV9/CBA-MECP2 (figure 6-19a). 
Whereas IC injection of ssAAV9/CBA-MECP2 showed significantly (p < 0.01) 
higher transduction efficiency than IV injection of scAAV9/MeP-MECP2 in the 
motor cortex. IC injection of scAAV9/MeP-MECP2 produced significantly higher 
cellular levels of exogenous MeCP2 than that produced by ssAAV9/CBA-MECP2 in 
the hippocampus (p < 0.01) and motor cortex (p< 0.001, figure 6-19b). There 
was no significant difference in MeCP2 expression levels between IV 
scAAV9/MeP-MECP2 injected mice and IC ssAAV9/CBA-MECP2 injected mice.  
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Figure 6-19 scAAV9 mediated higher transduction efficiency and transgene expression after 
IC injection in neonatal mice. 
(a) Plot showing comparison between the transduction efficiency of scAAV9/MeP-MECP2 
after IC and IV injection and that after IC injection of ssAAV9/CBA-MECP2 in neonatal mice. 
(b) Plot showing comparison between cellular levels of exogenous MeCP2 expressed by 
scAAV9/MeP-MECP2 after IC and IV injection and that expressed by ssAAV9/CBA-MECP2 
after IC injection in neonatal mice. ns; non-significant, *= p < 0.05; ** = p < 0.05, *** = p < 
0.001, one way ANOVA with tukey`s posthoc pairwise comparison. 
 
6.5 Discussion  
As described in chapter 5, direct neonatal brain injection of ssAAV9/CBA-MECP2 
virus was able to achieve significant, but modest, improvement in the phenotype 
trajectory and survival of Mecp2-null mice despite relatively modest 
transduction efficiency in the brain. Previous reactivation studies have shown a 
direct correlation between the degree of phenotype rescue and the percentage 
of cells expressing Mecp2 (after delayed activation, Robinson et al., 2012). 
Therefore we hypothesized that increasing the transduction efficiency by using a 
a 
b 
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newly developed highly efficient scAAV9 vector (Foust et al., 2009) might 
produce greater therapeutic benefits in Mecp2 knockout mice. To test this 
hypothesis, scAAV9/MeP-MECP2 virus particles were injected either 
intravenously (more clinically relevant) or directly into the brain (to achieve 
high transduction efficiency) into Mecp2stop/y mice and their WT littermates. The 
results showed that scAAV9/MeP-MECP2 virus particles resulted in mean MeCP2 
cellular levels between 100-150 % and 140-184 % of the endogenous Mecp2 levels 
after IV and IC neonatal injection respectively with ~5 fold greater transduction 
efficiency after IC injection. Distribution analysis of Mecp2 cellular levels 
revealed that endogenous Mecp2 levels are very tightly regulated whereas the 
exogenous MeCP2 showed broader distribution particularly after IC injection 
which could be explained by increased multiplicity of infection. A finding of 
major significance was the revelation that Mecp2stop/y mice treated with either 
IV or IC injection of scAAV9/MeP-MECP2 developed profound hindlimb motor 
dysfunction as early as 3 weeks of age after IV injection with a more delayed 
onset (~5 weeks) after IC injection. WT mice injected with this construct 
displayed variable results with about 67% of the injected mice displaying 
hindlimb dysfunction. This unexpected toxicity has not seen in WT and 
Mecp2stop/y mice treated with scAAV9/MeP-GFP viruses. The very early high 
phenotype severity score observed in the IV and IC treated Mecp2stop/y mice 
[normally these mice develop RTT-like phenotype at 5 weeks (Guy et al., 2007, 
Lioy et al., 2011) was mainly due to this unusual early hindlimb dysfunction 
which, though not considered a part of the RTT-like phenotype, impacts on 
several of the features measured in the scoring system (including gait, hindlimb 
clasping and mobility). The development of severe tail lesions and anal 
infection, which was aggravated by the hindlimb dysfunction, and the early 
termination of the experiment at around 6 weeks of age prohibited tracking the 
effect of exogenous MeCP2 on the other RTT-like phenotype (e.g. breathing, 
tremor, general condition and early mortality) the cause of these adverse 
reactions to the self-complementary AAV/MeP-MECP2 are not clear. MeCP2 
duplication has been reported to produce serious complications in human 
patients (Meins et al., 2005, Van Esch et al., 2005, Friez et al., 2006). In a 
mouse model, a two- to three-fold increase in the level of Mecp2 in post-mitotic 
neurons produced tremors, gait ataxia, and side-to side swaying (Luikenhuis et 
al., 2004) whereas modest overexpression (0.6-1 fold of the endogenous Mecp2 
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level) resulted in cognitive impairment, motor coordination deficits and an 
anxiety-like phenotype (Collins et al., 2004, Na et al., 2012). Interestingly we 
observed this severe motor dysfunction despite achieving levels of exogenous 
MeCP2 expression that is comparable to endogenous Mecp2 levels (after IV 
injection) and in a relatively low number of cells compared to the duplication 
studies where the overexpression is global.  
Previous study has shown that rapid activation of a conditionally silenced Mecp2 
in mice resulted in severe lethality. However, gradual activation avoided toxicity 
and achieved phenotype rescue (Guy et al., 2007). Thus, a possible explanation 
of the overt hind limb phenotype observed after expressing exogenous MeCP2 
using scAAV9 vector may be the rapid onset of transgene expression that is 
associated with self-complementary vectors (Ren et al., 2005). It also explains 
the absence of this toxicity after using ssAAV9 (more delayed onset of 
expression) vector to express the same MECP2 transgene. Previous study has 
shown that 2-3 fold increase in the expression level of Mecp2 resulted in motor 
disability, stunted growth and cataract in mice (Luikenhuis et al., 2004). These 
phenotypes were observed in mice injected intracranially with scAAV9/MECP2 
vector which indicates that these phenotypes are likely to be due to transgene-
related overexpression toxicity.  
The overt motor dysfunction was consistently observed only in the hindlimb with 
apparently normal forelimb function suggesting that the pathology is likely to be 
in the spinal cord, peripheral nerves of the hindlimb, hindlimb musculature or 
preferentially affects long fibres. Microscopic examination of the distal spinal 
cord region was carried out with particular focus on the lumbar regions. The 
demonstrated axonal degeneration in the dorsal columns of the lumbar spine 
indicates that the uncoordinated hindlimb movement observed is probably due 
to lack of sensory perception and not likely to be due to a genuine motor deficit. 
The occurrence of axonal degeneration only in the lumbar region of the spinal 
cord suggests that the degeneration process is potentially affecting long axons 
only. Other parts responsible for sensory perception such as dorsal root ganglia 
and peripheral nerves, which could be potentially involved in the pathogenesis 
of this problem, have yet to be investigated. 
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The presence of activated T-lymphocytes in the spinal cord of patients and 
animal models of motor neuron disease (e.g. ALS) suggests a potential 
involvement of immune inflammatory factors in the motor neuron disease 
process (Alexianu et al., 2001). Taken together with the modest immune 
response stimulation observed in patient treated with AAV viruses in clinical 
trials (Manno et al., 2003, Mingozzi and High, 2007, Mingozzi et al., 2007), I 
hypothesised that axonal degeneration of the dorsal column could be a 
consequence of AAV9- and/or exogenous MeCP2- inducing an immunological 
response. The broadly-distributed expression of CD3 receptors in the spinal cord 
sections prepared from AAV9/MECP2-treated and non-treated mice were 
however shown to be predominantly neuronal as indicated by co-localization 
with NeuN-immunolabelling. This result suggests that CD3 receptors are 
expressed in the spinal cord neurons and do not make a reliable assay for 
lymphocytic infiltration. Indeed, previous reports showed CD3 receptor 
expression in brain neurons (Garson et al., 1982, Schuller-Petrovic et al., 1983, 
Syken and Shatz, 2003) with a well-established role in neuronal morphogenesis 
and dendritic growth (Baudouin et al., 2008). Development of hindlimb motor 
dysfunction in RAG-/- knockout mouse [lack mature T and B cells (Mombaerts et 
al., 1992)] after neonatal IV injection with AAV9/MECP2 together with its 
absence in AAV9/GFP injected mice suggest that this hindlimb phenotype is not 
likely to be due to an adaptive immune response reaction to AAV9 virus 
particles. Moreover the absence of this hindlimb phenotype in the mice that 
were injected IC with ssAAV9/CBA-MECP2 (chapter 5) excludes exogenous MeCP2 
per se as a trigger to the immune response. Further experiments to investigate 
the role of the innate immune response need to be done. 
The rapid onset of the hindlimb motor dysfunction after IV injection (~3 weeks 
post-injection) compared to the more delayed onset after IC injection (~5 
weeks), despite the fact that IV injection produced lower levels of MeCP2 
expression in the brain and 5 fold less brain transduction compared to the IC 
injection suggests an important role for the peripheral organs in the 
pathogenesis of this phenotype. An interesting experiment will be to drive 
peripheral expression of exogenous MeCP2 from an AAV2 vector that cannot pass 
the BB barrier (Fu et al., 2003) to elucidate the role of peripherally-expressed 
exogenous MeCP2 in the development of the motor dysfunction phenotype. 
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The fact that early hindlimb motor dysfunction was seen in all Mecp2-null (N = 
10) mice treated with scAAV9/MECP2, regardless of the method of delivery, 
whereas only 67 % of the WT mice (N = 9) were affected indicates a putative 
genotype effect and suggests that the lack of endogenous Mecp2 is a 
contributing factor for the occurrence of this phenotype or conversely, that the 
healthy WT mice are more resilient and resistant to the toxicity. 
Human MeCP2 has previously been used for rescue of transgenic Mecp2-null mice 
without producing any detectable adverse effects (Collins et al., 2004). My 
previous data also showed that human MECP2, delivered by a ssAAV9/CBA-
hMECP2 vector, was tolerable in WT animals and produced modest improvement 
in Mecp2-null mice. To further exclude the possible role of human MECP2 in the 
development of the hindlimb phenotype, mice were injected with scAAV9/MeP-
mMecp2 that drives expression of mouse form of Mecp2. Nevertheless these 
injected mice displayed a similar motor dysfunction to those injected with 
human MECP2 in this study. Together these findings suggest that expression of 
human MeCP2 in a mice model is probably not a contributing factor in the 
development of the hindlimb abnormal phenotype.  
Interestingly Intravenous injection of scAAV9/MeP-MECP2 (5X1011vg) in juvenile 
Mecp2-null mice was without apparent toxicity and achieved prolonged survival 
(this work has been done by Dr. Steven Gray UNC Gene Therapy Centre, 
University of North Carolina, USA. Gadalla et al 2012 submitted) which indicates 
that the time of delivery is crucial at least with the construct we used in this 
experiment. The importance of treatment onset point has yet to be studied 
systematically however.   
Two possible factors haven‟t been tested in this experiment; the first is the 
effect of the promoter used in the construct (Mecp2 endogenous core promoter 
or chicken beta actin promoter) and the ssAAV9 versus scAAV9 virus construct. 
Due to the limited cloning capacity of scAAV9, it is not possible to generate 
scAAV9/CBA-MECP2. However a possible experiment would be to generate 
ssAAV9/MeP-MECP2 to investigate the possible role of the driving promoter in 
producing this phenotype. 
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Concluding remarks 
I showed in this chapter that, however, scAA9/MECP2 was capable of efficiently 
delivering MECP2 into the brain of Mecp2 knockout mice after peripheral and 
direct brain injection, this vector resulted in an unexpected and severe overt 
hindlimb motor dysfunction in Mecp2 knockout as well as in WT mice. The 
hindlimb dysfunction may be due to axonal degeneration of posterior columns of 
the lumbar spine, however other important elements of the sensory and motor 
control of the hindlimb cannot be ruled out. The exact cause of the axonal 
degeneration is unclear but it is not likely to be mediated through an adaptive 
immune response to the viral capsid or to the transgene. I showed previously 
that IC injection of ssAAV9/CBA-MECP2 in neonatal mice displayed amelioration 
in RTT-like phenotype without obvious toxicity in WT mice which indicates that 
the hindlimb phenotype is likely to be related to the difference in the vector 
design; transduction efficiency, onset of expression and levels of protein 
expression rather than the insert per se. This data highlights the extreme 
importance of choosing the right vector, method and age of delivery in any 
future attempts for RTT gene therapy application to avoid undesirable adverse 
effects and to achieve maximum therapeutic benefits.  
 
 
 
Chapter 7 
General discussion 
  
The principal aim of this thesis was to investigate the therapeutic potential of 
delivering MECP2 minigene exogenously, through viral vectors, to a mouse model 
of Rett syndrome. It was anticipated that such a study would provide 
fundamental information about the pattern and levels of exogenous MeCP2 
expression and give an insight into the vector and promoter combinations most 
capable of delivering therapeutic benefits. Initially I tried focal delivery of 
Mecp2 to a specific brain region using a Lentiviral vector to enable region-
specific rescue of the RTT-like phenotypes. However with the rapid advances in 
vector design this study was further extended to investigate the effect of both 
global and brain-specific delivery of MECP2, via an AAV2/9-based vector system, 
on the prevention/improvement of the RTT-like phenotype in a mouse model of 
Rett syndrome. This chapter will integrate the major findings and significant 
discoveries of this thesis and will evaluate the importance of these findings in 
relation to gene therapy and neuroscience research, and in particular to the 
evolving field of recent gene therapy in RTT. Further, I will discuss the technical 
difficulties experienced during this work, in particular the limitations of the 
methodology, and suggest possible ways to overcome these limitations. Finally, I 
will discuss possible future experiments to extend this work and derive the 
maximum benefits from the results I obtained in this study. 
7.1 Major findings 
The major findings/discoveries reported in this thesis are; 
1. Exogenous Mecp2 expression was achievable in vitro and in vivo by viral-
mediated delivery approaches. The expression pattern of the exogenous 
Mecp2 was similar to that of the endogenous Mecp2 in different species. 
2. Achieving near normal cellular levels of exogenous Mecp2 in vivo was 
possible using appropriate vector and promoter design. 
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3. Lentivirus-mediated delivery of exogenous Mecp2 demonstrated that: 
I. Lentivirus-based vector displayed a high neuronal transduction of 
Mecp2 in vivo and in vitro. 
II. Direct brain injection achieved high transduction efficiency around 
the injection sites, however with very limited spread making global 
delivery an unrealistic prospect. 
III. Synapsin1 promoter produced levels of Mecp2 expression close to the 
WT values (80% of the WT level) whereas PGK promoter produced 
relatively high (200% of the WT level) expression levels.  
IV. Reintroduction of Mecp2 resulted in normalization of nuclear volume 
measures in Mecp2 knockout mice. 
V. Exogenous Mecp2 maintained the characteristic site-specific 
phosphorylation at serine 421 seen in WT Mecp2. However the high 
transgenic delivery of Mecp2 was associated with higher levels of 
phosphorylation than seen at the basal conditions in WT. 
VI. Mecp2-overexpression in WT neurons led to decreased levels of 
histone 4 and acetylated H4 suggesting a potential role of Mecp2 in 
chromatin remodelling.  
4. AAV9-mediated brain delivery of exogenous MECP2 under the CBA 
promoter in neonatal mice demonstrated: 
I. Widespread expression of exogenous MeCP2 throughout the brain with 
near physiological cellular levels. Transgene spread to peripheral 
organs was also observed. 
II. Significant arrest/improvement in the RTT-like phenotype in Mecp2-
null mice including:  
a. Cellular phenotype improvement in the form of rescue of 
neuronal nuclear volume deficits to WT-comparable values. 
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b. Improvement/arrest of the RTT-like phenotype particularly in 
locomotion and exploratory activity. 
c. Notable impact on survival as Mecp2-null mice treated with 
ssAAV9/CBA-MECP2 exhibited a significantly higher median 
survival compared to the control group (GFP-treated).  
III. Overexpressing MeCP2 from the same vector in WT mice was without 
overt overexpression-related toxicity. 
5. Neonatal peripheral (IV) and direct brain (IC) injection of scAAV9/MeP-
MECP2 in Mecp2 knockout mice demonstrated: 
I.  Global brain delivery of MECP2 was achieved by both delivery routes 
(IV and IC), however with higher transduction efficiency and cellular 
levels of MeCP2 after direct brain injection. 
II.  Overt hindlimb motor abnormalities were observed in Mecp2stop/y and 
WT mice after both delivery methods but Mecp2stop/y mice displayed a 
more rapid onset and more severe phenotype. 
III.  This overt hindlimb dysfunction was observed in immunologically 
compromised mice (RAG-/- knockout mouse) after IV injection of the 
equivalent viruses suggesting that this phenotype is more likely to be 
due to a transgene-related toxicity. 
IV.  Axonal degeneration in the dorsal columns of the lumbar spine was 
observed in mice that suffered the hindlimb phenotype.  
7.1.1 Lenti-mediated Mecp2 delivery to Mecp2 knockout mice  
Lentivirus-based vectors are a well-established and widely used tool for gene 
delivery (Blomer et al., 1996, Azzouz et al., 2004a) because of their ability to 
transduce terminally differentiated neurons and provide enduring transgene 
expression with minimal stimulation to the immune response (Kay et al., 2001, Li 
et al., 2010). In this study I showed that Lentivirus-based vectors are capable of 
delivering exogenous Mecp2 to neurons and glia in vivo and in vitro with a 
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pattern of expression similar to that of the endogenous Mecp2 (Lewis et al., 
1992, Nan et al., 1996) in mouse- and rat-derived neurons. Exogenous Mecp2 was 
mainly expressed in neurons in vitro and in vivo regardless of the cell-type 
specificity of the expression-driving promoter (syn1 or PGK) which could be 
explained by the high tropism towards neurons particularly when lentiviruses are 
pseudo-typed with VSV-G envelope (Ho et al., 2008). The cellular level of 
exogenous Mecp2 expression was higher in neurons than in glia which could 
partially be explained by the difference in multiplicity of infection (Wanisch and 
Yanez-Munoz, 2009), and may be explained also by the difference in cellular 
machinery (Mecp2 is very abundant in neurons compared to glia (Nan et al., 
1997). These findings (increased exogenous Mecp2 expression in neurons 
compared to glia) recapitulate the expression levels of endogenous Mecp2 in the 
brain whereby Mecp2 is approximately 10 times more abundant in neurons than 
glia (Skene et al., 2010). 
The levels of exogenous Mecp2 varied according to the promoter used; a weak 
syn1 promoter produced near physiological levels of exogenous Mecp2 (80% of 
the WT levels) whereas a stronger promoter, such as PGK promoter (Owens et 
al., 2002) produced relatively high cellular levels (200% of the WT levels). This is 
particularly important when considering the danger of Mecp2 overexpression-
induced toxicity in humans because patients with MECP2 duplication showed 
overt neurological deficits (Meins et al., 2005, Friez et al., 2006). In addition, 
Mecp2 overexpression models showed that the phenotype severity increases as 
Mecp2  increases behind normal levels (Chao and Zoghbi, 2012) with the worst 
phenotype observed with 2-3 fold increase of Mecp2 levels (Luikenhuis et al., 
2004). Unfortunately the functional consequences of exogenous Mecp2 could not 
be evaluated at the organismal level due to the early mortality of the injected 
mice. However, cellular morphology was investigated instead and this showed 
that the deficit in nuclear volume in Mecp2 knockout mice, a constant finding in 
neurons lacking Mecp2 (Giacometti et al., 2007, Johnson et al., 2011), was 
restored to WT comparable values. This data agrees with the previous study that 
showed improvement in the dendritic arborization and spine density after 
lentivirus-mediated delivery of Mecp2 in cultured neurons (Rastegar et al., 
2009). This data indicates the possible reversibility/rescue of a well-established 
cellular phenotype in Mecp2 knockout mice by exogenous delivery of Mecp2. 
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Nuclear volume rescue could be primarily due to reintroducing a missed highly 
expressed nuclear protein (Mecp2) or is secondary to the effect of downstream 
genes whose activity is altered by exogenous Mecp2 expression; however, the 
functional consequences of this neuronal nuclear volume rescue such as 
restoration of normal cellular homeostasis are still to be investigated. 
A more detailed study of exogenous Mecp2 at the molecular level revealed that 
it retains the site-specific phosphorylation at serine 421, an activity-dependent 
regulator of Mecp2 function (Zhou et al., 2006, Cohen et al., 2011). The cellular 
levels of phosphorylation of exogenous Mecp2 were several folds higher than 
that of the endogenous protein under basal conditions. This difference could be 
explained by; (1) an overall increase of Mecp2 levels in transduced cells 
however, exogenous Mecp2 resulted in 2 fold increase in cellular levels of Mecp2 
and approximately 5 fold increase in the phosphorylated Mecp2 in transduced 
cells suggesting that the exogenously provided Mecp2 was disproportionately 
phosphorylated at this site; (2) overexpression of Mecp2 could probably produce 
abnormal distribution / binding of Mecp2 across the nucleus in a way that results 
in increased phosphorylation; (3) it could reflect a difference in response to 
basal neuronal activity; (4) Mecp2 binds to methylated CpGs mainly within the 
promoter area of genes to prevent their downstream expression. Once 
phosphorylated, Mecp2 was reported to be detached from its binding site and 
allows gene expression (Chen et al., 2003a, Martinowich et al., 2003). Thus 
phosphorylated Mecp2 is not probably active and the high phosphorylation 
observed in this study could potentially represent an attempt from transduced 
cells to compensate for excess Mecp2 expression. The functional consequences 
of the increased phosphorylation in the transduced cells and whether it could 
have a role in the overexpression-induced toxicity needs more investigations, 
particularly in the animal model of Mecp2 overexpression.   
Exogenous Mecp2, delivered by a lentivirus-based vector in WT neurons, is a 
simple and effective way of investigating the effects of overexpressing Mecp2 on 
cell structure and function and the possible effect of Mecp2 on other nuclear 
proteins (e.g. Histone proteins). Previous studies have shown that Mecp2 
absence is associated with alterations in either the total level of histone proteins 
or in the acetylated state of some histone proteins (Shahbazian et al., 2002a, 
Ghosh et al., 2010). In human, it has been reported that the level of AcH4 was 
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increased in RTT patients (Wan et al., 2001), however in mice models of RTT, it 
was ACH3 that reported to be increased with no significant alteration in AcH4 
(Urdinguio et al., 2007, Adachi et al., 2009). In this study I showed that the level 
of AcH4 decreased in cells overexpressing Mecp2 (transduced), however this 
reduction in the acetylation state was accompanied by a parallel reduction in 
the total cellular H4 levels suggesting that the reduction in the acetylated form 
of H4 is not likely to be genuine and it occurs as a consequence of reduced total 
H4. This data indicates potential competition between Mecp2 and H4 protein 
similar to that previously reported between Mecp2 and H1 (Nan et al., 1997, 
Ghosh et al., 2010, Skene et al., 2010) with potential role of Mecp2 in chromatin 
remodelling. My data also suggest that the previous reports of AcH3 
hyperacetylation in the Mecp2 knockout mice might reflect an overall increase in 
the total cellular level of H3. Analysis of the cellular levels of H4 and AcH4 in 
the cells expression and cells lacking Mecp2 in the heterozygous female mice, 
Mecp2-/+, would be a good experiment to further confirm the interaction 
between H4 and its acetylated state AcH4 and Mecp2. 
The global expression of Mecp2 together with the limited spread of the 
transgene delivery by lentivirus-based vector hinder the use of this vector for 
global Mecp2 delivery in RTT mice. Previous reports have shown different 
methods to enhance lentivirus-mediated gene delivery to the CNS after 
peripheral administration (Ikeda et al., 2002, Federici et al., 2009). I therefore 
attempted several methods to enhance Mecp2 delivery to the CNS using 
lentivirus-based vectors. Firstly I tried peripheral delivery of lenti-syn1-
ME1FlagRFP by intravenous injection in the tail vein of adult mice after 
disturbing the BBB by mannitol injection (Ikeda et al., 2002, McCarty et al., 
2009). Analysis of the brain tissue after 4 weeks of injection showed a complete 
absence of RFP or anti-Flag immunofluorescence across brain regions suggesting 
that even after putative mannitol disruption of the BBB, lentivirus is not capable 
of achieving reliable brain transduction. Secondly I pseudo-typed lentivirus 
particles with rabies virus glycoprotein coat to enable retrograde transport to 
the CNS after peripheral intramuscular delivery (Mentis et al., 2006, Federici et 
al., 2009). The virus was able to deliver Mecp2 to cultured neurons, however 
several attempts to deliver Mecp2 under either syn1 or PGK promoter to the CNS 
via IM injection of rabies-pseudo-typed lentivirus particles, were not successful 
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as no Flag or RFP immunopositive cells were detected in the spinal cord or in the 
brain of injected mice. Young animals have a larger extracellular space, that 
permits better spread of viral particles in the brain parenchyma (Cetin et al., 
2006), therefore I finally injected neonatal mice intracranially with lentivirus 
particles in an attempt to achieve widespread expression in the brain. The RFP 
signal was detected in the brain after 4 weeks of injection but the transgene was 
restricted mainly to the inner wall of the ventricles with very limited spread to 
the brain parenchyma. The relatively large lentivirus, 100-120nm (Fleury et al., 
2003) compared to limited extracellular spaces in the brain, 40-60nm (Thorne 
and Nicholson, 2006), is probably the main cause behind this limited spread. The 
difficulties in achieving effective brain transduction with lentivirus-based 
vectors motivated the move to the small-size AAV, 20-30 nm (Chen, 2007), virus 
to deliver widespread gene-expression in the brain.   
7.1.2 Phenotype rescue and prolonged survival after 
ssAAV9/CBA-MECP2 brain injection in Mecp2-null mice 
In chapter 5, I show for the first time ΄proof-of-concept΄ evidence that AAV9-
mediated exogenous MECP2 gene delivery to the brain of Mecp2-null mice is 
capable of achieving therapeutic benefits. I showed that modest brain 
transduction efficiencies coupled with cellular levels of exogenous MeCP2 
approximately equivalent to WT levels resulted in a reduction in several 
phenotype measures and a significant extension of lifespan. The longest-lived 
mice survived for 36 week with a relatively stable RTT-like severity score before 
they were perfused for immuno-histochemical analysis. Analysis of individual 
parameters of the phenotype severity score revealed that the greatest impact of 
the treatment was observed in motor behaviour. This was further supported by 
the improved performance on the open field and treadmill tests. Data from 
these tests revealed that the motor deficits observed in control Mecp2-null mice 
(GFP-treated) was genuine and unlikely to be due to lack of motivation or 
anxiety as these mice were partially capable of performing at low speed and 
failed to perform at the more challenging higher speed tests. This motor 
impairment was ameliorated by AAV9/MECP2 injection and was persistently 
improved in the long-lived mice throughout the experimental period (36 week). 
Furthermore it indicates that motor related deficits observed in RTT patients 
(Neul et al., 2010) could be potentially reversible. Another improvement was 
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observed in exploratory-related behaviours (rearing frequency), which indicates 
an improvement in the hippocampus-dependent tasks and also reflects an overall 
improvement in both the general condition of the animal and locomotor 
activities. 
Mecp2-null mice in this study showed a respiratory phenotype that mirrors the 
clinical picture in humans where apnoeas and rhythm irregularities are 
prominent features of RTT (Neul et al., 2010). Analysis of breathing in Mecp2-
null mice treated with ssAAV9-MECP2 showed no impact on the respiratory 
phenotype. However this breathing phenotype has previously been shown to be 
corrected after postnatal activation of Mecp2 globally (Robinson et al., 2012) or 
in glial cells (Lioy et al., 2011) which indicates that the respiratory phenotype is 
treatable at the gene level. The absence of any impact of AAV9/MECP2-
treatment on breathing phenotype in the mutant mice in this study could be 
explained by lack or insufficient expression of exogenous MeCP2 in the cells 
responsible for breathing rhythmogenesis or otherwise contributing to breathing. 
Brainstem-specific Mecp2 delivery through AAV9 or lentivirus in Mecp2-null mice 
could help elucidate the role of the breathing centre on rescue the breathing 
phenotype in RTT mice. 
At the cellular level, exogenous MeCP2 expression rescued the nuclear volume of 
previously Mecp2 deficient cells in Mecp2–null mice (Giacometti et al., 2007, 
Johnson et al., 2011) to WT comparable values. This effect is mostly cell 
autonomous as evidenced by comparing transduced and non-transduced cells 
from the same brain area and  also mirrors the difference in nuclear volume and 
soma size in neurons expressing Mecp2 and those lacking Mecp2 in the mosaic 
heterozygous brain (Ho et al., 2008).  
The failure of AAV9/MECP2–treated null mice to show substantial improvement 
in bodyweight indicates that the increased neuronal nuclear volume observed in 
these mice was unlikely to be related and paralleling overall growth gain in 
bodyweight. This data provides evidence for structural remodelling of 
AAV9/MECP2-transduced neurons but whether this reflects a broader change in 
dendritic complexity previously reported after Lentivirus-mediated delivery of 
Mecp2 in vitro (Rastegar et al., 2009) and in the delayed Mecp2 activation study 
(Robinson et al., 2012) has not yet been investigated. 
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In this study I provide the first evidence that MECP2 delivery by viral mediated 
approaches in mice, with this vector design and the delivery efficiency, is 
without detectable overexpression-related toxicity which was reported before in 
transgenic mice overexpressing Mecp2 (Collins et al., 2004, Luikenhuis et al., 
2004, Na et al., 2012) as indicated by an absence of overt phenotype in the WT-
injected mice, despite expressing approximately double the normal level of 
MeCP2. However a long-term study is required to investigate any potential 
delayed-onset toxicity (Collins et al., 2004). This data argues against concerns 
that any attempt to deliver Mecp2 to null cells in the heterozygous mosaic brain 
will invariably be accompanied by an overexpression-induced toxicity in the cells 
expressing WT endogenous Mecp2. Here I show that appropriate vector and 
promoter design is capable of achieving therapeutic benefits without obvious-
overexpression toxicity. 
In this study I showed at „proof-of-concept‟ level that delivery of exogenous 
MECP2 at a tolerable level to the brain of Mecp2-null mice was achievable by 
neonatal injection of ssAAV9/CBA-MECP2 vector and produced a partial 
improvement of the RTT-like phenotype and extended the survival of these 
mice. Moreover I showed that this level of exogenous MeCP2 expression was 
without obvious deleterious effect in the WT mice, suggesting a wider than 
expected window for gene therapy application in the treatment of Rett 
syndrome. 
7.1.3 Global and brain-specific delivery of exogenous MECP2 
using scAAV9/MeP-MECP2 vector in neonatal mice.  
A recent Mecp2 delayed-activation study has shown the direct correlation 
between number of cells in which endogenous Mecp2 is activated and 
improvement in RTT-like phenotypes (Robinson et al., 2012). This would suggest 
that the modest phenotype improvement and prolonged survival after exogenous 
MECP2 delivery by ssAAV9/CBA-MECP2 could be augmented by achieving higher 
transduction efficiencies. McCarty and colleagues have created a new version of 
AAV in which the single stranded DNA is replaced by double stranded DNA (self-
complementary). This vector is ready to express the transgene once inside the 
cell as, unlike the single stranded AAV, it does not require the host cell to 
generate the complementary strand (McCarty et al., 2003). As a result, this 
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vector confers high transduction efficiency compared to the single stranded AAV 
especially when injected into neonatal mice (Foust et al., 2009). The reduced 
cloning capacity of scAAV vector prohibited the use of CBA promoter to drive 
expression of endogenous MeCP2, therefore a small segment of the endogenous 
Mecp2 promoter (Adachi et al., 2005) was used instead. This 229bp promoter 
(MeP) segment of the Mecp2 endogenous promoter was recently reported to 
recapitulate the same cellular pattern of endogenous Mecp2 expression (Gray et 
al., 2011b). Two parallel experiments were conducted to investigate the 
therapeutic benefits of scAAV9/MeP-MECP2 vector in Mecp2stop/y mice, the first 
was to deliver these virus particles peripherally through facial vein injection as 
it is more relevant approach to human translation and it will help investigate the 
effect of global delivery of exogenous MECP2. The second was to achieve brain-
specific delivery of exogenous MECP2 with high transduction efficiency based on 
direct brain injection of the vector into neonatal mice.  
Direct brain injection of scAAV/Mep-MECP2 was ~ 5 fold more efficient in 
transducing brain cells compared to IV injection and it also produced a relatively 
higher cellular level of exogenous MeCP2 expression. The low brain transduction 
efficiency observed after IV injection (relative to IC injection) is likely to be due 
to loss of a large proportion of injected viruses in the peripheral organs (e.g. 
liver, heart and kidney) which is indicated by the widespread expression of 
exogenous MeCP2 in peripheral organs. Follow up observational analysis of 
Mecp2stop/y and WT mice showed that these mice injected with scAAV9/MeP-
MECP2 displayed overt hindlimb motor dysfunction as early as 3 weeks in the IV 
cohort and after 5 weeks in the IC injected cohort. The phenotype trajectory of 
Mecp2stop/y mice regularly starts at around 5 weeks and progressively worsens 
over the following weeks with early mortality around the age of 10-12 weeks. 
However, this hindlimb problem worsened 3 of the 6 phenotype criteria (gait, 
hindlimb clasping and mobility) and led to early scoring of a severe, but atypical 
RTT-like phenotype. MECP2 duplication has been reported to produce serious 
neurological complications in human patients (Meins et al., 2005, Van Esch et 
al., 2005, Friez et al., 2006). In a mouse model, a two to three fold increase in 
the level of Mecp2 in post-mitotic neurons produced tremors, gait ataxia, and 
side-to side swaying (Luikenhuis et al., 2004) whereas modest overexpression 
(160-200 % of the endogenous Mecp2 level) resulted in cognitive impairments, 
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motor coordination deficits and an anxiety-like phenotype (Collins et al., 2004, 
Na et al., 2012). In mice model of Mecp2 overexpression, Mecp2 was expressed 
at high levels in all cells/ neurons, however none of these studies has reported 
this overt motor dysfunction that was observed in the current study in which 
equivalent levels of exogenous MeCP2 was achieved in a relatively low number of 
cells. It is possible that the neurons have a threshold of Mecp2 tolerance behind 
which toxic effect takes place. It is also possible that the exogenous MECP2 was 
delivered to a sub-population of cells with altered/oversensitivity response to 
any changes in the Mecp2 levels. Further analysis of the type of cells transduced 
could help investigate this hypothesis.  
Histological examination of the spinal cord was carried out to investigate 
possible causes of this hindlimb phenotype, with particular attention paid to the 
lumbar section as dysfunction was mainly confined to the hindlimbs. This 
examination revealed  evidence of axonal degeneration in the dorsal columns of 
the lumbar spine indicating that the observed hindlimb problem is possibly due 
to the lack of sensory perception and not probably due to a genuine motor 
deficit. The occurrence of axonal degeneration only in the lumbar region of the 
spinal cord suggests that the degeneration process is potentially affecting long 
axons as observed in some neurological disorders (Fischer and Glass, 2007). 
Other regions responsible for sensory perception such as the dorsal root ganglia 
and peripheral nerves were not investigated but may nevertheless be an 
important locus for the transgene-related hindlimb toxicity. 
Early development of the hindlimb motor dysfunction after IV injection, 
compared to the relatively delayed onset after IC injection, in spite of achieving 
low transduction efficiency and a relatively more physiological level of 
exogenous MeCP2 expression, compared to the high transduction efficiency and 
higher level of exogenous MeCP2 expression after IC injection of the same 
vector, suggests a potential role for the peripherally expressed MeCP2 in this 
phenotype. Peripheral delivery of exogenous MECP2 by an AAV vector that 
cannot pass the BB barrier (Fu et al., 2003) could help clarify the role of 
peripherally expressed exogenous MeCP2 in the pathogenesis of this motor 
dysfunction phenotype. 
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The rapid onset of exogenous MeCP2 expression achieved by scAAV9 mediated 
delivery in Mecp2-null cells may partially explain the severity and consistency of 
motor dysfunction in the Mecp2 knockout mice as compared to the phenotype 
variability observed in the WT mice (100% of Mecp2-null mice and 67% of WT 
developed motor dysfunction), This hypothesis agrees with a previous reversal 
study in which rapid activation of endogenous Mecp2 resulted in  sudden death 
of the Mecp2stop-cre/y mice whereas gradual activation was able to rescue RTT-like 
phenotypes (Guy et al., 2007). This is also in agreement with my previous work 
(chapter 5) in which delivery of MECP2 by ssAAV9, which produces a relatively 
delayed onset of expression (McCarty et al., 2003, Gray et al., 2011a), was 
without obvious toxicity/ lethality.  
Many factors could be involved in the pathogenesis of the hindlimb motor 
dysfunction. One possibility is stimulating the immune response against either 
the AAV capsid (Manno et al., 2003, Mingozzi and High, 2007, Mingozzi et al., 
2007) or against the exogenous MeCP2 protein. An Initial attempt to investigate 
this hypothesis was carried out by estimating the level of CD3 protein 
expression, used as an indicator of lymphocytic infiltration in patient and animal 
models of motor neuron disorders (Alexianu et al., 2001). Previous reports have 
shown neuronal CD3 expression in the brain, but not in the spinal cord (Garson 
et al., 1982, Schuller-Petrovic et al., 1983, Syken and Shatz, 2003, Baudouin et 
al., 2008). Interestingly, CD3 expression in the lumbar section of the spinal cord 
of scAAV9/MECP2-treated and control untreated mice was observed and this co-
localized with NeuN immunofluorescence at the cellular level suggesting that 
these receptors are normally expressed on the surface of spinal cord neurons 
and not likely to be due to lymphocytic infiltration. The development of 
hindlimb phenotype in an immunocompromised (RAG-/- knockout mouse) after 
neonatal IV injection with scAAV9/MECP2 together with the absence of the 
hindlimb phenotype in the scAAV9/GFP-injected mice suggest that the most 
parsimonious explanation is that the abnormal phenotype is not likely to be due 
to the acquired immune response reaction to AAV9 virus particles but to some 
other transgene-specific toxicity. However, it remains possible that innate 
immunity system may play a role. The non-toxic and beneficial effects, in WT 
and null-mice respectively, of ssAAV9/CBA-MECP2 after IC injection (chapter 5) 
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in neonatal mice without producing observable motor problems suggest that the 
exogenous MeCP2 is unlikely to be a potential trigger of the immune system.  
Other possibilities investigated were the possible effect of expressing human 
protein in a murine model and potential mouse strain-specific responses to the 
injected construct. To investigate both hypotheses at the same time, a 
comparable virus construct delivering mouse Mecp2-e1 minigene was injected IV 
to Mecp2-null mice with C57BL/6 background (the Mecp2stop/y mice have a  
BALB/C background). The hindlimb problem was observed in all injected mice 
(WT and Mecp2-null mice) indicating absence of a strain-specific response to the 
viral construct. My results also agree with a previous report showing genetic 
rescue of RTT-like phenotypes by expressing human MeCP2 in transgenic mice 
without producing detectable deficits (Collins et al., 2004) and also agree with 
my previous data (chapter 5) that showed therapeutic benefits of human MECP2 
when delivered by ssAAV9 under the CBA promoter in Mecp2-null mice.    
This data shows for the first time a potential toxic effect of exogenous MeCP2 
delivered by scAAV9 under the control of the Mecp2 endogenous core promoter 
(229bp) in mice neonates and highlights the importance of vector and promoter 
design in any future attempts at RTT gene therapy. Further investigations are 
required to identify the underlying cause of the hindlimb Motor dysfunction and 
to fully evaluate the therapeutic effects of scAAV9/MeP-MECP2 vector that was 
prohibited by the development of the hindlimb phenotype. My results, despite 
being negative, highlights the importance of the delivery system in achieving 
therapeutic outcome as indicated by the controversial results obtained after IC 
injection of ssAAV9/CBA-MECP2 and scAAV9/MeP-MECP2 in spite of delivering 
the same transgene. Minimal differences between the delivery vectors, such as 
the percentage and type of transduced/expressing cells or the level of 
exogenous MeCP2 expression, could potentially be the reasons for the different 
outcomes. Achieving therapeutic benefits with ssAAV9/CBA-MECP2 delivery 
provides preliminary, however encouraging, evidence for the potential benefits 
of gene therapy application in RTT and prerequisite further comprehensive 
studies in the  Mecp2-/+ heterozygous females (the accurate model of RTT in 
human) to further investigate these therapeutic benefits. 
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7.2 Significance of this study 
Rett syndrome was for decades considered as a neurodevelopmental disorder 
that was thought to be incurable. However the reversal studies have shown the 
potential reversibility of RTT-like phenotypes in mice models. In this study I 
show the first evidence that RTT-like phenotype can be prevented / improved by 
delivering MECP2 to Mecp2 knockout model using viral vectors and I also 
highlight the potential neurological adverse effect of this approach. These data 
however at the proof of concept level should have an impact on the future 
therapeutic approaches not only for RTT but also for other related neurological 
disorders. The importance of this study is listed in the following key points; 
1. In this thesis I provide a comprehensive study investigating the efficiency 
of different viral vectors with a range of promoters to drive expression of 
exogenous Mecp2 in vivo and in vitro. This was further extended to 
evaluate the transfection efficiency and the levels of Mecp2 expressed 
under each promoter. These considerations are essential for the field of 
RTT gene therapy in order to properly design a therapeutic vector.  
2. In this thesis I showed that lentivirus–mediated Mecp2 delivery is a useful 
tool for highly localized delivery of Mecp2 in a particular brain area. This 
may be a valuable tool for studying Mecp2 function in discrete brain 
areas. It may also be a useful delivery tool for generating an easy model 
of Mecp2 overexpression and potential cell-type specific overexpression-
induced toxicity.  
3. My thesis provides the first proof of concept evidence for the possibility of 
achieving phenotypic and survival improvements in a mouse model of RTT 
by ssAAV9/CBA- mediated MECP2 delivery in neonates. This data, along 
with the observed lack of overt adverse effects of this vector in WT mice 
is positive for extending this work into heterozygous females, a more 
accurate model of human disease, before considering human translation. 
4. My thesis shows that virus-mediated exogenous MECP2 delivery has an 
impact on the cellular morphology of the Mecp2-null and WT neurons 
either at an early stage of the development (neonatal injection of ssAAV9) 
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or after the establishment of RTT-like phenotypes (adult injection of 
lentivirus). This indicates that RTT-associated morphological deficits are 
reversible regardless of the time of intervention. 
5. My thesis provides evidence of provoked overt neurological/motor 
phenotype after scAAV9/MeP-mediated MeCP2 expression in neonatal 
mice. This data shows the crucial importance of choosing the right vector 
design in any future attempts for RTT gene therapy application to 
minimize the drawbacks and achieve maximum therapeutic benefits. 
7.3 Technical considerations 
Most of the technical problems in this study were related to the Mecp2 knockout 
model.  Mecp2-null males are infertile therefore Mecp2 -/+ female must be 
mated with WT males to generated Mecp2-/y male mice (the genotype I was 
interested in). This breeding scheme means that the segregation ratio of   
Mecp2-/y is 25%. This low percentage is further complicated by the small litter-
size (3-5 pups) in Mecp2-null lines which further reduces the chances of getting 
the desired genotype. Moreover the numbers of pups that reach weaning age is 
also limited, either because of failure to compete with the WT or due to the 
increased incidence of infanticide (Jugloff et al., 2006). Many steps were taken 
to improve the breeding such as, doubling the number of heterozygous females 
in each age group, minimizing cage disturbance and decreasing environmental 
noise, especially around the delivery time, and avoiding unnecessary handling of 
the pups to prevent infanticide. Sunflower seeds were also added to the cage 
which has been previously reported to increase breeding efficiency (Jugloff et 
al., 2006).  
Another problem encountered was that Mecp2 knockout mice displayed tail 
lesions around the age of 7-8 weeks. This problem usually starts as small lesions 
around the tail-base which then progress to skin ulcers and eventually complete 
necrosis and loss of the tail. This condition is usually accompanied by perianal 
infection which necessitates culling the affected mice. Attempts were made to 
try and alleviate this condition by the application of topical antibiotics but this 
showed very limited benefit. Development of this phenotype in the virus-treated 
mice interfered with a full investigation of the therapeutic outcome e.g. 
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lentivirus injection (chapter 4) and scAAV9 injection (chapter 6). One possibility 
was that this lesion was due to animals fighting with each other, however caging 
mice individually did not prevent or improve this phenotype. Interestingly, this 
tail problem has been not observed in the cohort of mice injected with 
ssAAV9/CBA-MECP2 (chapter 5) except in 3 mice, however all of them have 
recovered without treatment. Further investigations are required to identify the 
underlying cause of this problem. 
7.4 Future studies 
The nature of this project has been to test various gene delivery processes and 
then to refine vector design, delivery strategies moving to proof of concept 
studies in RTT-mice. This represents a logical trajectory in reaching the ultimate 
goal of developing translational strategies in treating RTT in patients. The 
results shown in my thesis suggest important future experiments in various 
directions. 
1. Following the success of ssAAV9/CBA-MECP2 in producing therapeutic benefits 
after IC injection in neonates, I would recommend several more experiments 
to further investigate the potential for future human translation; 
I. The vast majority of RTT patients are females with a mosaic network of 
cells either expressing normal MeCP2 or lacking functional MeCP2. 
Therefore the next experiment should be to consider injecting adult pre-
symptomatic or symptomatic heterozygous female mice with scAAV9/MeP-
MECP2 through the tail vein to investigate the potential for phenotype 
prevention / rescue. Comprehensive behavioural analysis before and after 
the treatment is essential for complete evaluation of the therapeutic 
outcomes.  
II. The role of glia in the pathogenesis of RTT has become evident in the last 
few years (Ballas et al., 2009, Lioy et al., 2011) therefore it would be 
interesting to investigate the effect of scAAV9-mediated exogenous 
expression of Mecp2 in glia on the phenotype trajectory of Mecp2 
knockout mice. This may be achieved by using a glial-specific promoter 
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such as GFAP promoter or by using AAV capsid mutants showing high glial 
tropism. 
III. The peripheral delivery of exogenous MECP2 is the most clinically relevant 
method for gene delivery; however with the expected low transduction 
efficiency after peripheral injection in adult, direct brain injection of 
AAV9 could be an option, therefore an interesting experiment would be to 
investigate the effect of region-specific delivery of MECP2 on the reversal 
of a particular phenotype (breathing, motor behaviours) in heterozygous 
female mice. This would also address basic neurobiological questions by 
mapping aspects of RTT-phenotype/reversal to discrete brain regions. 
IV. Optimizing viral delivery methods to increase transduction efficiency in 
adult mice brain such as; intrathecal, intra-arterial or IV injection after 
disturbing the BBB with mannitol (Fu et al., 2003). 
V. Optimizing the vector construct to enable targeting of exogenous Mecp2 
to  null cells in heterozygous mosaic brain to avoid overexpression in the 
cells that express normal endogenous Mecp2 through: 
a. Designing a vector with a Mecp2 minigene and siRNA that can 
knockdown endogenous Mecp2 in the cells expressing the normal 
Mecp2 allele. 
b. Designing a vector that drives expression of exogenous Mecp2 under 
the control of Mecp2 target promoter (e.g. mouse BDNF exon 4 
promoter)(Chen et al., 2003a, Martinowich et al., 2003).This 
promoter could theoretically be silenced in cells that are already 
expressing normal Mecp2 which binds and represses the promoter 
but would not be in cells which contain no endogenous Mecp2 
(Gadalla et al., 2011). 
c. Screening a library of AAV capsid mutants for selective tropism to 
the Mecp2-null cells.  
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2. Since injection of scAAV9/MeP-MECP2 in mice neonates was accompanied by 
overt hindlimb motor dysfunction in contrast to the therapeutic benefits of 
ssAAV9/CBA-MECP2, the following experiments could help determine the 
reasons for this problem; 
I. Delivery of exogenous MECP2 under Mecp2 endogenous promoter by 
ssAAV9 (ssAAV9/MeP-MECP2) vector through direct brain injection in mice 
neonates. This experiment should help investigate the role of the MeP 
promoter in the development of the hindlimb phenotype, as the same 
vector with CBA promoter showed no apparent toxicities. 
II. Neonatal delivery of exogenous MECP2 under CBA promoter by scAAV9 
(scAAV9/CBA-MECP2) vector. This experiment could test the possible role 
of AAV9 vector-structure (sc versus ss) in the hindlimb pathology. 
However this experiment is difficult to carry out due to the limited 
cloning capacity of scAAV9. Nevertheless it may be possible to further 
truncate the CBA promoter to enable packaging. 
III. Peripheral delivery of exogenous MECP2 by pseudotyping scAAV/MeP using 
capsids 2 or 1 which are unable to cross the BBB. This experiment would 
help define the role of peripherally expressed MeCP2 in the abnormal 
phenotype. 
IV. Measurement  of  the innate immune response (e.g. cytokines)  in the 
affected mice to identify the role of immune response stimulation in this 
phenotype (as RAG-/- knockout mice experiment already excluded mature 
T and B cells as a cause of this problem). 
7.5 Summary 
The investigation of viral-mediated exogenous MECP2 delivery to the Mecp2 
knockout mice has been extremely productive in several respects. First it shows 
that Lentivirus-based vectors, despite producing enduring expression in neurons, 
are not suitable for global brain expression of Mecp2 due to limited spread of 
the virus. Nevertheless Lentivirus-based vectors are still potentially useful if 
localized brain injection is required. Second, this study shows the first proof of 
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therapeutic benefits (improved motor behaviours and prolonged survival) of 
exogenous MECP2 delivered in Mecp2-null mice by ssAAV9/CBA-MECP2 vector in 
neonatal mice.  Finally, my study is the first to report overt neurological/motor 
deficits in Mecp2 knockout mice after systemic and local delivery of exogenous 
MECP2 by scAAV9/MeP-MECP2 vector to neonates. I believe that this study 
provides the groundwork for further studies to identify the potential of achieving 
therapeutic benefits in Mecp2-/+ female mice, a more  accurate model of human 
RTT, and also for studies to investigate the underlying pathology of the hindlimb 
motor deficit to enable avoiding this problem in the future clinical translation.   
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